




## Year-over-Year Changes in the Patented Medicine Price Index 1988-1997

### Tenth Annual Report



**Visit us at our Web site: <http://www.pmprb-cepmb.gc.ca>  
or call us at our toll-free number: 1-877-861-2350**



The Patented Medicine Prices Review Board  
Standard Life Centre  
Box L40  
333 Laurier Avenue West  
Suite 1400  
Ottawa, Ontario  
K1P 1C1

Telephone: (613) 952-7360  
Facsimile: (613) 952-7626  
TTY: (613) 957-4373



May 29, 1998

The Honourable Allan Rock, P.C., Q.C., M.P.  
Minister of Health  
House of Commons  
Ottawa, Ontario  
K1A 0A6

Dear Minister:

I have the honour to present to you, in accordance with the provisions of sections 89 and 100 of the *Patent Act*, the Annual Report of the Patented Medicine Prices Review Board for the year ended December 31, 1997.

Yours very truly,

Robert G. Elgie  
Chairperson

## Mission and Values of the PMPRB

---

Photo courtesy of Health Canada



The mission of the Patented Medicine Prices Review Board (PMPRB) is to contribute to Canadian health care by ensuring that prices of patented medicines are not excessive. The PMPRB achieves this by:

- promoting voluntary compliance with Guidelines established by the Board
- reviewing prices and taking remedial action when necessary
- analysing and reporting to Canadians on price trends of all medicines and on research and development conducted by patentees
- consulting with interested parties on Guidelines and other matters of policy
- fostering awareness of the Board's mandate, activities and achievements through communication, dissemination of information and public education.

In fulfilling its mission the PMPRB is committed to innovative leadership based on the following values:

- effectiveness and efficiency
- fairness
- integrity
- mutual respect
- transparency of process
- a supportive and challenging work environment.

# Table of Contents

<b>Letter to the Minister</b>	<b>1</b>
<b>Mission and Values of the PMPRB</b>	<b>2</b>
<b>List of Tables and Figures</b>	<b>4</b>
<b>Chairperson's Message</b>	<b>5</b>
<b>The Patented Medicine Prices Review Board</b>	<b>8</b>
Mandate	8
Jurisdiction	8
Membership	9
<b>Consultations: <i>Examining the Role, Functions and Methods of the Patented Medicine Prices Review Board</i></b>	<b>10</b>
<b>Sales of Drugs in Canada in 1997</b>	<b>12</b>
The Pharmaceutical Industry in Canada	12
Sales of Pharmaceutical Drugs in Canada	12
<b>Trends in Drug Prices and Expenditures</b>	<b>15</b>
Prices of Patented Drugs in 1997	15
Price Trends of All Drugs — Patented and Non-Patented	15
Industrial Product Price Index (IPPI)	16
Non-Patented Medicine Price Index (NPMPI)	17
Price Trends in Canada and the United States	17
Relationship of Canadian Prices to Foreign Prices: Past and Present	18
Increased Expenditures on Drugs	19
Trends in Quantities of Sales of Patented Drug Products	20
Sales by Major Therapeutic Group	21
<b>Compliance and Excessive Price Guidelines</b>	<b>22</b>
New Patented Drug Products in 1997	22
New Active Substances in 1997	23
Price Review of New Patented Drug Products in 1997	24
Patent Pending	24
Price Review of Existing Patented Drugs in 1997	25
Update of the Ninth Annual Report	25
<b>Enforcement Activities</b>	<b>26</b>
Voluntary Compliance Undertaking — Humalog	26
<b>Analysis of Research-and-Development (R&amp;D) Expenditures</b>	<b>28</b>
Data Sources	28
R&D Expenditures	28
Revenues from Sales	29
R&D-to-Sales Ratios	29
<b>Glossary</b>	<b>35</b>
<b>List of PMPRB Publications</b>	<b>38</b>

# List of Tables and Figures

## Tables

Table 1	Manufacturers' Sales of All Drugs and Patented Drugs, 1990-1997	13
Table 2	Patented Drug Expenditures by Major Therapeutic Group, 1997	21
Table 3	New Patented Medicines in 1997 (Human)	24
Table 4	Total R&D Expenditures and R&D-to-Sales Ratios, 1988-1997	28
Table 5	Range of R&D-to-Sales Ratios by Number of Reporting Companies and Total Sales Revenues	29
Table 6	Current R&D Expenditures by Type of Research, 1996 and 1997	30
Table 7	Current R&D Expenditures by R&D Performer, 1996 and 1997	31
Table 8	Total R&D Expenditures by Source of Funds, 1996 and 1997	31
Table 9	Current R&D Expenditures by Location, 1996 and 1997	31
Table 10	Ratios of R&D Expenditures to Sales Revenues by Reporting Patentee, 1996 and 1997	32
Table 11	Current R&D Expenditures by Province and by R&D Performer, 1997	34
Table 12	Patented Drug Products Introduced in Canada in 1997	39
Table 13	Patented Drug Products and Canadian Patentees January 1, 1997 - December 31, 1997	41

## Figures

Figure 1	Manufacturers' Sales of Patented and Non-Patented Drugs, 1990-1997	13
Figure 2	Year-over-Year Changes in the PMPI, 1988-1997	15
Figure 3	Year-over-Year Changes in the PMPI, IPPI (pharma) and CPI, 1988-1997	15
Figure 4	Summary of Price Trends: Average Annual Percentage Changes 1982-1987; 1988-1997	16
Figure 5	Year-over-Year Changes in the IPPI (pharma), NPMPI and PMPI, 1988-1997	16
Figure 6	Year-over-Year Changes in Pharmaceutical Price Indices, Canada and the U.S., 1982-1997	17
Figure 7	Summary of Price Trends: Average Annual Percentage Changes, 1982-1987; 1988-1997	17
Figure 8	Ratio of Canadian Prices to Median International Prices, 1987-1997	18
Figure 9	Average Foreign to Canadian Price Ratios - All Patented Drug Products in 1987	18
Figure 10	Average Foreign to Canadian Price Ratios - All Patented Drug Products in 1997	19
Figure 11	Drug Expenditures as a Percentage of Total Health Expenditures, 1975-1996	19
Figure 12	Year-over-Year Changes in Drug Expenditures, 1976-1996	20
Figure 13	Year-over-Year Changes in the CPI (RX) Index, 1988-1997	20
Figure 14	Factors Affecting Total Drug Expenditures	20
Figure 15	Year-over-Year Changes in the PMPI and in the Quantity Index, 1988-1997	21
Figure 16	Categorization of New Patented Drug Products (Human)	23
Figure 17	Current R&D Expenditures by Type of Research, 1988-1997	30
Figure 18	Share of Current R&D Expenditures by Type of Research, 1988-1997	30

## Chairperson's Message

---

As it moved into its second decade of operations in 1997, the Patented Medicine Prices Review Board focussed on identifying ways which would enable it to become more effective, responsive and accessible to Canadians while functioning in an increasingly dynamic environment. New drugs, new medical technologies and an aging population are just some of the forces which are influencing the evolution of our health care system and the work of the PMPRB.

Consistently, health care ranks as the number one issue of importance to Canadians. In this context, Canada, along with many other countries, continues to look for ways to contain rising costs. In 1996, according to the latest figures published by Health Canada, drugs alone accounted for 14.4% of total health care expenditures, representing the fastest growing cost component within our health care system. This trend underscores the need for more and better information on key elements such as hospital, physician and drug costs and on cost drivers such as utilization, prescribing habits of physicians, pricing and other factors. The Federal/Provincial/Territorial Ministers of Health have assigned task forces to look into these matters.

Many of these concerns were voiced by witnesses during the hearings of the Standing Committee on Industry reviewing Bill C-91. Echoing these concerns in its April 1997 Report, the Standing Committee noted that "... many witnesses wanted [the PMPRB] to fulfill a wider role in a more publicly responsive way... [prompting the recommendation to the Government that] the mandate of the [PMPRB] be reviewed and strengthened." In addition, the Standing Committee recommended that "... the PMPRB consult with consumers, health care professionals, experts, and the provinces to assess its current statistical reporting and find out what other information it could provide to the public."

In 1997, the Board embarked on a comprehensive review and renewal process examining a range of issues, including those raised in the Standing Committee report. The Board initiated a broad consultation with its stakeholders to examine the role, functions and methods of the PMPRB with a view to being more relevant to the needs of those it serves. While the Board has always endeavored to consult widely, this expanded consultation process represented a major, new undertaking for the PMPRB.

In November 1997, the Board released a detailed Discussion Paper, followed in February and March 1998 by a series of public information sessions held in every province and territory. The purpose of the consultation was to solicit constructive input and suggestions regarding issues of concern that are within the Board's mandate and scope of activities. The main areas covered in the Discussion Paper include: drug prices and cost issues; consultation, information and transparency issues as they pertain to the Board's public accountability; and issues regarding pricing methods and guidelines.

To date, the consultation process has proven to be worthwhile on several levels. It has enabled the Board members to hear directly from consumers and others regarding their concerns as well as encouraging stakeholders to express their views on how these concerns could and should be addressed. Similarly, the consultations have furnished valuable feedback on how the Board might improve the "way we do business." In effect, the consultation process has already served to influence the way the Board functions in terms of an increasing emphasis on availability, access and two-way communications.



The impact and benefits of the consultation process can be measured in other ways as well. Results thus far have served to validate the Board's direction toward strengthening public accountability. From an operational perspective, the Board is currently working on the development and implementation of a formal consultation policy supporting the broader objective of further strengthening the PMPRB's public accountability. Work is also moving ahead on a review of the Board's pricing methods and Guidelines to ensure their appropriateness and, where possible, identify opportunities for improvement. In addition, the Board will be conducting further analyses and will be reporting on issues surrounding drug prices and cost drivers.



Photo courtesy of Health Canada

*In 1997, the Board worked to better identify and respond to the needs of consumers and other stakeholders, to promote a process of continuous dialogue and exchange of ideas, and to strengthen public accountability and operational transparency.*

The Board is always seeking to enhance the transparency of its operations by, for instance, developing mechanisms to report publicly on the Board's analyses of new medicines. In addition, the Board is also exploring new approaches to the way it operates as reflected by its recent invitation for comments relating to the drug Humalog prior to deciding whether to accept a proposed Voluntary Compliance Undertaking (VCU) to lower the price of this medicine.

In last year's Annual Report, the PMPRB signaled its intention to place greater emphasis on consultations with its stakeholders, to keep them better informed and to promote public debate on the pricing, usage and cost of drugs in Canada. In 1997, furthering these goals has been the focal point of our efforts as an organization. The Board has worked to better identify and respond to the needs of consumers and other stakeholders, to promote a process of continuous dialogue and exchange of ideas, and to strengthen public accountability and operational transparency. To further these goals, the Board continues to collaborate with the provinces in a variety of areas. In particular, the Board provides expertise to the Federal/Provincial/Territorial Task Force on Pharmaceutical Pricing Issues as well as being a member of the Pharmaceutical Issues Committee. The Board wants to ensure the highest possible degree of efficiency, integrity and fairness in Canada's patented medicine price review system.



As Chairperson of the PMPRB, I am especially proud of the Board members and PMPRB staff, particularly with respect to the professionalism they have demonstrated in supporting the consultation and renewal process which has involved so much additional effort during the past year.

In embarking on our second decade, yet another milestone in the life of our agency has been marked with the departure from the Board of Dr. Harry C. Eastman. Dr. Eastman served as Chairperson and Chief Executive Officer from the Board's founding in 1987 to 1995, as well as serving as a Board member from 1987 to 1997. On behalf of all Board members and PMPRB staff, I wish to thank Dr. Eastman for his invaluable contribution to the PMPRB over the past decade.

In renewing itself, the PMPRB is building upon the experience and accomplishments of its first ten years, while initiating the changes and improvements necessary to ensure its continued effectiveness in protecting the interests of Canadian consumers.

A handwritten signature in blue ink, reading "Robert G. Elgie". The signature is fluid and cursive, with a long horizontal stroke at the beginning.

Robert G. Elgie  
Chairperson

# The Patented Medicine Prices Review Board

---

## Mandate

---

The PMPRB is an independent quasi-judicial body created by Parliament in 1987 under the *Patent Act*. The PMPRB protects consumer interests and contributes to Canadian health care by regulating the prices charged by manufacturers of patented medicines to ensure that they are not excessive.

The PMPRB reports to Parliament through the Minister of Health. The Annual Report, which covers each calendar year, includes a review of the PMPRB's major activities, analyses of the prices of patented medicines and of the price trends of all drugs, and reports on the R&D expenditures by patent-holding drug manufacturers.

## Jurisdiction

---

The PMPRB is responsible for regulating the maximum prices that patentees may charge for prescription and non-prescription patented drugs sold in Canada for human and veterinary use. In most cases that price is the “factory-gate” price at which the manufacturer sells the product to wholesalers, hospitals or pharmacies. The PMPRB's jurisdiction includes patented medicines marketed or distributed under voluntary licences. The Board has no authority to regulate the prices of non-patented drugs, including generic drugs sold under compulsory licences, and does not have jurisdiction over prices charged by wholesalers or retailers nor over pharmacists' dispensing fees.


In Canada, Health Canada assesses new medicines to ensure that they conform with the *Food and Drugs Act and Regulations*. Formal authorization to market or distribute a medicine is granted through a Notice of Compliance (NOC). A medicine may be temporarily distributed with specified restrictions before receiving a NOC, as an Investigational New Drug or under the Special Access Program.

The PMPRB regulates the price of each patented drug product, including each strength of each dosage form of a patented medicine. This is normally the level at which Health Canada assigns a Drug Identification Number (DIN) or General Public (GP) number.

# Membership

---


The Board consists of no more than five part-time members appointed by the Governor in Council for a term of five years. There is currently one vacancy on the Board.



Chairperson:  
**Robert G. Elgie,**  
LL.B., M.D., F.R.C.S. (C)

Dr. Elgie, a lawyer and neurosurgeon, Fellow of the Royal College of Surgeons (Neurosurgery), was the founder and first Director of Dalhousie University's Health Law Institute from 1991 to 1996. He was also the part-time Chair of the

Workers' Compensation Board of Nova Scotia from 1992 to 1996. Dr. Elgie has taught at the Medical Schools of Queen's University and the University of Toronto, and has held several positions with the Scarborough General Hospital, including Chief of Medical Staff. In 1977, he was elected to the Ontario Legislative Assembly and subsequently served in several Cabinet positions. He resigned from the Ontario Legislature in September 1985 to become Chair of the Workers' Compensation Board of Ontario where he served until 1991. Dr. Elgie was appointed Member and Chairperson of the PMPRB in March 1995.



Vice-Chairperson:  
**Réal Sureau, FCA**

Mr. Sureau, a chartered accountant, is President of Sureau Management Limited and Director, Business Development, Montreal Baseball Club Inc.

From June 1995 to June 1996, he was President of the Order of Chartered


Accountants of Québec. Through the years, he was a member of several committees of the Order, including the Disciplinary Committee, the Professional Practice Committee, the Professional Development Committee and the Committee on Government Finances. He was Vice-President, Finance, at Forex and Canam-

Manac. Mr. Sureau sits on the board of directors of many organizations, including Gaz Métropolitain, the *Institut de réadaptation de Montréal* and la *Fondation des paraplégiques du Québec*. Mr. Sureau was appointed Member and Vice-Chairperson of the PMPRB in October 1995.

## Members:

**Judith L. Glennie, Pharm., D., FCSHP**

Dr. Glennie is a clinical pharmacist specializing in pharmacoeconomics. She is currently President of J. L. Glennie Consulting Inc. and works with the Ottawa General Hospital Pharmaceutical Outcomes Research Unit and various governmental and non-governmental health agencies. She is an affiliate researcher with the Loeb Research Institute and adjunct professor with the Faculty of Medicine, University of Ottawa. Dr. Glennie is completing a Masters of Science in Community Health Science, Faculty of Medicine, University of Manitoba. Dr. Glennie was appointed Member of the PMPRB in March 1995.



**Ysolde Gendreau,**  
B.C.L., LL.B., LL.M., Ph.D.

Dr. Gendreau is a professor in the Faculty of Law of the Université de Montréal, where she teaches intellectual property law and competition law. She is also sessional lecturer at McGill University, where she teaches intellectual property law. Dr. Gendreau was appointed Member of the PMPRB in October 1995.



## Consultations: Examining the Role, Functions and Methods of the Patented Medicine Prices Review Board

---

In April 1997, the Standing Committee on Industry reviewed the drug patent legislation, Bill C-91. Although the main issues during the review were the regulatory framework for drug patent policy, Linkage Regulations, patent terms, pharmacare and related matters, the mandate and activities of the Patented Medicine Prices Review Board were also examined and debated.

The Board's mandate flows from policy established by Parliament through the legislation and its regulations and is focussed on protecting consumer interests by ensuring that prices for patented drugs are not excessive. In its report, the Standing Committee noted that witnesses tended to give only limited recognition of the Board's success to date in controlling drug prices.

Consequently, the Committee made two recommendations directly related to the Board. The first such recommendation was addressed to the government and advocated:

- strengthening the mandate of the PMPRB;
- an audit by the Auditor General; and
- greater access to non-proprietary information filed with the PMPRB.

The second recommendation on the PMPRB was addressed directly to the Board. This recommendation urged the Board to consult with consumers, health care professionals, other experts, and the provinces to assess its current statistical reporting and to determine what other information might be gathered and shared with the public.

From its perspective, the Board recognized the value and appropriateness of looking at opportunities to improve the transparency of the regulatory and price review process. In addition, the Board acknowledged the need to further the discussion with respect to concerns that the Committee heard as to the growth of expenditures on drugs and the growing cost to the health care system.

### Responding to the Challenge

---

The Board initiated an internal review of its activities to examine existing functions and to relate them to potential new requirements arising out of the Committee's recommendations.

A major element of this review was to seek advice, on an informal basis, from some of our stakeholders who, traditionally, had not been closely involved in the work of the Board. The purpose of this advice gathering was to determine how the Board might enhance its consultations. The results of this initiative were used to help shape the consultation process that followed.

In November 1997, the Board launched a public consultation process through the publication of a Discussion Paper. The first step in the consultations centered on the role, functions and methods of the Board and on questions relating to the Board's role in disseminating information, strengthening its public accountability, as well as its price guidelines and price review methodologies.

## Process

---

We sought to ensure that the consultations would be as broad and inclusive as possible. Towards this end, the Discussion Paper was circulated to the people on our regular mailing list, approximately 900 recipients. As other interested parties were identified or came forward to request a copy of the Discussion Paper, we eventually reached a point of having more than 2,000 copies in circulation.

We also recognized the importance of ensuring the opportunity for face-to-face contact to encourage two-way communications. During February and early March, the Board held a series of public information sessions across Canada. These sessions were preceded by notifying people on our mailing list, issuing media advisories, and publishing notices in major regional newspapers — all designed to encourage public involvement in the review. A session was held in every province and territory. In total, thirteen meetings took place, conducted by the Board members and staff and were attended by close to 300 Canadians.

To further support the consultation process, we invited written submissions to be filed by the end of March. The Board received 60 substantive submissions from interested organizations and individuals. In total, these submissions run to more than several hundred pages of text.

At the end of April, the Board held a two-day policy hearing at which 24 organizations or individuals made presentations in support of their submissions. The purpose of this hearing was to ensure that interested stakeholders were afforded every opportunity to clarify and, as appropriate, elaborate upon the information contained in their submissions.

## Results and Next Steps

---

The Board is currently evaluating the submissions and plans to make a report in late summer which may set out some changes and proposals for further consultation.

We will be communicating these results through distribution of printed copies of the report, our web site and our NEWSLETTER. We are also encouraging stakeholders to communicate with us through our toll-free number: 1-877-861-2350 or via e-mail ([pmprb@pmprb-cepmb.gc.ca](mailto:pmprb@pmprb-cepmb.gc.ca)).

We have concluded that the release of the Discussion Paper and the holding of the consultation sessions across Canada were worthwhile initiatives for the Board. They have afforded us direct contact with consumers and other stakeholders while the submissions, oral and in writing, represent significant sources of new information and feedback on issues and how they might be addressed.

This expanded consultation process represents a new stage in the evolution of the Board with an increased emphasis on ensuring closer links with consumers and other stakeholders. The Board is committed to strengthening its public accountability including the transparency of its operations.

## Future Direction of the Board

---

Where we can identify ways of improving our effectiveness, we are doing so and will continue to do so. We recognize the need to remain relevant to the needs of consumers and our other stakeholders by promoting a constant exchange of information, improving the timeliness and quality of information we provide and ensuring that our pricing methods and guidelines are appropriate in helping us fulfill our mandate.



# Sales of Drugs in Canada in 1997

## The Pharmaceutical Industry in Canada

The global pharmaceutical industry is dominated by a number of large multinational enterprises based in several countries. Most of these companies have Canadian subsidiaries which, along with a few domestic pharmaceutical firms, account for the manufacture, sale and distribution of drugs in Canada. It has been reported that the top ten pharmaceutical companies accounted for approximately 50% of total sales in 1997, up from 45% in 1996.<sup>1</sup> Of the top ten firms, one was a Canadian company supplying generic products.<sup>2</sup>

It has been reported that sales of drugs worldwide increased in 1997 by 8.6% over 1996 to over \$400 billion. In Canada, total sales of drugs increased at about the same rate, 7.0%, to an estimated total of \$7.0 billion. The Canadian market for drugs has traditionally represented less than 2% of the world market.

In Canada, the PMPRB protects consumer interests by regulating the prices charged by pharmaceutical patentees during the time they benefit from patent protection. Ordinarily, a patentee is the exclusive supplier of a patented product, but there may also be other medicines available. Although a drug that is no longer protected by a patent may become the subject of competition, there are also instances where the manufacturer of a non-patented drug may nevertheless remain the sole supplier.



Photo courtesy of Health Canada

In 1997, 76 companies reported sales of patented medicines in Canada to the PMPRB, an increase from 72 in 1996.<sup>3</sup>

The pharmaceutical industry continued to account for less than 2% of all sales and employment in the manufacturing sector of the Canadian economy in 1997. Because of its research and development (R&D) activities, however, the industry accounted for approximately 10% of total R&D in that sector.<sup>4</sup> This is consistent with this industry's relative performance since 1987. (For a report on patentees' R&D expenditures in 1997, please refer to page 28).

## Sales of Pharmaceutical Drugs in Canada

Table 1 shows manufacturers' sales of all drugs and of patented drugs in Canada since 1990. Total sales by manufacturers of pharmaceuticals in 1997 in Canada are estimated

1 See IMS, Canadian Pharmaceutical Industry Review, 1997, Table 1.

2 In 1996, two Canadian companies were in the top ten, Apotex and Novopharm. In 1997, Novopharm moved to eleventh position. See IMS, Canadian Pharmaceutical Industry Review, 1997, Table 1.

3 A list of all reporting patentees and patented drug products appears in Table 13.

4 Statistics Canada Catalogues, 31-2003 and 88-202.

**Table 1 Manufacturers' Sales of All Drugs and Patented Drugs, 1990 - 1997**

Year	Total Sales (\$billions)	Total Change* (%)	Patented Sales (\$billions)	Patented Change* (%)	Patented as Percentage of Total
1997	7.0	7.0	3.7	22.6	52.3
1996	6.6	10.0	3.0	12.8	45.0
1995	6.0	1.7	2.6	10.8	43.9
1994	5.9	9.3	2.4	-2.1	40.7
1993	5.4	12.5	2.4	9.4	44.4
1992	4.8	9.1	2.2	14.0	43.8
1991	4.4	18.9	2.0	13.1	43.2
1990	3.7	-	1.7	-	43.2

\* Percentage changes reflect exact values and not rounded values.  
Source: PMPRB, Statistics Canada and IMS Canada.


at \$7.0 billion, an increase of 7.0% from 1996.<sup>5</sup> In 1997, patentees reported total factory-gate sales of patented drugs of \$3.7 billion, an increase of 22.6% from 1996. This increase

represents the largest annual growth in patented drug sales during the 1990's. Furthermore, for the first time patented drug sales accounted for over 50% of the total sales

by manufacturers. Since prices and sales have been tracked by the PMPRB patented drugs had never accounted for more than 45% of the total sales. For further comments on this issue, please refer to page 20, Trends in Quantities of Sales of Patented Drug Products.

Figure 1 shows the growth in annual sales of patented and non-patented drugs from 1990 to 1997. Sales of non-patented drugs can be estimated as the difference between the total sales of pharmaceuticals and the sales of patented drugs as reported to the PMPRB.

**Figure 1 Manufacturers' Sales of Patented and Non-Patented Drugs 1990-1997**



Sources: PMPRB, Statistics Canada and IMS Canada

<sup>5</sup> See Statistics Canada Cansim #'s D667757, D315488, D401624 and D451712.

The most recent figures on annual total sales from Statistics Canada are for 1995. The PMPRB relies on the most current annual report of sales by Statistics Canada when it becomes available. Beginning with the 1995 Annual Report the PMPRB has adopted a method of estimating total sales for the years that Statistics Canada's data are not available.

Patentees are required, under the Patented Medicines Regulations, to submit to the PMPRB annual total pharmaceutical sales information for both patented and non-patented drug products sold in Canada. IMS Canada Ltd. publishes reports of sales by individual firms. Total sales by all manufacturers can be estimated by adding the total sales of patentees and the estimated IMS sales for non-patentees. These estimates will be revised when the annual sales estimates published by Statistics Canada become available.



Non-patented medicines include products that were previously subject to patent protection, those that are not yet or never have been protected by a patent, and generic copies of existing patented drugs. Information filed by patentees with the PMPRB indicates that most non-patented drugs are sold by companies that also sell patented drugs. During the 1990's sales of non-patented drugs typically accounted for about 50% of the total drug sales of patentees. In 1997, the proportion of non-patented drug sales dropped substantially to about 40% while patented drug sales increased to about 60% of the total drug sales of patentees.

Non-patented sales also include sales by generic companies. IMS Canada estimates sales by non-patentees to be \$710 million or 11% of the total pharmaceutical market in 1997, a slight decline from 1996.<sup>6</sup>

The PMPRB regulates the maximum prices of individual patented drug products, including each strength and dosage form of them. A total of 981 patented drug products were sold in Canada during all or part of 1997. This number represents an increase from the 917 products sold in 1996. The number of patented drugs reported to the PMPRB is smaller than the 1,431 patented drugs with a Notice of Compliance (NOC) because not all products with a NOC were actually sold in Canada during the year. In addition, patented drugs that do not have a NOC but are sold as Investigational New Drugs or under the Special Access Program administered by Health Canada are subject to review by the PMPRB. In 1997, there were over 21,000 drug products sold in Canada. Of these drug products approximately 6,000 were prescription drugs. Although the number of patented drug products with a NOC in 1997 represented only 6% of the total number of drug products approved for sale, sales of patented drugs accounted for 52.3% of total sales as shown in Table 1.



Photo courtesy of Health Canada

<sup>6</sup> See IMS, *Canadian Pharmaceutical Market: Drug Store and Hospital Purchases*, December 1997. Generic companies include those that belong to the Canadian Drug Manufacturers Association (CDMA).

# Trends in Drug Prices and Expenditures

## Prices of Patented Drugs in 1997

The PMPRB maintains the Patented Medicine Price Index (PMPI), an index of manufacturers' prices for patented drugs as reported annually by the PMPRB. The PMPI measures the average change from the previous year in the actual prices of all patented drugs sold in Canada. Because the PMPI is derived from the actual prices charged by manufacturers for all patented medicines, it provides a precise measure of price changes for drugs reported to the PMPRB.<sup>7</sup>


In 1997, manufacturers' prices of patented drugs were virtually unchanged from 1996. The prices of patented drugs, as measured by the PMPI, fell by 0.1% from the level in 1996. As shown in Figure 2, prices for patented drugs had declined by about 2% per year in the previous two years; the PMPI went down 2.2% in 1996 and 1.9% in 1995.

## Price Trends of All Drugs — Patented and Non-Patented

The *Patent Act* provides that the PMPRB shall consider changes in the Consumer Price Index (CPI) in determining if the price of a patented medicine is excessive. As shown in Figure 3, consumer prices, as measured by the CPI, increased in every year since 1988 by an amount greater than the PMPI with the exception of 1992.<sup>8</sup> In 1997, consumer prices increased by 1.6%.


It is not unexpected that the overall increases in patented drug prices have been less than the increases in the CPI. The PMPRB limits apply on a product-by-product basis; in other words, no patented drug product can have its price increase by more than the CPI, and some will increase by less. The policies of some provincial governments also influence the annual rate of change in drug prices.

**Figure 2 Year-over-Year Changes in the PMPI 1988-1997**



\* Revised  
Source: PMPRB

**Figure 3 Year-over-Year Changes in PMPI, IPPI (pharma) and CPI 1988-1997**




Sources: PMPRB and Statistics Canada

<sup>7</sup> See the PMPRB's *A description of the Laspeyres methodology used to construct the Patented Medicine Price Index (PMPI)*, April, 1997, for an explanation of the PMPI.


<sup>8</sup> To facilitate and encourage compliance by patentees, the PMPRB's CPI-adjusted methodology uses the forecast rate of CPI inflation published by the Department of Finance. The methodology is self-correcting over time. The forecast CPI inflation rate for 1992 had been 3.2% but the actual rate was 1.5%. For a full explanation of the CPI-adjusted methodology please refer to Schedule 4 of the PMPRB's *Compendium of Guidelines, Policies and Procedures*.

**Figure 4 Summary of Price Trends  
Average Annual Percentage Changes  
1982-1987; 1988-1997**



Sources: PMPRB and Statistics Canada

**Figure 5 Year-over-Year Changes in the IPPI (pharma),  
NPMPI and PMPI 1988-1997**



Sources: PMPRB and Statistics Canada

## Industrial Product Price Index (IPPI)

The pharmaceutical component of the Industrial Product Price Index [IPPI (pharma)], published by Statistics Canada, provides an index of manufacturers' prices for all pharmaceuticals, including both patented and non-patented drugs. In 1997, the IPPI (pharma) decreased by 0.7%. This is the first year that the prices of all drugs, as measured by Statistics Canada, went down. Figure 3 also shows that, with the exception of 1997, the IPPI (pharma) has increased every year since the creation of the PMPRB by an amount greater than the PMPI, and closer to changes in the CPI. In 1997, the IPPI was slightly below the PMPI.

As summarized in Figure 4, from 1988 to 1997, the IPPI (pharma) has increased on average by 2.2%, about 20% less than the average annual increase in the CPI of 2.8%. In contrast, prices for patented drugs have increased at a significantly lower rate over that period, by 1.0% per year on average.

Figure 4 also shows information on pharmaceutical price trends prior to the creation of the PMPRB in 1987. From 1982 to 1987, when there was no direct regulation of drug prices, price increases of all drugs, as measured by the IPPI (pharma), averaged 9.0% per year as compared with increases in the CPI of 5.6% per year. The decline in the rate of increase in the prices of all drugs relative to the CPI coincided with the introduction of federal price regulation of patented drugs, which represented between 40.7% and 52.3% of the sales of all drugs since 1988.

These trends imply that limiting price increases for all patented drugs has contributed to keeping the rate of increase in prices for all drugs lower than would otherwise have been the case.

## Non-Patented Medicine Price Index (NPMPI)

There is no source of detailed price information for non-patented drugs that is comparable to the information for patented drugs. Therefore, it is necessary to estimate trends in prices of non-patented drugs from other sources. A non-patented medicine price index (NPMPI) can be derived from the IPPI (pharma) and the PMPI. The IPPI (pharma) and the PMPI track the factory-gate prices of drug products; the IPPI (pharma) includes all drugs regardless of patent status, while the PMPI captures the complete basket of patented drug products. Given these two indices, it is reasonable to derive the NPMPI.<sup>9</sup>


Figure 5 shows how the NPMPI increased at a higher annual rate relative to the IPPI (pharma) and the PMPI from 1987 to 1996. In 1997, this trend was reversed. The change in non-patented drug prices was about one percentage point below the change in patented drug prices; non-patented drug prices fell by 1.3%, while patented drug prices fell by 0.1%.

## Price Trends in Canada and the United States

The trends in drug prices in Canada can be compared with those in the United States. Figures 6 and 7 compare the annual changes in the pharmaceutical component of the U.S. Product Price Index [PPI (pharma)] to the annual changes in the IPPI (pharma) both before and after the introduction of federal price regulation in Canada. The U.S. PPI (pharma) measures price increases of all pharmaceuticals at the factory-gate. It is similar in construction to the Canadian IPPI.


Figure 6 shows the year-over-year changes in the U.S. PPI (pharma) and the Canadian IPPI (pharma) from 1982 and in the PMPI from 1988. Prior to the introduction of federal price regulation, the Canadian IPPI (pharma) increased in every year at a rate above the U.S. PPI (pharma). That trend reversed in 1987. In 1997, the U.S. PPI (pharma) increased by

**Figure 6** Year-over-Year Changes in Pharmaceutical Price Indices, Canada and the U.S.  
1982-1997



Sources: PMPRB, Statistics Canada and the U.S. Bureau of Labor Statistics

**Figure 7** Summary of Price Trends  
Average Annual Percentage Changes  
1982-1987; 1988-1997



Sources: Statistics Canada, the U.S. Bureau of Labor Statistics and the PMPRB

2.0% from 1996 compared to the decrease of 0.7% for the Canadian IPPI (pharma).

Figure 6 also shows that, since 1987, the PMPI grew every year at a much lower rate than the U.S. PPI (pharma).

9 See the PMPRB's *The Impact of Federal Regulation of Patented Drug Prices*, February 1997.

Figure 7 shows these trends in summary form during the periods prior to and after the introduction of federal price regulation. From 1982 to 1987, Canadian drug prices, as measured by the IPPI (pharma), increased by almost 9% per year, more than the average annual rate of increase of 7.1% in the U.S. By contrast, the average annual rate of increase in

the IPPI (pharma) declined to 2.2% from 1988 to 1997, well below the rate of 4.7% for the U.S. PPI (pharma). The average annual rate of increase of patented drug prices in Canada was only 1.0% from 1988 to 1997.

## Relationship of Canadian Prices to Foreign Prices: Past and Present


The above price indices demonstrate how prices of drugs in Canada have changed over time. Another important role of price controls is to limit the introductory prices of new drug products in the Canadian market. One way of examining the combined effect of controls on introductory prices and price increases is to examine the trend in the relationship of prices in Canada to those in other countries. The next three figures show the relationship between Canadian prices of patented drugs and foreign prices over time.

Figure 8 shows the relationship between Canadian prices and median prices in the seven countries used for price comparison purposes, as listed in the *Patented Medicines Regulations*, over the period from 1987 to 1997.<sup>10</sup> It shows that the average ratio of Canadian prices to median foreign prices has declined from 1.23 in 1987 to 0.89 in 1997. In other words, Canadian prices for patented drugs have declined from 23% above foreign prices to approximately 11% below. This represents about a 30% fall in the level of Canadian prices over this time period. This calculation is based on a revenue-weighted average of the ratio of the Canadian price to median international price for each patented drug product sold in that year.

Figures 9 and 10 show the relationship between Canadian prices and prices in each of the countries listed in the Regulations in 1987 and 1997. Figure 9 shows that in 1987, Canadian prices were, on average, below the U.S. but above the prices in all other countries. While Canadian prices were, on average, 36% below those in the U.S., they were almost twice as

**Figure 8 Ratio of Canadian Prices to Median International Prices**


1987-1997



Source: PMPRB

**Figure 9 Average Foreign to Canadian Price Ratios**

All Patented Drug Products in 1987



Source: PMPRB data, weighted by net sales

<sup>10</sup> France, Germany, Italy, Sweden, Switzerland, U.K., U.S.



*By 1997, Canada ranked third lowest, just below the U.K.*

high as prices in Italy and France. As shown in Figure 10, by 1997 Canadian prices relative to prices in each of the countries had changed dramatically. Canada ranked third lowest, just below the U.K. Prices


in the U.S., Switzerland, Germany and Sweden were higher, on average, while Italy and France were lower.

## Increased Expenditures on Drugs

The above price indices show that since 1987, manufacturers' prices of all drugs, and patented drugs in particular, have increased at a more modest rate than before or have declined. Despite this moderation in price increases, total expenditures (including the manufacturer's price, markup and dispensing fees) on drugs have increased more rapidly. In 1996, according to the latest figures published by Health Canada, total expenditures on drugs have increased faster than other major components of health care, and reached 14.4% of total health expenditures (see Figure 11). Overall drug expenditures increased by 2.7% in 1996, 4.0% in 1995 and 3.6% in 1994 (see Figure 12).


Several factors may account for this phenomenon of increasing total drug expenditures and moderating manufacturers' drug prices. The first issue which must be recognized in trying to explain any price-cost discrepancy is that total expenditures include wholesale or retail mark-ups as well as pharmacists' dispensing fees. Statistics Canada measures retail price changes of prescription drugs, including mark-ups and dispensing fees, with the Consumer Price Index for prescribed medicines, CPI (Rx). Since 1994, prices of prescription medicines at the retail level have been virtually constant as shown in Figure 13, even though total expenditures on drugs have been increasing.

**Figure 10 Average Foreign to Canadian Price Ratios**  
*All Patented Drug Products in 1997*



Source: PMPRB data, weighted by net sales

**Figure 11 Drug Expenditures as a Percentage of Total Health Expenditures 1975-1996**




Source: Health Canada

The second issue which contributes to the confusion of rising drug costs in the face of moderating prices is the fact that the total drug "bill" (i.e. expenditures) is a function of a number of factors as outlined in Figure 14.<sup>11</sup> These factors often have an independent impact on total expenditures of drugs.

<sup>11</sup> This figure is reproduced from the PMPRB's Discussion Paper, *Examining the Role, Functions and Methods of the Patented Medicine Prices Review Board*, November 1997.


Therefore, the control of one factor (e.g. drug prices at the factory or retail level) does not necessarily mean control of total expenditures. As an example, even if drug prices go down (as has more recently been the case), any change in the other factors affecting total expenditures may drive up total expenditures.

**Figure 12 Year-over-Year Changes in Drug Expenditures 1976-1996**



Source: Health Canada

**Figure 13 Year-over-Year Changes in the CPI (Rx) Index 1988-1997**



Source: Statistics Canada

**Figure 14 Factors Affecting Total Drug Expenditures**

- changes in the total population
- changes in the demographics and health status of the population (i.e. towards those with increased medication needs)
- changes in the unit prices of drugs (both patented and non-patented)
- changes in retail and wholesale mark-ups and dispensing fees
- changes in the prescribing habits of physicians (i.e. from older, less expensive medications to newer, relatively more expensive medications [± improved therapeutic effect] to treat the same underlying diagnosis)
- changes in utilization of drugs on a per patient basis (i.e. more medications per patient per year)
- trends towards using drug therapy instead of other treatments (e.g. as alternatives to surgery in some cases)
- new diseases to be treated
- old diseases to be treated, where there existed no treatment before; old diseases better treated

## Trends in Quantities of Sales of Patented Drug Products

Data available to the PMPRB allow it to measure changes in the quantities as well as the prices of patented drugs sold from year to year. This analysis reveals that the quantities of patented drugs sold have consistently increased at a much faster rate than prices. As shown in Figure 15, this trend has escalated in 1997.

In 1997, prices for patented medicines declined by 0.1%, on average, but the quantities sold increased by about 20%. In other words, while total sales of patented drugs increased by 22.6% in 1997, 88% of that increase is attributable to an increase in the amount of existing patented drugs consumed. About 12% of the increase in patented drug expenditures is attributable to the introduction of new patented drugs. Finally, the overall change in patented drug prices had virtually no impact in driving up the annual change in patented drug expenditures.

From 1988 to 1997, the average annual increase in quantities of patented drugs sold was approximately 10% as compared with an average annual increase of 1.0% in their prices.



The index for the quantities of patented drugs sold may not be representative of total sales of all pharmaceuticals because patented drugs have represented between 41% and 52% of total sales since 1990. Among other things, this analysis does not take into account shifts in utilization between patented drugs and non-patented drugs, nor does it account for changes in patent status. For example, drugs continue to be consumed even though their patents expire and their prices are no longer subject to the PMPRB's jurisdiction.


## Sales by Major Therapeutic Group

For price review purposes, the PMPRB classifies all drugs sold in Canada according to the Anatomical Therapeutic Chemical (ATC) classification system.

Table 2 breaks out the 981 patented drug products sold during 1997 according to major therapeutic groups, showing the total expenditures, proportion of total expenditures and growth in expenditures from 1996. (The breakdown for patented medicines may differ from that for all drugs, including non-patented medicines.)

As shown in Table 2, the largest growth in patented drug expenditures came from the Blood and blood forming organs, Sensory organs, Antineoplastics and immuno-modulating agents and Cardiovascular system groups. These groups experienced an increase in expenditures above 30% from the previous year. The average increase in expenditure over all therapeutic groups was 22.6%.

**Figure 15 Year-over-Year Changes in the PMPI and in the Quantity Index 1988-1997**



Source: PMPRB

**Table 2 Patented Drug Expenditures by Major Therapeutic Group, 1997**

Major Therapeutic Group	1997 Expenditures (\$Millions)	Proportion of total Expenditures in 1997	Growth in Expenditures from 1996	
			\$M	%
Alimentary tract and metabolism	526.1	14.4	78	17.4
Blood and blood forming organs	91.4	2.5	54	147.0
Cardiovascular system	1,125.7	30.8	278	32.7
Dermatologicals	89.0	2.4	7	8.5
Genito-urinary system and sex hormones	90.4	2.5	-33	-33.1
Systemic hormonal preparations, excluding sex hormones	28.1	0.8	25	0.9
General antiinfectives for systemic use	518.9	14.2	81	18.5
Antineoplastics and immunomodulating agents	213.8	5.9	60	38.8
Musculo-skeletal system	107.4	2.9	18	20.7
Nervous system	469.9	12.9	80	20.5
Antiparasitic products	0.6	0.0	0	0.0
Respiratory system	226.3	6.2	31	16.1
Sensory organs	32.3	0.9	10	46.8
Various	30.9	0.9	2	6.6
Veterinary products	104.1	2.9	13	14.4
<b>Totals</b>	<b>3,655.1</b>	<b>100</b>	<b>683</b>	<b>22.6</b>

Rows and columns may not add to totals due to rounding.  
Source: PMPRB

## Compliance and Excessive Price Guidelines

Under the *Patented Medicines Regulations (Regulations)*, patentees are required to report information on the sales and prices of new patented medicines and to continue to file detailed information on sales and prices of each patented drug for the first and last six-month period of each year. The PMPRB reviews this pricing information on an ongoing basis to ensure that the prices charged by patentees comply with the Guidelines established by the Board. The Guidelines are published in the PMPRB's *Compendium of Guidelines, Policies and Procedures*.

The Guidelines are based on the price determination factors in section 85 of the *Patent Act*. In summary, the Guidelines provide that:

- prices for most new drugs are limited such that the cost of therapy for the new drug is in the range of the cost of therapy for existing drugs used to treat the same disease in Canada;
- prices of breakthrough drugs and those which bring a substantial improvement are limited to the median of the prices charged for those drugs in other industrialized countries listed in the *Regulations* (France, Germany, Italy, Sweden, Switzerland, U.K. and U.S.);
- price increases for existing medicines are limited to changes in the Consumer Price Index (CPI); and
- the price of a patented drug in Canada may, at no time, exceed the range of the prices for the same drug in foreign countries.

and the manner of calculating benchmark prices, drug products introduced or patented in December are considered to be new patented products in the following year.

There were 98 new patented drug products (DINs) representing 61 medicines sold in 1997. This is slightly higher than the average number of patented drug products introduced annually in Canada over the last several years. All but five of the new patented DINs in 1997 are for human use. Drug products for veterinary use have always been a relatively small percentage of the total number of new patented drug products.

The Board's Guidelines establish three categories of new patented drug products for purposes of conducting introductory price reviews.<sup>12</sup>

- Category 1 — a new DIN of an existing or comparable dosage form of an existing medicine, usually a new strength of an existing drug (line extension).
- Category 2 — the first drug product to treat effectively a particular illness or which provides a substantial improvement over existing drug products, often referred to as “breakthrough” or “substantial improvement.”
- Category 3 — a new drug or new dosage form of an existing medicine that provides moderate, little or no improvement over existing medicines.

### New Patented Drug Products in 1997

For purposes of the review of prices by the PMPRB, new patented drug products in 1997 include those introduced on the market in Canada or those previously marketed but first patented between December 1, 1996 and November 30, 1997. Because of the timing of the filing requirements under the *Regulations*

Figure 16 provides a breakdown by category of the new patented DINs for human use between 1991 and 1997. The proportion of DINs in each category has been relatively constant over the years. The number of category 2 drugs has usually been less than 10%. The number of category 2 drugs in 1997, 13, appears to be higher than usual and warrants closer inspection. These 13 DINs represent 6 medicines; 7 of these DINs (3 medicines) were introduced on the market

<sup>12</sup> For complete definitions of the categories, refer to the *Compendium of Guidelines, Policies and Procedures*, Chapter 3, section 3.

*There were 28 new active substances among the new patented DINs for human use in 1997.*

in Canada well before 1997 but only came under the Board's jurisdiction when they received their first patent(s) in 1997. For example, Eprex has been sold in Canada since 1990 while 3TC has been on the market since 1995.


Table 12, on page 39, lists the drug products included in each category in 1997.

## New Active Substances in 1997

Among the new patented DINs for human use sold in Canada in data-year 1997, there were 28 new active substances (NASs) compared to 21 NASs in 1996 and 20 NASs in 1995. Of the 28 NASs, four were introduced on the market in Canada prior to 1997 but only received their first patent(s) in 1997. A listing of the NASs and their assigned categories appears in Table 3. A NAS may represent more than one drug product if it is sold in more than one strength or dosage form. The 28 NASs listed were marketed as 51 presentations (DINs) in 1997. Manufacturers filed category 2 submissions for 10 of the patented NASs (20 DINs) listed in Table 3; five of the 10 were classified by the Human Drug Advisory Panel (HDAP) as category 2 new medicines following review of the patentee's submission. One other new medicine, Indinavir, (trade name: Crixivan) was classified as a category 2 drug by the HDAP without a submission from the patentee. All three of the protease inhibitor drug products approved and introduced in Canada for HIV therapy in 1996 were considered to be category 2 new drug products (i.e. Norvir, Crixivan and Invirase).

The PMPRB's list of patented NASs in any year may differ from the list of NASs approved by the Health Protection Branch (HPB). In some circumstances, a patented drug may be sold under the Special Access Program (SAP) before it receives a Notice of

**Figure 16 Categorization of New Patented Drug Products (Human)**



Source: PMPRB

Compliance (NOC); or it may be approved but not be introduced until some time later. For example, 18 of the 28 patented NASs were granted a NOC by HPB in 1997; eight in 1996; one in 1995 and one in 1990. The HPB list of New Active Substances, which reports on the NASs that received a NOC in 1997, lists 42 NASs; not all were introduced to the market in that year. In addition, not all NASs approved by HPB are subject to the PMPRB's jurisdiction. Twenty-four of the 42 NASs approved by HPB in 1997 are patented medicines and four more are known to the PMPRB as having patents pending.




Photo courtesy of the National Research Council Canada

## Price Review of New Patented Drugs in 1997

All 98 of the 1997 new patented drug products (DINs) were categorized as listed in Table 12. The majority (94%) were found to be priced within the Guidelines.

Of the 98 products, six are under review pending the review of additional information and two have been found to be outside the Guidelines and are the subject of an investigation.

**Table 3 New Patented Medicines in 1997  
New Active Substances (Human)**

Chemical Name	Brand Name	Company	Category	ATC CLASS
<b>New Active Substances Introduced in 1997 (NAS)</b>				
ACELLULAR PERTUSSIS VACCINE	ACEL-P	WYETH-AYERST CANADA	3	J07AJ
ANISTREPLASE	EMINASE	ROBERTS PHARMACEUTICAL	3	B01AD
ATORVASTATIN	LIPITOR	WARNER-LAMBERT CANADA	3	C10AA
COAGULATION FACTOR IX	BENEFIX	GENETICS INSTITUTE	2	B02BD
DAPT VACCINE	TRIPACEL	CONNAUGHT LABORATORIES	3	J07AJ
DAPT-IPV VACCINE	QUADRACEL	CONNAUGHT LABORATORIES	3	J07AJ
DAPT-IPV-HIB VACCINE	PENTACEL	CONNAUGHT LABORATORIES	3	J07AG
DESFLURANE	SUPRANE	ZENECA PHARMA INC.	3	N01AB
DOLASETRON MESYLATE	ANZEMET	HOECHST MARION ROUSSEL	3	A04AA
DONEPEZIL HYDROCHLORIDE	ARICEPT	PFIZER CANADA INC.	2	N07AA
EPOPROSTENOL	FLOLAN	GLAXO WELLCOME INC.	3	B01AC
FEXOFENADINE HYDROCHLORIDE	ALLEGRA	HOECHST MARION ROUSSEL	3	R06AX
FORMOTEROL FUMARATE	FORADIL	SANDOZ CANADA	3	R03AC
IRINOTECAN HYDROCHLORIDE	CAMPTOSAR	PHARMACIA & UPJOHN INC.	2	L01XX
LATANOPROST	XALATAN	PHARMACIA & UPJOHN INC.	3	S01EX
LETROZOLE	FEMARA	SANDOZ CANADA	3	L02BG
PANTOPRAZOLE SODIUM	PANTOLOC	SOLVAY KINGSWOOD INC.	3	A02BC
ROPINIROLE HYDROCHLORIDE	REQUIP	SMITHKLINE BEECHAM PHARMA	3	N04BC
ROPIVACAINE HYDROCHLORIDE	NAROPIN	ASTRA PHARMA INC.	3	N01BB
TAZAROTENE	TAZORAC	ALLERGAN INC.	3	D05AX
TECHNETIUM TC-99M TETROFOSMIN	MYOVIEW	AMERSHAM CANADA LTD.	3	V09AG
TOLCAPONE	TASMAR	HOFFMAN-LA ROCHE LTD.	3	N04BX
TOPIRAMATE	TOPAMAX	JANSSEN PHARMACEUTICAL	3	N03AX
TOPOTECAN HYDROCHLORIDE	HYCAMTIN	SMITHKLINE BEECHAM	3	L01XX
<b>First Patent Granted in 1997 (FPG)</b>				
EPOETIN ALFA	EPREX	JANSSEN PHARMACEUTICAL	2	B03XA
INDINAVIR SULFATE	CRIVAN	MERCK FROSST CANADA	2	J05AE
LAMIVUDINE	3TC	GLAXO WELLCOME INC.	3	J05AB
SAQUINAVIR MESYLATE	INVIRASE	HOFFMAN-LA ROCHE LTD.	2	J05AE

## Patent Pending

When a medicine, subject to a pending patent, is being sold, the Board will, when the patent is issued, review the price at which the medicine was sold during the pre-grant infringement period. This is normally from the date the patent is first laid open for inspection. The Board encourages patentees to seek advisory assistance during this patent pending period to ensure that the medicine is not being sold at an excessive price before the patent issues.

On April 29, 1998, the Board accepted a Voluntary Compliance Undertaking (VCU) in respect of Humalog, a medicine for which the patent is pending. Details of the circumstances and the VCU can be found at page 26.

## Price Review of Existing Patented Drug Products in 1997

For the purposes of this report, existing medicines include all patented drug products that were on the market before 1997. The PMPRB's Guidelines limit the price changes for existing patented drugs to changes in the Consumer Price Index (CPI). In addition, the price of a patented drug product cannot exceed the highest price of the same drug product in the countries listed in the *Regulations*.<sup>13</sup>

A total of 893 existing patented drug products were sold during 1997. The prices of 880 drug products (over 98%) were reviewed and found to be within the Guidelines. A drug product is considered to be within the Guidelines if its price does not exceed the maximum allowable price and does not meet the criteria established for the commencement of an investigation.<sup>14</sup>



Photo courtesy of Health Canada

At the time of this report, the prices of 13 drug products (nine medicines) are under investigation. Of these 13 drug products, six involve similar issues and are being reviewed simultaneously. In the seven remaining cases, the manufacturers have been notified and the Board is awaiting their responses.

## Update of the Ninth Annual Report

In the 1996 Annual Report, the PMPRB had reported that eight drug products (new and existing) were under review. Since then, six cases have been resolved through receipt of additional evidence which showed that the prices had been within the Guidelines. The remaining two products continue to be under review and are included in the 13 existing drug products under investigation mentioned previously.

<sup>13</sup> France, Germany, Italy, Sweden, Switzerland, U.K. and U.S.

<sup>14</sup> For a full explanation of the criteria for commencing an investigation please refer to Schedule 5 of the PMPRB's *Compendium of Guidelines, Policies and Procedures*.



## Enforcement Activities

---

### Voluntary Compliance Undertakings

---

Under the Compliance and Enforcement Policy, patentees are given an opportunity to make a Voluntary Compliance Undertaking (VCU) when Board staff conclude, following an investigation, that a price appears to have exceeded the Guidelines. Approval of a VCU by the Chairperson or Board is an alternative to the commencement of formal proceedings through the issuance of a Notice of Hearing.

The Board did not approve any VCUs in 1997, but a major investigation during 1997 resulted in a VCU in 1998, discussed below.

### HUMALOG (insulin lispro)

---

#### Eli Lilly Canada Inc.

On April 29, 1998, the Chairperson of the Board approved a VCU by Eli Lilly Canada Inc. (Lilly) to reduce the manufacturer's price of Humalog by 23%, from \$30 to \$23.

On March 14, 1998, the Board had issued a public notice (Notice) in the Canada Gazette that it had received a VCU from Lilly in respect of the price of the medicine Humalog. The Notice observed that the Staff of the Board recommended the acceptance of the VCU by the Board and provided the provincial and territorial Ministers of Health and other interested persons with an opportunity to make submissions on the appropriateness of the VCU and its terms and provisions.

### Background

---

Humalog is a rapid-acting analog of human insulin that has been approved by Health Canada for the treatment of patients with diabetes mellitus who require insulin for the maintenance of glucose homeostasis. An application for a Canadian patent pertaining to Humalog, filed in 1990, is still pending but Lilly expects that a patent will be granted by the end of 1998.

In brief, the VCU provided that Lilly would lower the manufacturer's list price for Humalog by approximately 23%, such that the relationship between the prices of Humalog and regular insulin in Canada would reflect the relationship between the prices of those products in other countries.

In addition, the VCU proposed to offset all excess revenues which had been received by Lilly as a result of charging the higher price through a mechanism intended to provide Humalog at no charge to patients who had previously been treated with it.

### Submissions

---

The Board received submissions from or on behalf of Ministers of Health of six provinces: Alberta, British Columbia, Nova Scotia, Prince Edward Island, Québec and Saskatchewan. Submissions were also received from the Canadian Diabetes Association and Novo Nordisk Canada Inc.

Most of the parties agreed with the proposed price reduction and with the methodology for determining the maximum non-excessive (MNE) price.

However, all of the submissions objected to the proposed method of achieving the offset of excess revenues, being the proposed distribution of Humalog at no charge to patients who had used the medicine in the past.

### The Amended VCU

---

Following further discussions, on April 24, 1998, Lilly submitted an amended VCU that changed the proposed method of offsetting excess revenues. Pursuant to the amended VCU, Lilly undertook to make a payment to the Government of Canada to offset excess revenues of \$666,824. To the extent that any excess revenues may have been received in 1998 prior to the price reduction, they will be offset through further price reductions to ensure that the average price for Humalog in 1998 does not exceed the MNE price of \$22.1072.

## Decision

Having considered all of the submissions from interested parties and the amendments to the VCU, the Chairperson accepted the amended VCU on April 29, 1998.

While the Board was sensitive to the submissions of some parties who argued for a larger reduction in the price of Humalog, it was considered on balance that the amended VCU is consistent with the provisions of the *Patent Act* and the Board's Compliance and Enforcement Policy. The amended VCU establishes a reasonable basis for determining the MNE price for Humalog consistent with the factors set out in subsection 85(1) of the *Patent Act*. Furthermore, the amended VCU will result in an immediate price reduction for Humalog, together with the offset of past excess revenues in a manner consistent with the submissions of interested parties.

The acceptance of the amended VCU is based on the particular circumstances of the medicine Humalog and its context in the international market for analogs of human insulin. This exceptional case does not warrant a review or amendment of the Excessive Price Guidelines, which remain applicable to medicines subject to the Board's jurisdiction.

## Use of the Funds Paid to the Government of Canada

Under the *Patent Act*, the Board has no authority to order that funds paid to the Government of Canada to offset excess revenues be used for certain purposes. Pursuant to section 103 of the *Act*, the Ministers of Health in Canada have agreed in principle that funds collected as a result of Board Orders and VCUs be distributed to the provinces on a per capita basis. They further agreed that such funds should be used for pharmaceutical objectives.

In this case, the Canadian Diabetes Association recommended that any payment to governments should be directed towards a national diabetes related initiative. The Board brought that recommendation to the attention of governments.

Copies of the VCU, Public Notice and Reasons are available from the Secretary to the Board or on the Board's web site at <http://www.pmprb-cepmb.gc.ca>.

*The Board invited comments relating to Humalog prior to deciding whether to accept a proposed VCU to lower the price of this medicine.*



# Analysis of Research-and-Development (R&D) Expenditures

*The ratio of R&D expenditures to sales revenues for the patented pharmaceutical industry was 11.5% in 1997.*

With the adoption of the 1987 amendments to the *Patent Act*, the Pharmaceutical Manufacturers Association of Canada (PMAC) made a public commitment that the brand name pharmaceutical industry would increase its annual R&D expenditures as a percentage of sales to 10% by 1996.

Under the *Patent Act*, the PMPRB monitors and reports on R&D spending by patentees but it has no regulatory authority to influence the type of research or amount of R&D spending by patentees. The *Act* requires the PMPRB to report on how much each patentee spends annually on pharmaceutical R&D in relation to revenues and on how much the patented industry as a whole spends on R&D. For individual patentees, this calculation includes all revenues from Canadian sales of medicines, including revenues from licensing agreements.

## Data Sources

Companies that reported sales of patented medicines in 1997 were also required to file R&D data for that calendar year as per the

*Patented Medicines Regulations (Regulations)*. Only companies with active Canadian patents pertaining to a medicine sold in Canada are required by the *Patent Act* to report on R&D expenditures. As new patents are granted and others expire, the group of companies required to file R&D data may change from year to year.

For 1997, 75 companies, including 35 PMAC members, filed reports on R&D. The data from these firms are the basis of this report. The total R&D expenditures for the 35 PMAC members totalled \$657.4 million in 1997, or 90.7% of the total R&D expenditures for the patented pharmaceutical industry as a whole; and their sales revenues totalled \$5,098.2 million, accounting for 81.1% of the total sales revenues.

## R&D Expenditures

Pursuant to the *Regulations*, patentees must report those R&D expenditures that would have been eligible for an Investment Tax Credit for scientific research and experimental development under the provisions of the *Income Tax Act* in effect on December 1, 1987. Market research, sales promotions, quality control or routine testing of materials, devices or products and routine data collection are

**Table 4 Total R&D Expenditures\* and R&D-to-Sales Ratios, 1988 - 1997**

Year	Companies Reporting	Total R&D Expenditures* (\$M)	Change from Previous Year (%)	Total Sales Revenues (\$M)	Change from Previous Year (%)	R&D-to-Sales Ratio All Patentees (%)	R&D-to-Sales Ratio PMAC Patentees (%)
1997	75	725.1	9.0	6,288.4	7.4	11.5	12.9
1996	72	665.3	6.4	5,857.4	9.9	11.4	12.3
1995	71	625.5	11.5	5,330.2	7.5	11.7	12.5
1994	73	561.1	11.4	4,957.4	4.4	11.3	11.6
1993	70	503.5	22.1	4,747.6	14.0	10.6	10.7
1992	71	412.4	9.6	4,164.4	6.9	9.9	9.8
1991	65	376.4	23.2	3,894.8	18.1	9.7	9.6
1990	65	305.5	24.8	3,298.8	11.0	9.3	9.2
1989	66	244.8	47.4	2,973.0	9.4	8.2	8.1
1988	66	165.7	-	2,718.0	-	6.1	6.5

\* Total expenditures include federal and provincial government grants, capital equipment expenditures and allowable depreciation expenses.

Source: PMPRB

among the expenditures that are not eligible for an Investment Tax Credit and therefore are **not** included in the patentees' filings. Total R&D expenditures include current expenditures, capital equipment costs and allowable depreciation expenses.

## Revenues from Sales

The 75 patentees reported total revenues of \$6.3 billion from Canadian sales of patented and non-patented drugs in 1997, up 7.4% over 1996. Of total sales revenues, less than 1% was generated by licensing agreements.

## R&D-to-Sales Ratios

The ratio of R&D expenditures to sales revenues for the patented pharmaceutical industry was 11.5% in 1997, up from 11.4% in 1996. The ratio for the 35 companies that were members of the PMAC was 12.9% in 1997, up from 12.3% in 1996.

As shown in Table 5, of the 75 reporting companies, 18 companies (24.0%) reported having performed no R&D in 1997 compared to 11 in 1996. Sales revenues for companies with no R&D totalled \$335.2 million in 1997 accounting for 5.3% of total sales revenues for the patented pharmaceutical companies. The category of R&D-to-sales ratios between 0% and 10% experienced both a decrease in the number of companies and in the total sales revenues in 1997. There were 32 companies with total sales of \$1,879.8 million in 1997 as compared to 34 companies with total sales of \$2,000.4 million in 1996. The sales revenues



Photo courtesy of the National Research Council Canada

for companies with ratios of 10% or more experienced an increase of 8.8% in the total sales from \$3,744.6 million in 1996 to \$4,073.4 million in 1997 while the number of companies included in this category fell by 7.4%.

As shown in Table 4, patentees reported total R&D expenditures of \$725.1 million in 1997, an increase of 9.0% over 1996. Current expenditures accounted for \$679.2 million or 93.7% of total R&D expenditures. Capital equipment costs and allowable depreciation expenses amounted to 4.9% and 1.4% respectively.

Table 6 shows how current expenditures on R&D in 1997 were allocated among basic, applied, and other qualifying R&D. Total current expenditures on R&D rose by 7.8% in 1997.

**Table 5 Range of R&D-to-Sales Ratios by Number of Reporting Companies and Total Sales Revenues**

Range of R&D-to-Sales Ratio	1997			1996			% Change in Number of Reporting Companies 1997/1996	% Change in Total Sales Revenues 1997/1996
	Number of Reporting Companies	Total Sales Revenues (\$M)	%	Number of Reporting Companies	Total Sales Revenues (\$M)	%		
0%	18	335.2	5.3	11	112.4	1.9	63.6	198.2
0% to 10%	32	1,879.8	29.9	34	2,000.4	34.2	-5.9	-6.0
>10%	25	4,073.4	64.8	27	3,744.6	63.9	-7.4	8.8
Total	75	6,288.4	100	72	5,857.4	100	4.2	7.4

Source: PMPRB


**Table 6 Current R&D Expenditures\* by Type of Research, 1996 and 1997**

Type of Research	1997		1996		Change in Expenditures 1997/1996 %
	\$M	%	\$M	%	
Basic	140.4	20.7	136.6	21.7	2.8
Applied	421.3	62.0	396.4	62.9	6.3
Other Qualifying	117.5	17.3	97.1	15.4	21.0
<b>Total</b>	<b>679.2</b>	<b>100</b>	<b>630.1</b>	<b>100</b>	<b>7.8</b>

\* Current expenditures exclude capital equipment and depreciation expenditures.


Source: PMPRB

**Figure 17 Current R&D Expenditures by Type of Research 1988-1997**



Source: PMPRB

**Figure 18 Share of Current R&D Expenditures by Type of Research 1988-1997**



Source: PMPRB

Spending on basic research was \$140.4 million or 20.7% of the total. Basic research is defined as work that advances scientific knowledge without a specific application in view. The lion's share of R&D spending continued to be on applied research, \$421.3 million or 62.0% of the total. Applied research is directed towards some practical application, comprising the

manufacturing process, pre-clinical trials and clinical trials. Clinical trials accounted for 79.2% of total applied research expenditures, \$333.7 million, while manufacturing process accounted for \$51.0 million, or 12.1% of the total, and pre-clinical trials accounted for \$36.6 million or 8.7% of the total. Other qualifying research expenditures are for drug regulation submissions, bioavailability studies and Phase IV clinical trials.

Figure 17 shows current expenditures on R&D by type of research from 1988 to 1997 and Figure 18 shows their shares of expenditures during those years.

While spending on basic research went up by 2.8% in 1997, its share of total R&D continued to decline from 21.7% in 1996 to 20.7% in 1997.

Pharmaceutical patentees may report their expenditures on research they conduct themselves (intra-mural) and research performed by others, including universities and hospitals and other manufacturers (extra-mural). Table 7 presents the current R&D expenditures by R&D performer and identifies the intra-mural and extra-mural expenditures. Most R&D was carried out by patentees. In 1997, 55.3% of R&D expenditures was directed to R&D performed by the patentee, compared with 55.6% in 1996. Expenditures on R&D performed by universities and hospitals decreased by 2.8% to \$142.7 million from 1996. Expenditures on R&D performed by other companies on behalf of patentees increased, from \$70.3 million in 1996 to \$79.4 million in 1997, a 12.9% increase. The largest increase occurred in the category "others."

The category “others” includes individuals, organizations such as private clinics, and federal and provincial governments. This category incurred an increase of 30.3%.

In 1997, as in previous years, most of the R&D expenditures of pharmaceutical patentees were funded internally. Table 8 shows that in 1997, more than 98% of all patentees’ R&D was funded by internal funds and funds provided by associated companies. The share of funding by governments increased to 1.0% and the share of others slightly decreased to 0.8%.

In 1997, R&D spending increased in all regions. The largest increases occurred in the Atlantic and Western provinces, by 45.5% and 11.3% respectively. There was no significant change in the regional distribution of R&D spending in 1997. As shown in Table 9, almost 90% of total expenditures continued to be made in Ontario and Québec. Table 11, on page 34, lists the current R&D expenditures by province and by R&D performer for 1997.

**Table 7 Current R&D Expenditures\* by R&D Performer, 1996 and 1997**

R&D Performer	1997		1996		Change 1997/1996 %
	\$M	%	\$M	%	
Intra-mural					
Patentees	375.8	55.3	350.6	55.6	7.2
Extra-mural					
Universities and Hospitals	142.7	21.0	146.8	23.3	-2.8
Other Companies	79.4	11.7	70.3	11.2	12.9
Others	81.3	12.0	62.4	9.9	30.3
Total	679.2	100	630.1	100	7.8

\* Current expenditures exclude capital equipment and depreciation expenditures.

\* Current expenditures exclude capital equipment and depreciation expenditures.

Source: PMPRB

**Table 8 Total R&D Expenditures\* by Source of Funds, 1996 and 1997**

Source of Funds	1997		1996		Change 1997/1996 %
	\$M	%	\$M	%	
Company Funds	712.1	98.2	654.4	98.4	8.8
Federal/Provincial Governments	7.3	1.0	4.7	0.7	55.3
Others	5.7	0.8	6.2	0.9	-8.1
<b>Total</b>	<b>725.1</b>	<b>100</b>	<b>665.3</b>	<b>100</b>	<b>9.0</b>

\* Total expenditures include capital equipment and allowable depreciation.

Source: PMPRB

**Table 9 Current R&D Expenditures\* by Location, 1996 and 1997**

Location of R&D	1997		1996		Change 1997/1996 %
	\$M	%	\$M	%	
Atlantic Provinces	16.0	2.4	11.0	1.8	45.5
Québec	290.6	42.8	264.7	42.0	9.8
Ontario	296.6	43.7	286.1	45.4	3.7
Western Provinces	76.0	11.2	68.3	10.8	11.3
Yukon and N.W.T.	0.17	0.0	0.0	0.0	n/a
<b>Total</b>	<b>679.41<sup>1</sup></b>	<b>100</b>	<b>630.1</b>	<b>100</b>	<b>7.8</b>

\* Current expenditures exclude capital equipment and depreciation expenditures.

<sup>1</sup> Table may not balance due to roundings. For more details on provincial breakdown, refer to Table 11.

Source: PMPRB

**Table 10 Ratios of R&D Expenditures to Sales Revenues  
by Reporting Patentee<sup>1</sup>, 1996 and 1997**

Company	R&D-to-Sales Ratio (%)	
	1997	1996
3M Pharmaceuticals, 3M Canada Inc.	2.3	2.0
Abbott Laboratories, Limited	1.7	1.9
Alcon Canada Inc.	0.0	0.02
Allergan Inc.	7.2	15.6
Alpha Therapeutic Corporation	0.0	0.0
AltiMed Pharmaceutical Company	0.0	0.0
Amersham Canada Limited	2.9	1.2
Amgen Canada Inc.	79.9 <sup>2</sup>	99.9 <sup>2</sup>
Astra Pharma Inc.	12.1	13.9
Ayerst Veterinary Laboratories	0.0	0.8
Baxter Corporation	0.2	0.2
Bayer Inc.	8.3	8.7
Bayer Inc., Agriculture Division	4.5	4.7
Berlex Canada Inc.	10.3	8.0
Block Drug Company (Canada) Ltd.	0.0	0.0
Boehringer Ingelheim (Canada) Ltd.	46.4	37.3
Boehringer Mannheim Canada Ltd.	5.7	8.0
Bracco Diagnostics Canada Inc.	0.0	0.0
Bristol-Myers Squibb Pharmaceutical Group	10.5	11.9
Canderm Pharma Inc.	3.0	2.5
Cangene Corporation	183.6 <sup>2</sup>	271.5 <sup>2</sup>
Carter-Horner Inc.	6.2	6.0
CIBA Vision Canada Inc.	1.8	<sup>3</sup>
Colgate Oral Pharmaceuticals (not a patentee in 1996)	0.0	
Dahi Animal Health Inc.	0.0	0.0
Dermik Laboratories Canada Inc.	0.0	0.0
Draxis Health Inc.	5.3	10.9
Du Pont Merck Pharma Inc.	8.3	9.4
Eli Lilly Canada Inc. (includes Elanco Animal Health Division)	15.2	12.2
Fabrigen Inc.	0.0	0.0
Ferring Inc.	3.9	2.5
Fournier Pharma Inc.	10.3	11.1
Fujisawa Canada Inc.	14.0	17.9
Galderma Canada Inc.	0.0	0.0
GenDerm Canada Inc.	1.2	0.9
Genetics Institute Inc. (not a patentee in 1996)	0.0	
Glaxo Wellcome Inc.	12.9	11.5
Hoechst Marion Roussel Canada Inc.	20.9	15.1
Hoffmann-La Roche Limited	9.4	10.2
ICN Canada Limited	4.8	7.0
Immuno (Canada) Ltd.	0.0	0.8
Janssen-Ortho Inc.	13.6	10.6
Johnson & Johnson Merck Consumer Pharmaceuticals of Canada	0.0	0.05

continued

**Table 10 continued**

Company	R&D-to-Sales Ratio (%)	
	1997	1996
Leo Laboratories Canada Ltd.	8.5	8.7
Ligand Pharmaceuticals (Canada)	48.0 <sup>2</sup>	98.8 <sup>2</sup>
Mallinckrodt Medical Inc.	1.1	1.3
Mallinckrodt Veterinary Inc.	3.5	1.3
McNeil Consumer Products Company	1.9	2.5
Merck Frosst Canada Inc.	13.1	14.4
Nexstar Pharmaceuticals Inc.	0.0	0.0
Novartis Animal Health Canada Inc.	0.3	4
Novartis Consumer Health Canada Inc.	2.9	5
Novartis Pharmaceuticals Canada Inc.	10.7	6
Novo Nordisk Canada Inc.	0.5	1.4
Nycomed (Canada) Inc. (not a patentee in 1996)	0.0	
Organon Canada Ltd.	2.0	2.2
Pasteur Mérieux Connaught Canada <sup>7</sup>	70.0	68.8
Pfizer Canada Inc.	12.5	11.3
Pharmacia & Upjohn Inc.	11.0	11.6
Procter & Gamble Pharmaceuticals Canada, Inc.	10.2	14.1
Purdue Frederick	6.4	7.9
Rhône-Poulenc Rorer Canada Inc.	11.0	10.1
Roberts Pharmaceutical Canada Inc. (not a patentee in 1996)	0.0	
Sanofi Winthrop	13.6	11.8
Schering Canada Inc.	13.2	7.1
Searle Canada Inc.	11.4	6.2
SmithKline Beecham Pharma Inc.	10.0	9.0
Solvay Pharma Inc.	9.3	14.2
The Liposome Company Inc.	5.0	0.0
Warner-Lambert Canada Inc. (Parke-Davis)	12.0 <sup>8</sup>	17.6
Warner-Wellcome Consumer Health Products	2.0	2.4
Westwood-Squibb	0.7	0.5
Wyeth-Ayerst Canada Inc.	13.1	12.6
Yamanouchi Pharmaceutical Co., Ltd.	0.0	0.0
Zeneca Pharma Inc.	7.6	7.6

1 The revenues from royalties are included in calculating each company's ratio, but are deducted, when appropriate, for the industry-wide aggregation to avoid double-counting. Federal and provincial government grants have been netted from the expenditures used to calculate the individual R&D-to-sales ratios but are included in the aggregate statistics. Differences between the list of firms filing data on prices and those filing R&D data are due to differences in reporting practices between patentees and their affiliates or licensees.

2 These ratios have been verified with the firm and are due to the fact that funding for R&D expenditures was provided by associated companies.

3 Formerly under CIBA-Geigy Canada Ltd. The R&D-to-sales ratio for CIBA-Geigy Canada Ltd. was 7.6% in 1996.

4 Sandoz Canada Inc. and CIBA-Geigy Canada Ltd. merged in 1997. The R&D-to-sales ratio for Sandoz Canada Inc. and CIBA-Geigy Canada Ltd. were, respectively, 12.0% and 7.6% in 1996. Novartis Animal Health Canada Inc. includes veterinary products that were previously sold by CIBA-Geigy Canada Ltd.

5 Sandoz Canada Inc. and CIBA-Geigy Canada Ltd. merged in 1997. The R&D-to-sales ratio for Sandoz Canada Inc. and CIBA-Geigy Canada Ltd. were, respectively, 12.0% and 7.6% in 1996. Novartis Consumer Health Canada Inc. includes over counter products that were previously sold by CIBA-Geigy Canada Ltd. and Sandoz Canada Inc.

6 Sandoz Canada Inc. and CIBA-Geigy Canada Ltd. merged in 1997. The R&D-to-sales ratio for Sandoz Canada Inc. and CIBA-Geigy Canada Ltd. were, respectively, 12.0% and 7.6% in 1996. Novartis Pharmaceuticals Canada Inc. includes prescription drug products for human use previously sold by CIBA-Geigy Canada Ltd. and Sandoz Canada Inc.

7 Formerly known as Connaught Laboratories Limited.

8 Warner-Lambert Canada Inc. (Parke-Davis) purchased Jouvenal Inc. in 1997. The R&D-to-sales ratio for Jouvenal Inc. was 2.8% in 1996.

Source: PMPRB



**Table 11 Current R&D Expenditures by Province and by R&D Performer, 1997**

Province		R&D Performer						Percentage of Expenditures
		Patentees	Other Companies	University	Hospitals	Others	Total	
Newfoundland	\$(000) %	831.94 29.1	211.24 7.4	681.19 23.8	761.33 26.6	373.64 13.1	2,859.32 100	0.42
Prince Edward Island	\$(000) %	84.14 24.6	22.30 6.5	121.15 35.4	5.04 1.5	109.93 32.1	342.56 100	0.05
Nova Scotia	\$(000) %	1,325.43 12.8	947.36 9.1	2,703.19 26.1	3,700.90 35.7	1,699.88 16.4	10,376.76 100	1.53
New Brunswick	\$(000) %	127.10 5.3	661.99 27.7	189.55 7.9	724.76 30.4	683.75 28.6	2,387.15 100	0.35
Quebec	\$(000) %	185,502.21 63.8	41,489.24 14.3	8,411.60 2.9	23,905.16 8.2	31,247.54 10.8	290,555.75 100	42.78
Ontario	\$(000) %	174,089.80 58.7	25,798.85 8.7	15,945.84 5.4	45,264.76 15.3	35,476.6 12.0	296,575.84 100	43.66
Manitoba	\$(000) %	5,705.95 45.2	663.17 5.3	1,519.92 12.1	3,218.54 25.5	1,504.55 11.9	12,612.14 100	1.86
Saskatchewan	\$(000) %	544.12 8.5	703.44 11.0	2,175.99 34.1	1,606.29 25.2	1,345.82 21.1	6,375.66 100	0.94
Alberta	\$(000) %	3,714.49 11.8	6,122.33 19.4	9,935.44 31.5	5,721.53 18.1	6,041.68 19.2	31,535.46 100	4.64
British Columbia	\$(000) %	3,870.69 15.2	2,609.01 10.2	7,845.53 30.8	8,282.76 32.5	2,849.45 11.2	25,457.44 100	3.75
Yukon & N.W.T.	\$(000) %	1.96 1.2	163.65 97.4	2.21 1.3	0.00 0.0	0.22 0.1	168.04 100	0.02
Canada	\$(000) %	375,797.82 55.3	79,392.57 11.7	49,531.61 7.3	93,191.07 13.7	81,333.06 12.0	679,246.12 100	100

- The percentage under each R&D category gives the percentage of all money spent in that category in that province.
- Expenditures as a percentage of total means percentage of R&D expenditures in that province compared to total R&D in Canada.
- Rows and columns may not equal totals due to rounding.
- Current expenditures plus capital expenditures (equipment + depreciation) = total R&D expenditures.

Source: PMPRB



# Glossary

---

**Note To Reader:** This glossary is included for the convenience of the reader. For more detailed information and definitions please refer to the *Patent Act*, the *Patented Medicines Regulations* and the *Compendium of Guidelines, Policies and Procedures*, or contact the PMPRB.

**Active Ingredient:** Chemical responsible for the claimed pharmacologic effect of a drug product.

**Advance Ruling Certificate (ARC):** A non-binding certificate may be issued pursuant to subsection 98(4) of the *Act* at the request of a patentee when the Board is satisfied that the price or proposed price of the medicine would not exceed the maximum non-excessive price under the Board's Guidelines.

**ATC:** Anatomical Therapeutic Chemical classification system that divides drugs into different groups according to their site of action and therapeutic and chemical characteristics. This system is used as a guide for selecting comparable medicines for purposes of price review.

**Dedication of Patent:** A practice whereby a patentee notifies the Commissioner of Patents that it has surrendered its rights and entitlements flowing from the patent for the benefit of the public to use and enjoy (PMPRB Bulletin 15, January 1995, p.4).

**Drug Identification Number (DIN):** A registration number that the Health Protection Branch of Health Canada assigns to each prescription and non-prescription drug product marketed under the *Food and Drug Regulations*. The DIN is assigned using information in the following areas: manufacturer of the product; active ingredient(s); strength of active ingredient(s); pharmaceutical dosage form; brand/trade name; and route of administration.

**Drug Product:** A particular presentation of a medicine characterized by its pharmaceutical dosage form and the strength of the active ingredient(s).

**Drug Product, Existing:** An existing drug product is a DIN for which a benchmark price has been established in accordance with the Board's Guidelines. (See Chapter 1, subsection 3.3 of the *Compendium of Guidelines, Policies and Procedures*.)

**Drug Product, New:** A new drug product is one for which the introductory price is under review. Patented drug products are considered new in the year during which they are first introduced on the market in Canada or the year they receive their first patent(s) if previously marketed. For price review purposes, new drug products for a given year are those introduced between December 1, of the previous year and November 30, of the reporting year. Because of the filing requirements under the *Patented Medicines Regulations* and the manner of calculating benchmark prices, drug products introduced in December are considered to have been introduced in the following year. (See Chapter 1, subsection 3.2 of the *Compendium of Guidelines, Policies and Procedures*.)

**Emergency Drug Release (EDR) Program:** See Special Access Program.

**Generic Product:** A drug product with the same active ingredient, strength and dosage form of a brand name drug product.

**General Public (GP) Number:** A number that the Health Protection Branch of Health Canada assigns to proprietary medicines that are registered according to the requirements of Division 10 of the *Food and Drug Regulations*. These products may be sold in non-pharmacy outlets in certain provinces.

**Investigational New Drug (IND):** A drug that has been authorized for clinical evaluation (i.e., testing on humans) by Health Canada but that is not yet approved for sale for the indication under study.

**Licence, Compulsory:** A licence granted by the Commissioner of Patents in accordance with subsection 39(4) of the *Patent Act* that has been continued pursuant to subsection 11(1) of the *Patent Act Amendment Act, 1992*, which permits the licensee to import, make, use or sell a patented invention pertaining to a medicine. Royalties payable are determined by the Commissioner of Patents who sets the terms of licences pursuant to subsection 39(5) of the *Patent Act*. Except for those compulsory licences issued prior to December 20, 1991, which are continued pursuant to subsection 11(1) of the *Patent Act*, licences issued after December 20, 1991 have no effect.

**Licence, Voluntary:** A contractual agreement between a patent holder and a licensee under which the licensee is entitled to enjoy the benefit of the patent or to exercise any rights in relation to the patent for some consideration (i.e., royalties in the form of a share of the licensee's sales).

**Medicine:** Any substance or mixture of substances made by any means, whether produced biologically, chemically, or otherwise, that is applied or administered *in vivo* in humans or in animals to aid in the diagnosis, treatment, mitigation or prevention of disease, symptoms, disorders, abnormal physical states, or modifying organic functions in humans and or animals, however administered.

For greater certainty, this definition includes vaccines, topical preparations, anaesthetics and diagnostic products used *in vivo*, regardless of delivery mechanism (e.g., transdermal, capsule form, injectable, inhaler, etc.). This definition excludes medical devices, *in vitro* diagnostic products and disinfectants that are not used *in vivo* (*Compendium of Guidelines, Policies and Procedures*, Introduction, subsection 1.5).

**Notice of Compliance (NOC):** A notice in respect of a medicine issued by the Health Protection Branch of Health Canada under section C.08.004 of the *Food and Drug Regulations*. The issuance of an NOC indicates that a drug product meets the required Health Canada standards for use in humans or animals and that the product is approved for sale in Canada.

**Patent:** An instrument issued by the Commissioner of Patents in the form of letters patent for an invention that provides its holder with a monopoly limited in time, for the claims made within the patent. A patent gives the patentee the exclusive right to make, sell or otherwise exploit the invention for the term of the patent.

**Patentee:** As defined by subsection 79(1) of the *Patent Act*, "the person for the time being entitled to the benefit of the patent for that invention (pertaining to a medicine) and includes, where any other person is entitled to exercise any rights in relation to that patent other than under a licence continued by subsection 11(1) of the *Patent Act Amendment Act, 1992*, that other person in respect of those rights;"

**Research and Development (R&D):** Basic or applied research for the purpose of creating new, or improving existing, materials, devices, products or processes (e.g., manufacturing processes).

**Research and Development — Applied Research:** Work that advances scientific knowledge with a specific practical application in view such as creating new or improved products or processes through manufacturing processes or through preclinical or clinical studies.

**Research and Development — Basic Research:** Work that advances scientific knowledge without a specific application in view.

**Research and Development — Clinical Research:** The assessment of the effect of a new medicine on humans. It typically consists of three successive phases, beginning with limited testing for safety in healthy humans then proceeding to further safety and efficacy studies in patients suffering from the target disease.

**Research and Development — Preclinical Research:** Tests on animals to evaluate the pharmacological and toxicological effects of medicines.

**Research and Development Expenditures:**

For the purposes of the Patented Medicines Regulations, 1994, in particular sections 5 and 6, research and development includes activities for which expenditures would have qualified for the investment tax credit for scientific research and experimental development under the *Income Tax Act* as it read on December 1, 1987.

**Special Access Program (SAP):** A program operated by Health Canada to give practitioners access to drugs that are not approved or otherwise available for sale in Canada. (Formerly the EDR Program.)

**Voluntary Compliance Undertaking (VCU):**

A written undertaking by a patentee to adjust its price to conform with the PMPRB's Excessive Price Guidelines (see Chapter 1 of the *Compendium of Guidelines, Policies and Procedures*). Pursuant to the Board's Compliance and Enforcement Policy (see Chapter 2, section 7) the Chairperson or the Board may approve a VCU in lieu of issuing a Notice of Hearing if it is consistent with the *Patent Act* and the policies of the Board and in the public interest. The Board reports publicly on all VCUs approved by the Chairperson or the Board.

# List of Publications

- *Patent Act*
- *Patented Medicines Regulations*
- Compendium of Guidelines, Policies and Procedures
- Patentees' Guide to Reporting (1995)

## ANNUAL REPORT Series (1989 to 1997)

## NEWSletter Series (1997 to 1998)

## BULLETIN Series (1988 to 1996)

## ARTICLE Series

- Dr. H. C. Eastman Article "Pharmaceutical Price Review in Canada," 1992
- Dr. R. G. Elgie Article "Regulating Prices of Patented Pharmaceuticals in Canada: The Patented Medicine Prices Review Board," 1996

## VCUs and DECISIONS of the Board (1993 to 1998)

- 1998: Humalog

## SPEECH Series (1989 to 1998)

- Chairperson's presentation to the Standing Committee on Industry, March 4, 1997
- CPIC'97 - Chairperson's presentation to the Canadian Pharmaceutical Industry Conference 1997, October 20, 1997
- Chairperson's Introductory Remarks to the Standing Committee on Health, April 28, 1998

## STUDY Series

- S-9301: International Price Comparison
- S-9302: International Price Comparison of the Top 200 Selling Patented Products Sold in Canada
- S-9303: Further Analyses on Introductory Medicines and Top-Selling Medicines
- S-9404: The Top 200 Selling Patented Drug Products in Canada (1993)
- S-9405: Interprovincial Price Comparisons in Canada (1988-1993)
- S-9506: Estimated Savings from Compliance and Enforcement Activities
- S-9607: The Top 200 Selling Patented Drug Products in Canada (1994)
- S-9708: The Impact of Federal Regulation of Patented Drug Prices
- S-9709: A Comparison of Pharmaceutical Research and Development Spending in Canada and Selected Countries
- S-9710: A Description of the Laspeyres Methodology Used to Construct the Patented Medicine Price Index (PMPI)

## DISCUSSION PAPER Series

- D-9401: Measurement of Cost Savings to the Canadian Health Care System

**Toll-Free Number:**  
**1-877-861-2350**

If you have any questions or comments, please contact:

Sylvie Dupont-Kirby  
Box L40  
Standard Life Centre  
333 Laurier Avenue West  
Suite 1400  
Ottawa, Ontario  
K1P 1C1

Tel: (613) 954-8299  
E-mail:  
sdupont@pmprb-cepmb.gc.ca

TTY: (613) 957-4373  
Fax: (613) 952-7626  
E-mail:  
pmprb@pmprb-cepmb.gc.ca  
WEBSITE:  
<http://www.pmprb-cepmb.gc.ca>

TO ORDER PMPRB PUBLICATIONS,  
contact Céline Carré at  
(613) 952-3303

# Table 12

## Patented Drug Products Introduced in Canada in 1997

### HUMAN

#### Category 1

Brand Name	DIN	Company
ACTHREL NF - 0.1MG/VIAL		FERRING INC.
CERVIDIL 0.3 - 10MG/POUCH	02231047	FERRING INC.
EPREX - 10000UNIT/SYRINGE	02231587	JANSSSEN-ORTHO INC.
EPREX - 1000UNIT/SYRINGE	02231583	JANSSSEN-ORTHO INC.
EPREX - 2000UNIT/SYRINGE	02231584	JANSSSEN-ORTHO INC.
EPREX - 3000UNIT/SYRINGE	02231585	JANSSSEN-ORTHO INC.
EPREX - 4000UNIT/SYRINGE	02231586	JANSSSEN-ORTHO INC.
FOSAMAX - 5MG/TAB	02233055	MERCK FROSST CANADA INC.
FRAGMIN - 25000UNIT/ML	02231171	PHARMACIA & UPJOHN INC.
HAVRIX 720 JUNIOR - 1440UNIT/ML	02231056	SMITHKLINE BEECHAM PHARMA INC.
HUMATROPE - 13.3MG/CART	02229693	ELI LILLY CANADA INC.
HUMATROPE - 6.7MG/CART	02229692	ELI LILLY CANADA INC.
IMODIUM LINGUAL - 2MG/TAB	02230542	MCNEIL CONSUMER PRODUCTS COMPANY
INNOHEP - 10000UNIT/ML	02229755	LEO LABORATORIES CANADA LTD.
INNOHEP - 20000UNIT/ML	02229515	LEO LABORATORIES CANADA LTD.
INTRON-A - 18000000UNIT/VIAL	02231651	SCHERING CANADA INC.
LOSEC - 10MG/TAB	02230737	ASTRA PHARMA INC.
LUPRON DEPOT - 22.5MG/VIAL	02230248	ABBOTT LABORATORIES LIMITED
MIRALUMA		DU PONT MERCK PHARMA INC.
NAROPIN - 7.5MG/ML	02229416	ASTRA PHARMA INC.
NUTROPIN - 5MG/VIAL	02216183	HOFFMANN-LA ROCHE LIMITED
NUTROPIN AQ - 5MG/ML	02229722	HOFFMANN-LA ROCHE LIMITED
PAXIL - 10MG/TAB	02027887	SMITHKLINE BEECHAM PHARMA INC.
PEPCID AC - 10MG/TAB	02185911	JOHNSON & JOHNSON-MERCK
PNU-IMUNE 23	02230175	WYETH-AYERST CANADA INC.
PULMICORT NEBUAMP - 0.125MG/ML	02229099	ASTRA PHARMA INC.
REACTINE - 5MG/TAB	02223546	PFIZER CANADA INC.
RHINOCORT AQ NASAL AEROSOL - 0.064MG/DOSE	02231923	ASTRA PHARMA INC.
ROFERON-A - 4500000UNIT/VIAL	02217023	HOFFMANN-LA ROCHE LIMITED
ROFERON-A - 6000000UNIT/VIAL	02217031	HOFFMANN-LA ROCHE LIMITED
SENSODYNE-F 5%/0.24%	02083310	BLOCK DRUG COMPANY (CANADA) LTD.
SERZONE - 50MG/TAB	02087294	BRISTOL-MYERS SQUIBB PHARMACEUTICAL GROUP
SUPREFACT DEPOT - 6.6MG/VIAL	02228955	HOECHST MARION ROUSSEL CANADA INC.
ZITHROMAX - 600MG/TAB	02231143	PFIZER CANADA INC.

#### Category 2

Brand Name	DIN	Company	New Active Substance
ARICEPT - 10MG/TAB	02232044	PFIZER CANADA INC.	NAS
ARICEPT - 5MG/TAB	02232043	PFIZER CANADA INC.	NAS
BENEFIX - 1000UNIT/VIAL	02231020	GENETICS INSTITUTE, INC.	NAS
BENEFIX - 250UNIT/VIAL	02231018	GENETICS INSTITUTE, INC.	NAS
BENEFIX - 500UNIT/VIAL	02231019	GENETICS INSTITUTE, INC.	NAS
CAMPTOSAR - 20MG/ML	02231622	PHARMACIA & UPJOHN INC.	NAS
CRIXIVAN - 200MG/CAP	02229161	MERCK FROSST CANADA INC.	FPG <sup>1</sup>
CRIXIVAN - 400MG/CAP	02229196	MERCK FROSST CANADA INC.	FPG
EPREX - 10000UNIT/ML	02126591	JANSSSEN-ORTHO INC.	FPG
EPREX - 20000UNIT/ML	02206072	JANSSSEN-ORTHO INC.	FPG
EPREX - 2000UNIT/ML	02126575	JANSSSEN-ORTHO INC.	FPG
EPREX - 4000UNIT/ML	02126583	JANSSSEN-ORTHO INC.	FPG
INVIRASE - 200MG/CAP	02216965	HOFFMANN-LA ROCHE LIMITED	FPG

#### Category 3

Brand Name	DIN	Company	New Active Substance
3TC - 10MG/ML	02192691	GLAXO WELLCOME INC.	FPG
3TC - 150MG/TAB	02192683	GLAXO WELLCOME INC.	FPG
ACEL-P	02215071	WYETH-AYERST CANADA INC.	NAS

ALLEGRA - 60MG/TAB	02231462	HOECHST MARION ROUSSEL CANADA INC.	NAS
ANZEMET - 100MG/TAB	02231379	HOECHST MARION ROUSSEL CANADA INC.	NAS
ANZEMET - 20MG/ML	02231380	HOECHST MARION ROUSSEL CANADA INC.	NAS
ANZEMET - 50MG/TAB	02231378	HOECHST MARION ROUSSEL CANADA INC.	NAS
DAUNOXOME - 50MG/VIAL	02218046	NEXSTAR PHARMACEUTICALS INC.	
EMINASE - 30UNIT/VIAL	02229390	ROBERTS PHARMACEUTICAL CANADA INC.	NAS
ENTOCORT - 3MG/CAP	02229293	ASTRA PHARMA INC.	
FEMARA - 2.5MG/TAB	02231384	NOVARTIS PHARMA CANADA INC.	NAS
FLOLAN - 0.5MG/VIAL	02230845	GLAXO WELLCOME INC.	NAS
FLOLAN - 1.5MG/VIAL	02230848	GLAXO WELLCOME INC.	NAS
FLOLAN STERILE DILUENT	02230857	GLAXO WELLCOME INC.	NAS
FORADIL - 0.012MG/DOSE	02230898	NOVARTIS PHARMA CANADA INC.	NAS
HYCAMTIN - 4MG/VIAL	02231116	SMITHKLINE BEECHAM PHARMA INC.	NAS
IMITREX - 20MG/DOSE	02230420	GLAXO WELLCOME INC.	
IMITREX - 5MG/DOSE	02230418	GLAXO WELLCOME INC.	
LIPITOR - 10MG/TAB	02230711	WARNER-LAMBERT CANADA INC. (PARKE-DAVIS)	NAS
LIPITOR - 20MG/TAB	02230713	WARNER-LAMBERT CANADA INC. (PARKE-DAVIS)	NAS
LIPITOR - 40MG/TAB	02230714	WARNER-LAMBERT CANADA INC. (PARKE-DAVIS)	NAS
MIREZE - 20MG/ML	02230446	ALLERGAN INC.	
MYOVUE		AMERSHAM CANADA LIMITED	NAS
NAROPIN - 10MG/ML	02229418	ASTRA PHARMA INC.	NAS
NAROPIN - 2MG/ML	02229411	ASTRA PHARMA INC.	NAS
NAROPIN - 5MG/ML	02229415	ASTRA PHARMA INC.	NAS
PANTOLOC - 40MG/TAB	02229453	SOLVAY PHARMA INC.	NAS
PENTACEL	02231343	CONNAUGHT LABORATORIES LTD.	NAS
PYLORID - 400MG/TAB	02231831	GLAXO WELLCOME INC.	
QUADRACEL	02230946	CONNAUGHT LABORATORIES LTD.	NAS
REQUIP - 0.25MG/TAB	02232565	SMITHKLINE BEECHAM PHARMA INC.	NAS
REQUIP - 1MG/TAB	02232567	SMITHKLINE BEECHAM PHARMA INC.	NAS
REQUIP - 2MG/TAB	02232568	SMITHKLINE BEECHAM PHARMA INC.	NAS
REQUIP - 5MG/TAB	02232569	SMITHKLINE BEECHAM PHARMA INC.	NAS
SPORANOX - 10MG/ML	02231347	JANSSEN-ORTHO INC.	
SUPRANE	02227428	ZENECA PHARMA INC.	NAS
TASMAR - 100MG/TAB	02235914	HOFFMANN-LA ROCHE LIMITED	NAS
TASMAR - 200MG/TAB	02235921	HOFFMANN-LA ROCHE LIMITED	NAS
TAZORAC - 0.5MG/G	02230784	ALLERGAN INC.	NAS
TAZORAC - 1MG/G	02230785	ALLERGAN INC.	NAS
TOPAMAX - 100MG/TAB	02230894	JANSSEN-ORTHO INC.	NAS
TOPAMAX - 200MG/TAB	02230896	JANSSEN-ORTHO INC.	NAS
TOPAMAX - 25MG/TAB	02230893	JANSSEN-ORTHO INC.	NAS
TRIPACEL	02224143	CONNAUGHT LABORATORIES LTD.	NAS
TWINRIX 720/20	02230578	SMITHKLINE BEECHAM PHARMA INC.	
XALATAN - 0.05MG/ML	02231493	PHARMACIA & UPJOHN INC.	NAS

## VETERINARY

### Category 3

Brand Name	DIN	Company	New Active Substance
AVIAX - 50000MG/KG	02229543	PFIZER CANADA INC.,ANIMAL HEALTH GROUP	NAS
SENTINEL 115/5.75	02229547	NOVARTIS ANIMAL HEALTH CANADA INC.	
SENTINEL 230/11.5	02229548	NOVARTIS ANIMAL HEALTH CANADA INC.	
SENTINEL 46/2.3	02229551	NOVARTIS ANIMAL HEALTH CANADA INC.	
SENTINEL 460/23	02229549	NOVARTIS ANIMAL HEALTH CANADA INC.	

1 FPG: First patent granted in 1997.



**Table 13**  
**Patented Drug Products and Canadian Patentees,**  
**January 1 - December 31, 1997**

DIN/GP	Brand Name	Generic Name	ATC*	Dosage Form	Comments
<b>3M PHARMACEUTICALS, 3M CANADA INC.</b>					
<b>Human:</b>					
02162806	MINITRAN 0.2 - 18MG/PATCH	nitroglycerin	C01DA	transdermal patch	
02163527	MINITRAN 0.4 - 36MG/PATCH	nitroglycerin	C01DA	transdermal patch	
02163535	MINITRAN 0.6 - 54MG/PATCH	nitroglycerin	C01DA	transdermal patch	
02164337	MINITRAN 0.8 - 72MG/PATCH	nitroglycerin	C01DA	transdermal patch	not sold
01966197	TAMBOCOR - 50MG/TAB	flecainide acetate	C01BC	tablet	
01966200	TAMBOCOR - 100MG/TAB	flecainide acetate	C01BC	tablet	
00817155	TAMBOCOR - 150MG/TAB	flecainide acetate	C01BC	tablet	not sold
00628239	TAMBOCOR - 200MG/TAB	flecainide acetate	C01BC	tablet	not sold
<b>ABBOTT LABORATORIES LIMITED</b>					
<b>Human:</b>					
02146908	BIAXIN - 25MG/ML	clarithromycin	J01FA	powder for oral suspension	
01984853	BIAXIN - 250MG/TAB	clarithromycin	J01FA	tablet	
02126710	BIAXIN - 500MG/TAB	clarithromycin	J01FA	tablet	
00891738	CALCIJEX - 0.001MG/ML	calcitriol	A11CC	injectable solution	
00891746	CALCIJEX - 0.002MG/ML	calcitriol	A11CC	injectable solution	
00596418	EPIVAL - 125MG/TAB	divalproex sodium	N03AG	enteric-coated tablet	
00596426	EPIVAL - 250MG/TAB	divalproex sodium	N03AG	enteric-coated tablet	
00596434	EPIVAL - 500MG/TAB	divalproex sodium	N03AG	enteric-coated tablet	
00893862	ERYBID - 500MG/TAB	erythromycin	J01FA	tablet	
00682268	ERYTHROCIN ADD-VANTAGE - 500MG/VIAL	erythromycin lactobionate	J01FA	powder for injectable solution	
00682276	ERYTHROCIN ADD-VANTAGE - 1000MG/VIAL	erythromycin lactobionate	J01FA	powder for injectable solution	
00818658	HYTRIN - 1MG/TAB	terazosin hydrochloride	C02CA	tablet	
00818682	HYTRIN - 2MG/TAB	terazosin hydrochloride	C02CA	tablet	
00818666	HYTRIN - 5MG/TAB	terazosin hydrochloride	C02CA	tablet	
00818674	HYTRIN - 10MG/TAB	terazosin hydrochloride	C02CA	tablet	
02187876	HYTRIN-STARTER PACK	terazosin hydrochloride	C02CA	tablet	expired
00884502	LUPRON DEPOT - 3.75MG/VIAL	leuprolide acetate	L02AE	powder for injectable solution	
00836273	LUPRON DEPOT - 7.5MG/VIAL	leuprolide acetate	L02AE	powder for injectable solution	
02148722	LUPRON DEPOT - 11.25MG/VIAL	leuprolide acetate	L02AE	powder for injectable solution	not sold
02148730	LUPRON DEPOT - 15MG/VIAL	leuprolide acetate	L02AE	powder for injectable solution	not sold
02230248	LUPRON DEPOT - 22.5MG/VIAL	leuprolide acetate	L02AE	powder for injectable solution	introduced
02229137	NORVIR - 100MG/CAP	ritonavir	J05AE	capsule	
02229145	NORVIR - 80MG/ML	ritonavir	J05AE	oral solution	
00769991	PCE DISPERTAB - 333MG/TAB	erythromycin	J01FA	tablet	
02165503	PREVACID - 15MG/CAP	lansoprazole	A02BC	sustained-release capsule	
02165511	PREVACID - 30MG/CAP	lansoprazole	A02BC	sustained-release capsule	
02172763	SEVORANE	sevoflurane	N01AB	inhalation anesthetic	
02016109	SURVANTA - 25MG/ML	beractant	R07AA	endo-tracheal suspension	
<b>ALCON CANADA INC.</b>					
<b>Human:</b>					
00695688	BETOPTIC - 5MG/ML	betaxolol hydrochloride	S01ED	ophthalmic solution	expired
01908448	BETOPTIC S - 2.5MG/ML	betaxolol hydrochloride	S01ED	ophthalmic suspension	
00568082	BSS PLUS	sodium bicarbonate/ dextrose/glutathione			
01945270	CILOXAN - 3MG/ML	ciprofloxacin hydrochloride	S01XA	ophthalmic solution	
02076306	IOPIDINE - 5MG/ML	apraclonidine hydrochloride	S01XA	ophthalmic solution	
00888354	IOPIDINE - 10MG/ML	apraclonidine hydrochloride	S01XA	ophthalmic solution	
02233143	PATANOL - 1MG/ML	olopatadine hydrochloride		ophthalmic solution	not sold
00575240	PILOPINE-HS - 40MG/G	pilocarpine hydrochloride	S01EB	ophthalmic gel	
02132710	PROFENAL - 10MG/ML	suprofen	M01AE	ophthalmic solution	not sold
00390291	TEARS NATURALE 1/3	dextran/hydroxypropyl methylcellulose			
00743445	TEARS NATURALE II 1/3	dextran/hydroxypropyl methylcellulose	S01XA	ophthalmic solution	expired
00778915	TOBRADEX 3/1	tobramycin/dexamethasone	S01XA	ophthalmic drops	expired
00778907	TOBRADEX 3/1	tobramycin/dexamethasone	S01CA	ophthalmic ointment	
		tobramycin/dexamethasone	S01CA	ophthalmic suspension	

DIN/GP	Brand Name	Generic Name	ATC*	Dosage Form	Comments
<b>ALLERGAN INC.</b>					
<b>Human:</b>					
01968300	ACULAR - 5MG/ML ILOTYCIN - 5MG/G	ketorolac tromethamine erythromycin	S01BC S01AA	ophthalmic solution ointment	
02230446	MIREZE - 20MG/ML	nedocromil sodium	S01GX	ophthalmic drops	introduced
02011255	NAFTIN - 10MG/G	naftifine hydrochloride	D01AE	cream	expired
02011263	NAFTIN - 10MG/G	naftifine hydrochloride	D01AE	gel	expired
02143291	OCUFLOX - 3MG/ML	ofloxacin	S01AA	ophthalmic solution	
02230784	TAZORAC - 0.5MG/G	tazarotene	D05AX	gel	introduced (nas)
02230785	TAZORAC - 1MG/G	tazarotene	D05AX	gel	introduced (nas)

## ALPHA THERAPEUTIC CORPORATION

<b>Human:</b>					
01924745	ALPHANINE - 1UNIT/DOSE	factor IX(human)	B02BD	injectable solution	not sold
	ALPHANINE SD - 1UNIT/DOSE	factor IX(human)	B02BD	injectable solution	
00740780	PROFILATE - 1UNIT/DOSE	antihemophilic factor	B02BD	injectable solution	not sold

## ALTIMED PHARMACEUTICALS INC.

<b>Human:</b>					
01912070	DOMPERIDONE MALEATE - 10MG/TAB	domperidone maleate	A03FA	tablet	expired
02128918	KENRAL-CEFACLO - 250MG/CAP	cefaclor	J01DA	capsule	not sold
02128926	KENRAL-CEFACLO - 500MG/CAP	cefaclor	J01DA	capsule	not sold
02128977	KENRAL-CEFACLO - 25MG/ML	cefaclor	J01DA	powder for oral suspension	not sold
02128985	KENRAL-CEFACLO - 50MG/ML	cefaclor	J01DA	powder for oral suspension	not sold
02128993	KENRAL-CEFACLO - 75MG/ML	cefaclor	J01DA	powder for oral suspension	not sold
02128845	KENRAL-FLUOXETINE - 10MG/CAP	fluoxetine hydrochloride	N06AB	capsule	not sold
02128853	KENRAL-FLUOXETINE - 20MG/CAP	fluoxetine hydrochloride	N06AB	capsule	not sold
02128861	KENRAL-FLUOXETINE - 4MG/ML	fluoxetine hydrochloride	N06AB	oral solution	not sold
02128888	KENRAL-NIZATIDINE - 150MG/CAP	nizatidine	A02BA	capsule	not sold
02128896	KENRAL-NIZATIDINE - 300MG/CAP	nizatidine	A02BA	capsule	not sold
00756814	NAXEN - 500MG/SUP	naproxen	M01AE	suppository	
00615307	NAXEN - 125MG/TAB	naproxen	M01AE	tablet	not sold
00615315	NAXEN - 250MG/TAB	naproxen	M01AE	tablet	
00615323	NAXEN - 375MG/TAB	naproxen	M01AE	tablet	
00615331	NAXEN - 500MG/TAB	naproxen	M01AE	tablet	
02039478	NAXEN SR - 750MG/TAB	naproxen	M01AE	sustained-release tablet	not sold
02039567	NAXEN SR - 1000MG/TAB	naproxen	M01AE	sustained-release tablet	not sold
00828823	RANITIDINE HYDROCHLORIDE - 150MG/TAB	ranitidine hydrochloride	A02BA	tablet	
00828688	RANITIDINE HYDROCHLORIDE - 300MG/TAB	ranitidine hydrochloride	A02BA	tablet	
00878715	SALBUTAMOL SULFATE - 0.4MG/ML	salbutamol sulfate	R03CC	oral solution	not sold
00851639	SYN-CAPTAPRIL - 12.5MG/TAB	captopril	C09AA	tablet	
00851883	SYN-CAPTAPRIL - 25MG/TAB	captopril	C09AA	tablet	
00851647	SYN-CAPTAPRIL - 50MG/TAB	captopril	C09AA	tablet	
00851655	SYN-CAPTAPRIL - 100MG/TAB	captopril	C09AA	tablet	
00878790	SYN-FLUNISOLIDE - 0.25MG/ML	flunisolide	R01AD	nasal aerosol	
00675369	SYNFLEX - 275MG/TAB	naproxen sodium	M01AE	tablet	
01900897	SYNFLEX DS - 550MG/TAB	naproxen sodium	M01AE	tablet	

## AMERSHAM CANADA LIMITED

<b>Human:</b>					
	CERETEC	technetium tc-99m exametazime	V09AA	powder for injectable solution	
	HEPATATE II	technetium tc-99m tin colloid	V09DB	powder for injectable solution	
	MEDRONATE II	technetium tc-99m medronate sodium	V09BA	powder for injectable solution	
	MYOVIEW	technetium tc-99m tetrofosmin	V09AG	powder for injectable solution	introduced (nas)

## AMGEN CANADA INC.

<b>Human:</b>					
01968017	NEUPOGEN - 0.3MG/ML	filgrastim	L03AA	injectable solution	

DIN/GP	Brand Name	Generic Name	ATC*	Dosage Form	Comments
<b>ASTRA PHARMA INC.</b>					
<b>Human:</b>					
02148641	BAMBEC - 10MG/TAB	bambuterol hydrochloride	R03CC	tablet	not sold
02148668	BAMBEC - 20MG/TAB	bambuterol hydrochloride	R03CC	tablet	not sold
00719846	BETALOC - 1MG/ML	metoprolol tartrate	C07AB	injectable solution	
00402605	BETALOC - 50MG/TAB	metoprolol tartrate	C07AB	tablet	
00402540	BETALOC - 100MG/TAB	metoprolol tartrate	C07AB	tablet	
02028727	BETALOC CR - 47.5MG/TAB	metoprolol succinate	C07AB	sustained-release tablet	not sold
02028735	BETALOC CR - 95MG/TAB	metoprolol succinate	C07AB	sustained-release tablet	not sold
02028743	BETALOC CR - 190MG/TAB	metoprolol succinate	C07AB	sustained-release tablet	not sold
00497827	BETALOC DURULES - 200MG/TAB	metoprolol tartrate	C07AB	sustained-release tablet	
00444774	BRICANYL SPACER - 0.25MG/DOSE	terbutaline sulfate	R03AC	aerosol for inhalation	expired
00786616	BRICANYL TURBUHALER - 0.5MG/DOSE	terbutaline sulfate	R03AC	powder for inhalation	
01958100	CARDURA-1 - 1MG/TAB	doxazosin mesylate	C02CA	tablet	expired
01958097	CARDURA-2 - 2MG/TAB	doxazosin mesylate	C02CA	tablet	expired
01958119	CARDURA-4 - 4MG/TAB	doxazosin mesylate	C02CA	tablet	expired
00886858	EMLA 25/25	lidocaine/prilocaine	D04AB	cream	
02057794	EMLA 25/25	lidocaine/prilocaine	D04AB	transdermal patch	
02166062	EMLA STERILE 25/25	lidocaine/prilocaine	D04AB	cream	not sold
02229293	ENTOCORT - 3MG/CAP	budesonide	A07EA	sustained-release capsule	introduced
02052431	ENTOCORT - 0.02MG/ML	budesonide	A07EA	enema	
02134810	FOSCAVIR - 24MG/ML	foscarnet sodium	J05AD	injectable solution	not sold
02119579	LOSEC - 10MG/CAP	omeprazole	A02BC	capsule	not sold
00846503	LOSEC - 20MG/CAP	omeprazole	A02BC	capsule	not sold
02016788	LOSEC - 40MG/CAP	omeprazole	A02BC	capsule	not sold
02230737	LOSEC - 10MG/TAB	omeprazole magnesium	A02BC	sustained-release tablet	introduced
02190915	LOSEC - 20MG/TAB	omeprazole magnesium	A02BC	sustained-release tablet	
02229411	NAROPIN - 2MG/ML	ropivacaine hydrochloride	N01BB	injectable solution	introduced (nas)
02229415	NAROPIN - 5MG/ML	ropivacaine hydrochloride	N01BB	injectable solution	introduced (nas)
02229416	NAROPIN - 7.5MG/ML	ropivacaine hydrochloride	N01BB	injectable solution	introduced
02229418	NAROPIN - 10MG/ML	ropivacaine hydrochloride	N01BB	injectable solution	introduced (nas)
00749362	NITROGARD-SR - 1MG/TAB	nitroglycerin	C01DA	sustained-release tablet	not sold
00749397	NITROGARD-SR - 2MG/TAB	nitroglycerin	C01DA	sustained-release tablet	not sold
00749389	NITROGARD-SR - 3MG/TAB	nitroglycerin	C01DA	sustained-release tablet	not sold
00749370	NITROGARD-SR - 5MG/TAB	nitroglycerin	C01DA	sustained-release tablet	not sold
00627127	PENGLOBE - 400MG/TAB	bacampicillin hydrochloride	J01CA	tablet	
00627135	PENGLOBE - 800MG/TAB	bacampicillin hydrochloride	J01CA	tablet	
02057778	PLENDIL - 2.5MG/TAB	felodipine	C08CA	sustained-release tablet	
00851779	PLENDIL - 5MG/TAB	felodipine	C08CA	sustained-release tablet	
00851787	PLENDIL - 10MG/TAB	felodipine	C08CA	sustained-release tablet	
00817228	PULMICORT INHALER - 0.05MG/DOSE	budesonide	R03BA	aerosol for inhalation	not sold
00634549	PULMICORT INHALER - 0.2MG/DOSE	budesonide	R03BA	aerosol for inhalation	not sold
02229099	PULMICORT NEBUAMP - 0.125MG/ML	budesonide	R03BA	suspension for inhalation	introduced
01978918	PULMICORT NEBUAMP - 0.25MG/ML	budesonide	R03BA	suspension for inhalation	
01978926	PULMICORT NEBUAMP - 0.5MG/ML	budesonide	R03BA	suspension for inhalation	
00634530	PULMICORT SPACER - 0.05MG/DOSE	budesonide	R03BA	aerosol for inhalation	not sold
00814091	PULMICORT SPACER - 0.2MG/DOSE	budesonide	R03BA	aerosol for inhalation	not sold
00852074	PULMICORT TURBUHALER - 0.1MG/DOSE	budesonide	R03BA	powder for inhalation	
00851752	PULMICORT TURBUHALER - 0.2MG/DOSE	budesonide	R03BA	powder for inhalation	
00851760	PULMICORT TURBUHALER - 0.4MG/DOSE	budesonide	R03BA	powder for inhalation	
02051788	RAMACE - 1.25MG/CAP	ramipril	C09AA	capsule	not sold
02051796	RAMACE - 2.5MG/CAP	ramipril	C09AA	capsule	not sold
02051818	RAMACE - 5MG/CAP	ramipril	C09AA	capsule	not sold
00636460	RHINOCORT - 0.05MG/DOSE	budesonide	R01AD	nasal aerosol	not sold

DIN/GP	Brand Name	Generic Name	ATC*	Dosage Form	Comments
02231922	RHINOCORT AQUA - 0.032MG/DOSE	budesonide	R01AD	nasal aerosol	not sold
01974424	RHINOCORT AQUA - 0.05MG/DOSE	budesonide	R01AD	nasal aerosol	not sold
02231923	RHINOCORT AQUA - 0.064MG/DOSE	budesonide	R01AD	nasal aerosol	introduced
01974432	RHINOCORT AQUA - 0.1MG/DOSE	budesonide	R01AD	nasal aerosol	
02035324	RHINOCORT TURBUHALER - 0.1MG/DOSE	budesonide	R01AD	powder for nasal inhalation	
02035340	RHINOCORT TURBUHALER - 0.2MG/DOSE	budesonide	R01AD	powder for nasal inhalation	not sold
02036363	ROXIAM - 75MG/CAP	remoxipride hydrochloride	N05AL	capsule	not sold
02036371	ROXIAM - 150MG/CAP	remoxipride hydrochloride	N05AL	capsule	not sold
02036398	ROXIAM - 300MG/CAP	remoxipride hydrochloride	N05AL	capsule	not sold
02036401	ROXIAM - 100MG/ML	remoxipride hydrochloride	N05AL	injectable solution	not sold

## AYERST VETERINARY LABORATORIES

### Veterinary:

00844306	AMIGLYDE - V - 50MG/ML	amikacin sulfate		injectable solution	not sold
00844292	AMIGLYDE - V - 250MG/ML	amikacin sulfate		injectable solution	
00849413	CEFA - 50MG/ML	cefadroxil		powder for oral solution	
00844284	CEFA - 50MG/TAB	cefadroxil		tablet	
00844241	CEFA - 100MG/TAB	cefadroxil		tablet	
00844233	CEFA - 200MG/TAB	cefadroxil		tablet	
00844225	CEFA - 1000MG/TAB	cefadroxil		tablet	
02215713	CYDECTIN - 10MG/ML	moxidectin		injectable solution	not sold
02228386	CYDECTIN POUR-ON - 5MG/ML	moxidectin		topical solution	not sold
	ECOLAN	escherichia coli vaccine		injectable suspension	not sold
	ECOLAN-RC	escherichia coli rota corona vaccine		injectable suspension	
02148676	GUARDIAN - 0.03MG/TAB	moxidectin		tablet	not sold
02148684	GUARDIAN - 0.068MG/TAB	moxidectin		tablet	not sold
02148692	GUARDIAN - 0.136MG/TAB	moxidectin		tablet	not sold
	HEVLAN TC (VACCINE)	hemorrhagic enteritis vaccine		injectable suspension	not sold
02231660	QUEST - 20MG/ML	moxidectin		oral gel	not sold
00845000	TORBUGESIC - 10MG/ML	butorphanol tartrate		injectable solution	
00844977	TORBUTROL - 1MG/TAB	butorphanol tartrate		tablet	
00844985	TORBUTROL - 5MG/TAB	butorphanol tartrate		tablet	
00844993	TORBUTROL - 10MG/TAB	butorphanol tartrate		tablet	

## BAXTER CORPORATION

### Human:

00781339	ANTITHROMBIN III IMMUNO	antithrombin III	B01AB	powder for injectable solution	not sold
00781339	BEBULIN VH	factor IX complex (human)	B02BD	powder for injectable solution	not sold
00781347	BEBULIN VH	factor IX complex (human)	B02BD	powder for injectable solution	
	CMV IVEEGAM IMMUNO - 1000MG/VIAL	cmv immune globulin intravenous (human)	J06BB	powder for injectable solution	not sold
02230772	CRITILIP 20%	medium and long chain triglycerides	B05BA	injectable suspension	not sold
	FACTOR VII IMMUNO VH	factor VII concentrate	B02BD	powder for injectable solution	
00609137	FEIBA VH IMMUNO	factor VIII anti inhibitor	B02BD	powder for injectable solution	
	GAMMAGARD S/D - 50MG/ML	immune globulin intravenous (human)	J06BA	powder for injectable solution	
00808709	HEMOFIL-M	factor VIII	B02BD	powder for injectable solution	
02206021	IMMUMINE VH	factor IX (human)	B02BD	powder for injectable solution	
01959379	IVEEGAM IMMUNO - 500MG/VIAL	immune globulin intravenous (human)	J06BA	powder for injectable solution	not sold
01959336	IVEEGAM IMMUNO - 1000MG/VIAL	immune globulin intravenous (human)	J06BA	powder for injectable solution	not sold
01959328	IVEEGAM IMMUNO - 2500MG/VIAL	immune globulin intravenous (human)	J06BA	powder for injectable solution	not sold
01959301	IVEEGAM IMMUNO - 5000MG/VIAL	immune globulin intravenous (human)	J06BA	powder for injectable solution	
01959298	IVEEGAM IMMUNO - 7500MG/VIAL	immune globulin intravenous (human)	J06BA	powder for injectable solution	not sold
01959344	IVEEGAM IMMUNO - 10000MG/VIAL	immune globulin intravenous (human)	J06BA	powder for injectable solution	not sold
00719603	KRYOBULIN VH	factor VIII complex (human)	B02BD	powder for injectable solution	not sold
00719811	KRYOBULIN VH	factor VIII complex (human)	B02BD	powder for injectable solution	not sold

DIN/GP	Brand Name	Generic Name	ATC*	Dosage Form	Comments
00719838	KRYOBULIN VH	factor VIII complex (human)	B02BD	powder for injectable solution	not sold
01958968	TISSEEL KIT VH 0.5	fibrin sealant	B02BC	powder for topical solution	
01949020	TISSEEL KIT VH 1.0	fibrin sealant	B02BC	powder for topical solution	
01949012	TISSEEL KIT VH 2.0	fibrin sealant	B02BC	powder for topical solution	
01974327	TISSEEL KIT VH 5.0	fibrin sealant	B02BC	powder for topical solution	

## BAYER INC.

### Human:

00852082	ADALAT FT - 10MG/TAB	nifedipine	C08CA	tablet	not sold
02155907	ADALAT XL - 30MG/TAB	nifedipine	C08CA	sustained-release tablet	
02155990	ADALAT XL - 60MG/TAB	nifedipine	C08CA	sustained-release tablet	
00629243	CANESTEN 1 - 500MG/TAB	clotrimazole	G01AF	vaginal insert	not sold
02150948	CANESTEN 1 COMBI-PAK	clotrimazole	G01AF	vaginal insert and cream	
02155931	CIPRO - 100MG/TAB	ciprofloxacin hydrochloride	J01MA	tablet	
02155958	CIPRO - 250MG/TAB	ciprofloxacin hydrochloride	J01MA	tablet	
02155966	CIPRO - 500MG/TAB	ciprofloxacin hydrochloride	J01MA	tablet	
02155974	CIPRO - 750MG/TAB	ciprofloxacin hydrochloride	J01MA	tablet	
02155982	CIPRO IV - 10MG/ML	ciprofloxacin lactate	J01MA	injectable solution	
02178842	GAMIMUNE N - 50MG/ML	immune globulin intravenous (human)	J06BA	injectable solution	
01902695	GAMIMUNE N - 100MG/ML	immune globulin intravenous (human)	J06BA	injectable solution	not sold
	GAMIMUNE N HT - 50MG/ML	immune globulin intravenous (human)	J06BA	injectable solution	
02155923	NIMOTOP - 30MG/CAP	nimodipine	N07XC	capsule	
02155915	NIMOTOP IV - 0.2MG/ML	nimodipine	N07XC	injectable solution	
02190885	PRANDASE - 50MG/TAB	acarbose	A10BF	tablet	
02190893	PRANDASE - 100MG/TAB	acarbose	A10BF	tablet	
02204592	PROLASTIN - 25MG/ML	alpha1-proteinase	R07AX	powder for injectable solution	not sold
02204606	PROLASTIN - 25MG/ML	alpha1-proteinase	R07AX	powder for injectable solution	
02189135	THROMBATE III - 500UNIT/VIAL	antithrombin III	B01AB	powder for injectable solution	
02189143	THROMBATE III - 1000UNIT/VIAL	antithrombin III	B01AB	powder for injectable solution	

## BAYER INC., AGRICULTURAL DIVISION

### Veterinary:

00812285	BAYTRIL - 22.7MG/ML	enrofloxacin		injectable solution	not sold
00719757	BAYTRIL - 32.3MG/ML	enrofloxacin		egg dip concentrate	
01923781	BAYTRIL - 50MG/ML	enrofloxacin		injectable solution	
	BAYTRIL - 100MG/ML	enrofloxacin		oral suspension	not sold
	BAYTRIL - 100MG/ML	enrofloxacin		injectable solution	not sold
00719765	BAYTRIL - 5.7MG/TAB	enrofloxacin		tablet	
00719773	BAYTRIL - 22.7MG/TAB	enrofloxacin		tablet	
00719781	BAYTRIL - 68MG/TAB	enrofloxacin		tablet	
00469319	CUTTER PASTE - 455MG/G	febantel		oral paste	expired
02076241	DRONTAL PLUS 113.4/22.7/22.7	febantel/praziquantel/pyrantel		tablet	expired
02076268	DRONTAL PLUS 340.2/68/68	febantel/praziquantel/pyrantel		tablet	expired
00573795	NEGABOT PLUS 67.5/400	febantel/metrifonate		oral paste	expired
00597856	VERCOM 34/3.4	febantel/praziquantel		oral paste	expired

## BERLEX CANADA INC.

### Human:

02169649	BETASERON - 0.3MG/VIAL	interferon beta-1b	L03AA	powder for injectable solution	
02231509	CLIMARA 0.05 - 3.9MG/PATCH	estradiol 17b	G03CA	transdermal patch	
02231510	CLIMARA 0.1 - 7.8MG/PATCH	estradiol 17b	G03CA	transdermal patch	
02227347	LEVOVIST 999/1	galactose/palmitic acid	V08DA	powder for injectable solution	not sold
02229102	LEVOVIST 999/1	galactose/palmitic acid	V08DA	powder for injectable solution	not sold
01989987	MAGNEVIST - 469MG/ML	gadopentetate dimeglumine	V08CA	injectable solution	
02202603	OSMOVIST 240 - 512.59MG/ML	iotrolan	V08AB	injectable solution	
02187051	OSMOVIST 280 - 598MG/ML	iotrolan	V08AB	injectable solution	not sold
02202611	OSMOVIST 300 - 640.75MG/ML	iotrolan	V08AB	injectable solution	
02078597	ULTRAVIST 240 - 499MG/ML	iopromide	V08AB	injectable solution	
02078600	ULTRAVIST 300 - 623MG/ML	iopromide	V08AB	injectable solution	
02078619	ULTRAVIST 370 - 769MG/ML	iopromide	V08AB	injectable solution	



DIN/GP	Brand Name	Generic Name	ATC*	Dosage Form	Comments
<b>BLOCK DRUG COMPANY (CANADA) LTD.</b>					
<b>Human:</b>					
02178796	COLPERMIN - 187MG/CAP	peppermint oil	A02DA	enteric-coated capsule	
01945092	SENSODYNE-F 5%/0.24%	potassium nitrate/sodium fluoride	A01AA	toothpaste	
02083310	SENSODYNE-F 5%/0.24%	potassium nitrate/sodium fluoride w/baking soda	A01AA	toothpaste	introduced
00624098	SENSODYNE-F 5%/0.8%	potassium nitrate/sodium monofluorophosphate	A01AA	toothpaste	
<b>BOEHRINGER INGELHEIM (CANADA) LTD.</b>					
<b>Human:</b>					
00790486	BRONALIDE - 0.25MG/DOSE	flunisolide	R03BA	aerosol for inhalation	expired
02057735	PROSTEP 11 - 15MG/PATCH	nicotine	N07BA	transdermal patch	
02057743	PROSTEP 22 - 30MG/PATCH	nicotine	N07BA	transdermal patch	
<b>Veterinary:</b>					
02080001	SEDIVET - 10MG/ML	romifidine		injectable solution	expired
00698229	SPUTOLYSIN - 5MG/G	dembrexin		oral powder	expired
	SPUTOLYSIN - 5MG/ML	dembrexin		injectable solution	expired
02126214	SUPER-OV - 7.5UNIT/ML	follicle stimulating hormone (porcine origin)		powder for injectable solution	
<b>BOEHRINGER MANNHEIM CANADA LTD.</b>					
<b>Human:</b>					
02232770	BONDRONAT - 1MG/ML	ibandronate	M05BA	injectable solution	not sold
02129094	DEMADEX - 10MG/ML	torsemide	C03CA	injectable solution	not sold
02129000	DEMADEX - 5MG/TAB	torsemide	C03CA	tablet	not sold
02129019	DEMADEX - 10MG/TAB	torsemide	C03CA	tablet	not sold
02129027	DEMADEX - 20MG/TAB	torsemide	C03CA	tablet	
02129035	DEMADEX - 100MG/TAB	torsemide	C03CA	tablet	not sold
02231763	EUCARDIC - 3.125MG/TAB	carvedilol	C07AG	tablet	not sold
02231764	EUCARDIC - 6.25MG/TAB	carvedilol	C07AG	tablet	not sold
02231765	EUCARDIC - 12.5MG/TAB	carvedilol	C07AG	tablet	not sold
02231766	EUCARDIC - 25MG/TAB	carvedilol	C07AG	tablet	not sold
01927078	OSTAC - 400MG/CAP	clodronate disodium	M05BA	capsule	
02233013	RETAVASE - 10.8UNIT/VIAL	reteplase	B01AD	powder for injectable solution	not sold
<b>BRACCO DIAGNOSTICS CANADA INC.</b>					
<b>Human:</b>					
	CHOLETEC - 45MG/VIAL	technetium tc-99m mebrofenin	V09DA	powder for injectable solution	
02229056	PROHANCE - 279.3MG/ML	gadoteridol	V08CA	injectable solution	
<b>BRISTOL-MYERS SQUIBB PHARMACEUTICAL GROUP</b>					
<b>Human:</b>					
01911570	AZACTAM - 500MG/VIAL	aztreonam	J01DF	powder for injectable solution	not sold
01911562	AZACTAM - 1000MG/VIAL	aztreonam	J01DF	powder for injectable solution	not sold
01911554	AZACTAM - 2000MG/VIAL	aztreonam	J01DF	powder for injectable solution	not sold
00695661	CAPOTEN - 12.5MG/TAB	captopril	C09AA	tablet	
00546283	CAPOTEN - 25MG/TAB	captopril	C09AA	tablet	
00546291	CAPOTEN - 50MG/TAB	captopril	C09AA	tablet	
00546305	CAPOTEN - 100MG/TAB	captopril	C09AA	tablet	
00891843	CAPOZIDE 25/12.5	captopril/hydrochlorothiazide	C09BA	tablet	not sold
02015099	CAPOZIDE 25/15	captopril/hydrochlorothiazide	C09BA	tablet	not sold
00620998	CAPOZIDE 25/25	captopril/hydrochlorothiazide	C09BA	tablet	not sold
00621005	CAPOZIDE 50/15	captopril/hydrochlorothiazide	C09BA	tablet	not sold
00621013	CAPOZIDE 50/25	captopril/hydrochlorothiazide	C09BA	tablet	not sold
	CARDIOTEC	technetium tc-99m teboroxime	V09GA	powder for injectable solution	not sold
02163675	CEFZIL - 25MG/ML	cefprozil	J01DA	powder for oral suspension	
02163683	CEFZIL - 50MG/ML	cefprozil	J01DA	powder for oral suspension	
02163659	CEFZIL - 250MG/TAB	cefprozil	J01DA	tablet	
02163667	CEFZIL - 500MG/TAB	cefprozil	J01DA	tablet	
00702277	DESYREL - 150MG/TAB	trazodone hydrochloride	N06AX	tablet	
00824135	DESYREL - 300MG/TAB	trazodone hydrochloride	N06AX	tablet	not sold
02230986	ETOPOPHOS - 100MG/VIAL	etoposide phosphate	L01CB	powder for injectable solution	not sold



DIN/GP	Brand Name	Generic Name	ATC*	Dosage Form	Comments
02168529	MAXIPIME - 1000MG/BOTTLE	cefepime hydrochloride	J01DA	powder for injectable solution	not sold
02168863	MAXIPIME - 2000MG/BOTTLE	cefepime hydrochloride	J01DA	powder for injectable solution	not sold
02163624	MAXIPIME - 500MG/VIAL	cefepime hydrochloride	J01DA	powder for injectable solution	not sold
02163632	MAXIPIME - 1000MG/VIAL	cefepime hydrochloride	J01DA	powder for injectable solution	
02163640	MAXIPIME - 2000MG/VIAL	cefepime hydrochloride	J01DA	powder for injectable solution	
01907093	MONOPRIL - 5MG/TAB	fosinopril	C09AA	tablet	not sold
01907107	MONOPRIL - 10MG/TAB	fosinopril	C09AA	tablet	
01907115	MONOPRIL - 20MG/TAB	fosinopril	C09AA	tablet	
00893749	PRAVACHOL - 10MG/TAB	pravastatin sodium	C10AA	tablet	
00893757	PRAVACHOL - 20MG/TAB	pravastatin sodium	C10AA	tablet	
02222051	PRAVACHOL - 40MG/TAB	pravastatin sodium	C10AA	tablet	
02087294	SERZONE - 50MG/TAB	nefazodone hydrochloride	N06AX	tablet	introduced
02087375	SERZONE - 100MG/TAB	nefazodone hydrochloride	N06AX	tablet	
02087383	SERZONE - 150MG/TAB	nefazodone hydrochloride	N06AX	tablet	
02087391	SERZONE - 200MG/TAB	nefazodone hydrochloride	N06AX	tablet	
02087405	SERZONE - 300MG/TAB	nefazodone hydrochloride	N06AX	tablet	not sold
02113031	STADOL NS - 10MG/ML	butorphanol tartrate	N02AF	injectable solution	
01940511	VIDEX - 25MG/TAB	didanosine	J05AB	tablet	
01940538	VIDEX - 50MG/TAB	didanosine	J05AB	tablet	
01940546	VIDEX - 100MG/TAB	didanosine	J05AB	tablet	
01940554	VIDEX - 150MG/TAB	didanosine	J05AB	tablet	
01940589	VIDEX - 100MG/VIAL	didanosine	J05AB	powder for oral solution	not sold
01940597	VIDEX - 167MG/VIAL	didanosine	J05AB	powder for oral solution	not sold
01940600	VIDEX - 250MG/VIAL	didanosine	J05AB	powder for oral solution	not sold
01940619	VIDEX - 375MG/VIAL	didanosine	J05AB	powder for oral solution	not sold
01940627	VIDEX - 2000MG/VIAL	didanosine	J05AB	powder for oral solution	not sold
01940635	VIDEX - 4000MG/VIAL	didanosine	J05AB	powder for oral solution	not sold
02216078	ZERIT - 5MG/CAP	stavudine	J05AX	capsule	not sold
02216086	ZERIT - 15MG/CAP	stavudine	J05AX	capsule	
02216094	ZERIT - 20MG/CAP	stavudine	J05AX	capsule	
02216108	ZERIT - 30MG/CAP	stavudine	J05AX	capsule	
02216116	ZERIT - 40MG/CAP	stavudine	J05AX	capsule	

**Veterinary:**

00673064	TORBUTROL - 2MG/ML	butorphanol tartrate		injectable solution	not sold
----------	--------------------	----------------------	--	---------------------	----------

**CANDERM PHARMA INC.**

**Human:**

01945149	CONDYLINE - 5MG/ML	podofilox	D11AF	topical solution	
----------	--------------------	-----------	-------	------------------	--

**CANGENE CORPORATION**

**Human:**

01930605	WINRHO - 0.12MG/VIAL	RHo(D) immune globulin (human)	J06BB	powder for injectable solution	not sold
01919326	WINRHO - 0.3MG/VIAL	RHo(D) immune globulin (human)	J06BB	powder for injectable solution	not sold
02022842	WINRHO SDF - 0.12MG/VIAL	RHo(D) immune globulin (human)	J06BB	powder for injectable solution	
02022834	WINRHO SDF - 0.3MG/VIAL	RHo(D) immune globulin (human)	J06BB	powder for injectable solution	
02230397	WINRHO SDF - 1MG/VIAL	RHo(D) immune globulin (human)	J06BB	powder for injectable solution	not sold

**CARTER-HORNER INC.**

**Human:**

00511641	DEPEN - 250MG/TAB	penicillamine	M01CC	tablet	
----------	-------------------	---------------	-------	--------	--

**CIBA-VISION**

**Human:**

02029901	AQUASITE 2/1	polyethylene glycol 400/dextran 70	S01XA	ophthalmic drops	
02131625	LIVOSTIN - 0.5MG/ML	levocabastine hydrochloride	S01GX	ophthalmic suspension	
01940414	VOLTAREN OPHTHA - 1MG/ML	diclofenac sodium	S01BC	ophthalmic drops	

DIN/GP	Brand Name	Generic Name	ATC*	Dosage Form	Comments
COLGATE ORAL PHARMACEUTICALS					
Human:					
02048213	VIADENT - 0.3MG/ML	sanguinarine	A01AD	oral rinse	not sold
02048221	VIADENT - 1.2MG/ML	sanguinarine	A01AD	toothpaste	
02048248	VIADENT FLUORIDE - 14MG/ML	sanguinarine	A01AD	toothpaste	
CONNAUGHT LABORATORIES LTD.					
Human:					
01905023	MULTITEST CMI	skin test antigens	V04CX	injectable suspension	introduced (nas)
02231343	PENTACEL	DaPT-IPV-Hib vaccine	J07AG	injectable suspension	
00764221	PROHIBIT	Hib vaccine	J07AG	injectable suspension	
02230946	QUADRACEL	DaPT-Hib vaccine	J07AJ	injectable suspension	introduced (nas)
02224143	TRIPACEL	DaPT vaccine	J07AJ	injectable suspension	introduced (nas)
DERMIK LABORATORIES CANADA INC.					
Human:					
02225271	BENZAMYCIN 50/30	benzoyl peroxide/ erythromycin	D10AF	topical gel	
DISTA PRODUCTS LIMITED					
Human:					
01968041	TALIDAN - 10MG/CAP	fluoxetine hydrochloride	N06AB	capsule	not sold
01968033	TALIDAN - 20MG/CAP	fluoxetine hydrochloride	N06AB	capsule	not sold
DRAXIS HEALTH INC.					
Human:					
02123312	ELDEPRYL - 5MG/TAB	selegiline hydrochloride	N04BD	tablet	not sold
02123320	PERMAX - 0.05MG/TAB	pergolide mesylate	N04BC	tablet	
02123339	PERMAX - 0.25MG/TAB	pergolide mesylate	N04BC	tablet	
02123347	PERMAX - 1MG/TAB	pergolide mesylate	N04BC	tablet	
01927272	SD DEPRENYL - 5MG/TAB	selegiline hydrochloride	N04BD	tablet	
DU PONT MERCK PHARMA INC.					
Human:					
02211114	BIANDA - 25MG/VIAL	losoxantrone hydrochloride	L01XX	powder for injectable solution	not sold
	CARDIOLITE	technetium tc-99m sestamibi	V09GA	powder for injectable solution	introduced
	MIRALUMA	technetium tc-99m sestamibi	V09GA	powder for injectable solution	
	NEUROLITE - 20MCI/TEST	technetium tc-99m bicsate	V09AA	powder for injectable solution	
02028786	SINEMET CR 25/100	carbidopa/levodopa	N04BA	sustained-release tablet	
00870935	SINEMET CR 50/200	carbidopa/levodopa	N04BA	sustained-release tablet	
ELI LILLY CANADA INC.					
Human:					
00778338	AXID - 150MG/CAP	nizatidine	A02BA	capsule	not sold
00778346	AXID - 300MG/CAP	nizatidine	A02BA	capsule	
00465186	CECLOR - 250MG/CAP	cefaclor	J01DA	capsule	
00465194	CECLOR - 500MG/CAP	cefaclor	J01DA	capsule	
00465208	CECLOR - 25MG/ML	cefaclor	J01DA	powder for oral suspension	
00832790	CECLOR - 37.4MG/ML	cefaclor	J01DA	powder for oral suspension	
00465216	CECLOR - 50MG/ML	cefaclor	J01DA	powder for oral suspension	not sold
00832804	CECLOR BID - 75MG/ML	cefaclor	J01DA	powder for oral suspension	
02161761	CECLOR CD - 375MG/TAB	cefaclor	J01DA	sustained-release tablet	
02161788	CECLOR CD - 500MG/TAB	cefaclor	J01DA	sustained-release tablet	not sold
00548375	CESAMET - 1MG/CAP	nabilone	A04AD	capsule	not sold
02229863	DYNABAC - 250MG/TAB	dirithromycin	J01FA	tablet	not sold
00555665	ELDISINE - 5MG/VIAL	vindesine sulfate	L01CA	powder for injectable solution	expired
02218054	ETHYOL - 500MG/VIAL	amifostine	V03AF	powder for injectable solution	
02230308	GEMZAR - 200MG/VIAL	gemcitabine hydrochloride	L01BC	powder for injectable solution	
02230309	GEMZAR - 1000MG/VIAL	gemcitabine hydrochloride	L01BC	powder for injectable solution	introduced
00015377	GLUCAGON - 1MG/ML	glucagon hydrochloride	H04AA	powder for injectable solution	
02229692	HUMATROPE - 6.7MG/CARTRIDGE	somatropin	H01AC	powder for injectable solution	
02229693	HUMATROPE - 13.3MG/CARTRIDGE	somatropin	H01AC	powder for injectable solution	introduced
02229694	HUMATROPE - 26.6MG/CARTRIDGE	somatropin	H01AC	powder for injectable solution	not sold
00745626	HUMATROPE - 5MG/VIAL	somatropin	H01AC	powder for injectable solution	
00889113	HUMULIN-10/90 - 100UNIT/ML	insulin (regular/isophane) human biosynthetic	A10AE	injectable suspension	

DIN/GP	Brand Name	Generic Name	ATC*	Dosage Form	Comments
01962639	HUMULIN-10/90 - 100UNIT/ML	insulin (regular/isophane) human biosynthetic	A10AE	injectable suspension	
00889105	HUMULIN-20/80 - 100UNIT/ML	insulin (regular/isophane) human biosynthetic	A10AE	injectable suspension	
01962655	HUMULIN-20/80 - 100UNIT/ML	insulin (regular/isophane) human biosynthetic	A10AE	injectable suspension	
00795879	HUMULIN-30/70 - 100UNIT/ML	insulin (regular/isophane) human biosynthetic	A10AE	injectable suspension	
01959212	HUMULIN-30/70 - 100UNIT/ML	insulin (regular/isophane) human biosynthetic	A10AE	injectable suspension	
00889091	HUMULIN-40/60 - 100UNIT/ML	insulin (regular/isophane) human biosynthetic	A10AE	injectable suspension	
01962647	HUMULIN-40/60 - 100UNIT/ML	insulin (regular/isophane) human biosynthetic	A10AE	injectable suspension	
00889121	HUMULIN-50/50 - 100UNIT/ML	insulin (regular/isophane) human biosynthetic	A10AE	injectable suspension	
01962663	HUMULIN-50/50 - 100UNIT/ML	insulin (regular/isophane) human biosynthetic	A10AE	injectable suspension	
00646148	HUMULIN-L - 100UNIT/ML	insulin (lente) human biosynthetic	A10AC	injectable suspension	
00587737	HUMULIN-N - 100UNIT/ML	insulin (isophane) human biosynthetic	A10AC	injectable suspension	
01959239	HUMULIN-N - 100UNIT/ML	insulin (isophane) human biosynthetic	A10AC	injectable suspension	
00586714	HUMULIN-R - 100UNIT/ML	insulin (regular) human biosynthetic	A10AB	injectable solution	
01959220	HUMULIN-R - 100UNIT/ML	insulin (regular) human biosynthetic	A10AB	injectable solution	
00733075	HUMULIN-U - 100UNIT/ML	insulin (ultralente) human biosynthetic	A10AD	injectable suspension	
00514535	Iletin-II LENTE PORK - 100UNIT/ML	pork insulin/zinc	A10AC	injectable suspension	
00514551	Iletin-II NPH PORK - 100UNIT/ML	pork insulin/zinc/protamine	A10AC	injectable suspension	
00513644	Iletin-II REGULAR PORK - 100UNIT/ML	pork insulin/zinc	A10AB	injectable solution	
00446580	Iletin-LENTE - 100UNIT/ML	pork/bovine insulin/zinc	A10AC	injectable suspension	
00446572	Iletin-NPH - 100UNIT/ML	pork/bovine insulin/zinc/ protamine	A10AC	injectable suspension	
00446610	Iletin-PROTAMINE ZINC - 100UNIT/ML	pork/bovine insulin/zinc/protamine	A10AD	injectable suspension	not sold
00446564	Iletin-REGULAR - 100UNIT/ML	pork/bovine insulin/zinc	A10AB	injectable solution	
00446602	Iletin-SEMILENTE - 100UNIT/ML	pork/bovine insulin/zinc	A10AC	injectable suspension	not sold
00446599	Iletin-ULTRALENTE - 100UNIT/ML	pork/bovine insulin/zinc	A10AD	injectable suspension	not sold
00015202	ILOSONE - 250MG/CAP	erythromycin estolate	J01FA	capsule	
00015474	ILOSONE - 25MG/ML	erythromycin estolate	J01FA	oral suspension	
00210641	ILOSONE - 50MG/ML	erythromycin estolate	J01FA	oral suspension	
00244384	ILOSONE - 500MG/TAB	erythromycin estolate	J01FA	tablet	not sold
00015369	KEFLIN - 1000MG/VIAL	cephalothin sodium	J01DA	powder for injectable solution	expired
00244406	KEFLIN - 2000MG/VIAL	cephalothin sodium	J01DA	powder for injectable solution	expired
00298484	KEFLIN - 4000MG/VIAL	cephalothin sodium	J01DA	powder for injectable solution	expired
00659150	KEFLIN - 20000MG/VIAL	cephalothin sodium	J01DA	powder for injectable solution	expired
00752525	KEFLIN ADD-VANTAGE - 1000MG/VIAL	cephalothin sodium	J01DA	powder for injectable solution	not sold
00752533	KEFLIN ADD-VANTAGE - 2000MG/VIAL	cephalothin sodium	J01DA	powder for injectable solution	not sold
00322288	KEFZOL - 500MG/VIAL	cefazolin sodium	J01DA	powder for injectable solution	
00322296	KEFZOL - 1000MG/VIAL	cefazolin sodium	J01DA	powder for injectable solution	
00411450	KEFZOL - 10000MG/VIAL	cefazolin sodium	J01DA	powder for injectable solution	
00411434	KEFZOL ADD-VANTAGE - 500MG/VIAL	cefazolin sodium	J01DA	powder for injectable solution	not sold
00411442	KEFZOL ADD-VANTAGE - 1000MG/VIAL	cefazolin sodium	J01DA	powder for injectable solution	
02044757	LORABID - 200MG/CAP	loracarbef	J01DA	capsule	not sold
02044749	LORABID - 400MG/CAP	loracarbef	J01DA	capsule	not sold
02161206	LORABID - 20MG/ML	loracarbef	J01DA	powder for oral suspension	not sold
02161214	LORABID - 40MG/ML	loracarbef	J01DA	powder for oral suspension	not sold
00439304	MANDOL - 500MG/VIAL	cefamandole nafate	J01DA	powder for injectable solution	not sold
00439320	MANDOL - 1000MG/VIAL	cefamandole nafate	J01DA	powder for injectable solution	
00439312	MANDOL - 2000MG/VIAL	cefamandole nafate	J01DA	powder for injectable solution	

DIN/GP	Brand Name	Generic Name	ATC*	Dosage Form	Comments
00648930	MANDOL ADD-VANTAGE - 1000MG/VIAL	cefamandole nafate	J01DA	powder for injectable solution	not sold
00842621	MANDOL ADD-VANTAGE - 2000MG/VIAL	cefamandole nafate	J01DA	powder for injectable solution	not sold
00569755	MOXAM - 1000MG/VIAL	moxalactam disodium	J01DA	powder for injectable solution	expired
00569763	MOXAM - 2000MG/VIAL	moxalactam disodium	J01DA	powder for injectable solution	expired
00851825	NEBCIN ADD-VANTAGE - 10MG/ML	tobramycin sulfate	J01GB	injectable solution	not sold
00611182	ONCOVIN - 1MG/ML	vincristine sulfate	L01CA	injectable solution	
02018985	PROZAC - 10MG/CAP	fluoxetine hydrochloride	N06AB	capsule	
00636622	PROZAC - 20MG/CAP	fluoxetine hydrochloride	N06AB	capsule	
01917021	PROZAC - 4MG/ML	fluoxetine hydrochloride	N06AB	oral solution	
02216973	REOPRO - 2MG/ML	abciximab	B01AC	injectable solution	
00888338	TAZIDIME - 500MG/VIAL	ceftazidime pentahydrate	J01DA	powder for injectable solution	not sold
00886971	TAZIDIME - 1000MG/VIAL	ceftazidime pentahydrate	J01DA	powder for injectable solution	
00886955	TAZIDIME - 2000MG/VIAL	ceftazidime pentahydrate	J01DA	powder for injectable solution	
00886963	TAZIDIME - 6000MG/VIAL	ceftazidime pentahydrate	J01DA	powder for injectable solution	
00887129	TAZIDIME ADD-VANTAGE - 1000MG/VIAL	ceftazidime pentahydrate	J01DA	powder for injectable solution	
01980645	TAZIDIME ADD-VANTAGE - 2000MG/VIAL	ceftazidime pentahydrate	J01DA	powder for injectable solution	
00800430	VANCOCIN - 125MG/CAP	vancomycin hydrochloride	J01XA	capsule	
00788716	VANCOCIN - 250MG/CAP	vancomycin hydrochloride	J01XA	capsule	
02015110	VANCOCIN - 1000MG/VIAL	vancomycin hydrochloride	J01XA	powder for injectable solution	
00015423	VANCOCIN C.P. - 500MG/VIAL	vancomycin hydrochloride	J01XA	powder for injectable solution	
00722146	VANCOCIN C.P. - 1000MG/VIAL	vancomycin hydrochloride	J01XA	powder for injectable solution	
00803510	VANCOCIN C.P. ADD-VANTAGE - 500MG/VIAL	vancomycin hydrochloride	J01XA	powder for injectable solution	
00803537	VANCOCIN C.P. ADD-VANTAGE - 1000MG/VIAL	vancomycin hydrochloride	J01XA	powder for injectable solution	
02229250	ZYPREXA - 2.5MG/TAB	olanzapine	N05AH	tablet	expired
02229269	ZYPREXA - 5MG/TAB	olanzapine	N05AH	tablet	expired
02229277	ZYPREXA - 7.5MG/TAB	olanzapine	N05AH	tablet	expired
02229285	ZYPREXA - 10MG/TAB	olanzapine	N05AH	tablet	expired

## FABRIGEN INC.

### Human:

02078465	AVIRAX - 200MG/CAP	acyclovir	J05AB	capsule	not sold
02078473	AVIRAX - 50MG/G	acyclovir	D06BB	ointment	not sold
02078503	AVIRAX - 50MG/G	acyclovir	D06BB	cream	not sold
02078643	AVIRAX - 40MG/ML	acyclovir	J05AB	oral suspension	not sold
02078627	AVIRAX - 200MG/TAB	acyclovir	J05AB	tablet	
02078635	AVIRAX - 400MG/TAB	acyclovir	J05AB	tablet	
02078651	AVIRAX - 800MG/TAB	acyclovir	J05AB	tablet	
02078481	AVIRAX - 1000MG/VIAL	acyclovir sodium	J05AB	powder for injectable solution	not sold

## FAULDING (CANADA) INC.

### Human:

ONCOSCINT CR/OV - 1MG/KIT	satumomab pendetide	V09IB	injectable solution	not sold
---------------------------	---------------------	-------	---------------------	----------

## FERRING INC.

### Human:

02231047	ACTHREL - 0.1MG/VIAL	corticotropin ovine triflutate	V04CD	powder for injectable solution	not sold
00836362	ACTHREL NF - 0.1MG/VIAL	corticotropin ovine triflutate	V04CD	powder for injectable solution	introduced
00873993	CERVIDIL 0.3 - 10MG/POUCH	dinoprostone	G02AD	vaginal insert	introduced
00402516	DDAVP - 0.01MG/DOSE	desmopressin acetate	H01BA	nasal aerosol	
00824305	DDAVP - 0.004MG/ML	desmopressin acetate	H01BA	injectable solution	
00824143	DDAVP - 0.1MG/ML	desmopressin acetate	H01BA	nasal solution	
02125226	DDAVP - 0.1MG/TAB	desmopressin acetate	H01BA	tablet	
02024179	DDAVP - 0.2MG/TAB	desmopressin acetate	H01BA	tablet	
00780197	NIDAGEL - 7.5MG/G	metronidazole	G01AF	vaginal gel	
02153521	OCTOSTIM - 0.15MG/DOSE	desmopressin acetate	H01BA	nasal aerosol	
02153548	OCTOSTIM - 0.015MG/ML	desmopressin acetate	H01BA	injectable solution	
02153556	OCTOSTIM - 1.5MG/ML	desmopressin acetate	H01BA	nasal solution	not sold
02153564	QUINTASA - 1000MG/DOSE	5-aminosalicylic acid	A07EC	rectal suspension	
	QUINTASA - 2000MG/DOSE	5-aminosalicylic acid	A07EC	rectal suspension	
	QUINTASA - 4000MG/DOSE	5-aminosalicylic acid	A07EC	rectal suspension	
	QUINTASA - 1000MG/SUP	5-aminosalicylic acid	A07EC	suppository	

DIN/GP	Brand Name	Generic Name	ATC*	Dosage Form	Comments
FOURNIER PHARMA INC.					
Human:					
02230283	LIPIDIL MICRO - 67MG/CAP	fenofibrate	C10AB	capsule	not sold
02146959	LIPIDIL MICRO - 200MG/CAP	fenofibrate	C10AB	capsule	
FUJISAWA CANADA INC.					
Human:					
02139294	ADENOSCAN - 3MG/ML	adenosine	C01EB	injectable solution	
	AMBISOME - 50MG/VIAL	amphotericin b	J02AA	powder for injectable solution	
02175991	PROGRAF - 1MG/CAP	tacrolimus	L04AA	capsule	
02175983	PROGRAF - 5MG/CAP	tacrolimus	L04AA	capsule	
02176009	PROGRAF - 5MG/ML	tacrolimus	L04AA	injectable solution	
GALDERMA CANADA INC.					
Human:					
02148749	DIFFERIN - 1MG/G	adapalene	D10AD	topical gel	not sold
02231592	DIFFERIN - 1MG/G	adapalene	D10AD	topical cream	
02148757	DIFFERIN - 1MG/ML	adapalene	D10AD	topical solution	
02092832	METROGEL - 7.5MG/G	metronidazole	D06BX	topical gel	
GENDERM CANADA INC.					
Human:					
02142147	ZONALON - 50MG/G	doxepin hydrochloride	D04AA	cream	
00740306	ZOSTRIX - 0.25MG/G	capsaicin	M02AB	cream	
02004240	ZOSTRIX-HP - 0.75MG/G	capsaicin	M02AB	cream	
GENETICS INSTITUTE, INC.					
Human:					
02231018	BENEFIX - 250UNIT/VIAL	coagulation factor IX (recombinant)	B02BD	powder for injectable solution	introduced (nas)
02231019	BENEFIX - 500UNIT/VIAL	coagulation factor IX (recombinant)	B02BD	powder for injectable solution	introduced (nas)
02231020	BENEFIX - 1000UNIT/VIAL	coagulation factor IX (recombinant)	B02BD	powder for injectable solution	introduced (nas)
GLAXO WELLCOME INC.					
Human:					
02192691	3TC - 10MG/ML	lamivudine	J05AB	oral solution	introduced (nas)
02192683	3TC - 150MG/TAB	lamivudine	J05AB	tablet	introduced (nas)
00828521	BECLODISK - 0.1MG/DOSE	beclomethasone dipropionate	R03BA	powder for inhalation	
00828548	BECLODISK - 0.2MG/DOSE	beclomethasone dipropionate	R03BA	powder for inhalation	
02215039	BECLOVENT - 0.1MG/CAP	beclomethasone dipropionate	R03BA	powder for inhalation	
02215047	BECLOVENT - 0.2MG/CAP	beclomethasone dipropionate	R03BA	powder for inhalation	
01943049	CEFTIN - 25MG/ML	cefuroxime axetil	J01DA	powder for oral suspension	
02145286	CEFTIN - 250MG/POUCH	cefuroxime axetil	J01DA	powder for oral suspension	not sold
00886882	CEFTIN - 125MG/TAB	cefuroxime axetil	J01DA	tablet	
00886890	CEFTIN - 250MG/TAB	cefuroxime axetil	J01DA	tablet	
00886904	CEFTIN - 500MG/TAB	cefuroxime axetil	J01DA	tablet	not sold
01974394	CEPTAZ - 500MG/VIAL	ceftazidime pentahydrate	J01DA	powder for injectable solution	
01974408	CEPTAZ - 1000MG/VIAL	ceftazidime pentahydrate	J01DA	powder for injectable solution	
01974416	CEPTAZ - 2000MG/VIAL	ceftazidime pentahydrate	J01DA	powder for injectable solution	introduced (nas)
01968092	CEPTAZ - 10000MG/VIAL	ceftazidime pentahydrate	J01DA	powder for injectable solution	
01927175	EXOSURF - 108MG/KIT	colfosceril palmitate	R07AA	endo-tracheal suspension kit	
02038269	EXOSURF - 67.5MG/VIAL	colfosceril palmitate	R07AA	endo-tracheal suspension vial	not sold
01927183	EXOSURF - 108MG/VIAL	colfosceril palmitate	R07AA	endo-tracheal suspension vial	not sold
02230845	FLOLAN - 0.5MG/VIAL	epoprostenol sodium	B01AC	powder for injectable solution	introduced (nas)
02230848	FLOLAN - 1.5MG/VIAL	epoprostenol sodium	B01AC	powder for injectable solution	introduced (nas)
02230857	FLOLAN STERILE DILUENT	epoprostenol sodium	B01AC	powder for injectable solution	introduced (nas)
02048043	FLONASE - 0.05MG/DOSE	fluticasone propionate	R01AD	nasal spray	
02213583	FLOVENT - 0.025MG/DOSE	fluticasone propionate	R03BA	aerosol for inhalation	
02213591	FLOVENT - 0.05MG/DOSE	fluticasone propionate	R03BA	aerosol for inhalation	
02213621	FLOVENT - 0.05MG/DOSE	fluticasone propionate	R03BA	powder for inhalation	not sold
02213648	FLOVENT - 0.1MG/DOSE	fluticasone propionate	R03BA	powder for inhalation	not sold
02213605	FLOVENT - 0.125MG/DOSE	fluticasone propionate	R03BA	aerosol for inhalation	not sold
02213613	FLOVENT - 0.25MG/DOSE	fluticasone propionate	R03BA	aerosol for inhalation	
02213656	FLOVENT - 0.25MG/DOSE	fluticasone propionate	R03BA	powder for inhalation	
02213664	FLOVENT - 0.5MG/DOSE	fluticasone propionate	R03BA	powder for inhalation	not sold



DIN/GP	Brand Name	Generic Name	ATC*	Dosage Form	Comments
00640026	FORTAZ - 500MG/VIAL	ceftazidime pentahydrate	J01DA	powder for injectable solution	
00640034	FORTAZ - 1000MG/VIAL	ceftazidime pentahydrate	J01DA	powder for injectable solution	
00640042	FORTAZ - 2000MG/VIAL	ceftazidime pentahydrate	J01DA	powder for injectable solution	
00791679	FORTAZ - 6000MG/VIAL	ceftazidime pentahydrate	J01DA	powder for injectable solution	
02230418	IMITREX - 5MG/DOSE	sumatriptan hemisulphate	N02CC	nasal spray	introduced
02230419	IMITREX - 10MG/DOSE	sumatriptan hemisulphate	N02CC	nasal spray	not sold
02230420	IMITREX - 20MG/DOSE	sumatriptan hemisulphate	N02CC	nasal spray	introduced
02212188	IMITREX - 12MG/ML	sumatriptan succinate	N02CC	injectable solution	
02212153	IMITREX - 50MG/TAB	sumatriptan succinate	N02CC	tablet	
02212161	IMITREX - 100MG/TAB	sumatriptan succinate	N02CC	tablet	
02142082	LAMICTAL - 25MG/TAB	lamotrigine	N03AX	tablet	
02142090	LAMICTAL - 50MG/TAB	lamotrigine	N03AX	tablet	not sold
02142104	LAMICTAL - 100MG/TAB	lamotrigine	N03AX	tablet	
02142112	LAMICTAL - 150MG/TAB	lamotrigine	N03AX	tablet	
02142120	LAMICTAL - 200MG/TAB	lamotrigine	N03AX	tablet	not sold
02142139	LAMICTAL - 250MG/TAB	lamotrigine	N03AX	tablet	not sold
02217422	MEPRON - 150MG/ML	atovaquone	P01XA	oral suspension	
02009358	MEPRON - 250MG/TAB	atovaquone	P01XA	tablet	
02087308	MIVACRON - 2MG/ML	mivacurium chloride	M03AC	injectable solution	
02091283	NAVELBINE - 10MG/ML	vinorelbine tartrate	L01CA	injectable solution	
02229422	NIMBEX - 2MG/ML	cisatracurium besylate	M03AC	injectable solution	expired
02229423	NIMBEX - 10MG/ML	cisatracurium besylate	M03AC	injectable solution	expired
01924656	NUROMAX - 1MG/ML	doxacurium chloride	M03AC	injectable solution	
02231831	PYLORID - 400MG/TAB	ranitidine bismuth citrate	A02BA	tablet	introduced
01902660	RETROVIR - 100MG/CAP	zidovudine	J05AB	capsule	
01902644	RETROVIR - 10MG/ML	zidovudine	J05AB	injectable solution	
01902652	RETROVIR - 10MG/ML	zidovudine	J05AB	syrup	
02136139	SEREVENT - 0.025MG/DOSE	salmeterol xinafoate	R03AC	aerosol for inhalation	
02136147	SEREVENT - 0.05MG/DOSE	salmeterol xinafoate	R03AC	powder for inhalation	
02231129	SEREVENT DISKUS - 0.05MG/DOSE	salmeterol xinafoate	R03AC	powder for inhalation	not sold
00675210	TRACRIUM - 10MG/ML	atracurium besylate	M03AC	injectable solution	expired
02230409	ULTIVA - 1MG/VIAL	remifentanil hydrochloride	N01AH	powder for injectable solution	
02230410	ULTIVA - 2MG/VIAL	remifentanil hydrochloride	N01AH	powder for injectable solution	
02230411	ULTIVA - 5MG/VIAL	remifentanil hydrochloride	N01AH	powder for injectable solution	
02219492	VALTREX - 500MG/TAB	valacyclovir hydrochloride	J05AB	tablet	
02214997	VENTODISK - 0.2MG/DOSE	salbutamol sulfate	R03AC	powder for inhalation	
02215004	VENTODISK - 0.4MG/DOSE	salbutamol sulfate	R03AC	powder for inhalation	
02213215	VENTOLIN - 0.2MG/CAP	salbutamol sulfate	R03AC	powder for inhalation	
02212323	VENTOLIN - 0.4MG/CAP	salbutamol sulfate	R03AC	powder for inhalation	
02035421	VENTOLIN - 0.4MG/ML	salbutamol sulfate	R03CC	oral solution	
00782351	VOLMAX - 4MG/TAB	salbutamol sulfate	R03CC	sustained-release tablet	expired
00782378	VOLMAX - 8MG/TAB	salbutamol sulfate	R03CC	sustained-release tablet	expired
01959077	WELLFERON - 3000000UNIT/ML	interferon alpha-n1	L03AA	injectable solution	
02161176	WELLFERON - 5000000UNIT/ML	interferon alpha-n1	L03AA	injectable solution	not sold
01959069	WELLFERON - 10000000UNIT/ML	interferon alpha-n1	L03AA	injectable solution	
00782386	ZANTAC - 15MG/ML	ranitidine hydrochloride	A02BA	oral solution	
00603791	ZANTAC - 25MG/ML	ranitidine hydrochloride	A02BA	injectable solution	
00553379	ZANTAC - 150MG/TAB	ranitidine hydrochloride	A02BA	tablet	
00641790	ZANTAC - 300MG/TAB	ranitidine hydrochloride	A02BA	tablet	
00849421	ZANTAC C - 150MG/CAP	ranitidine hydrochloride	A02BA	capsule	
00849448	ZANTAC C - 300MG/CAP	ranitidine hydrochloride	A02BA	capsule	
01951831	ZANTAC EFFERVESCENT - 150MG/POUCH	ranitidine hydrochloride	A02BA	effervescent granules	not sold
01951823	ZANTAC EFFERVESCENT - 300MG/POUCH	ranitidine hydrochloride	A02BA	effervescent granules	not sold
02076284	ZANTAC EFFERVESCENT - 150MG/TAB	ranitidine hydrochloride	A02BA	effervescent tablet	not sold
02076292	ZANTAC EFFERVESCENT - 300MG/TAB	ranitidine hydrochloride	A02BA	effervescent tablet	not sold
00577227	ZINACEF - 250MG/VIAL	cefuroxime sodium	J01DA	powder for injectable solution	not sold
00497843	ZINACEF - 750MG/VIAL	cefuroxime sodium	J01DA	powder for injectable solution	
00481890	ZINACEF - 1500MG/VIAL	cefuroxime sodium	J01DA	powder for injectable solution	
00890936	ZINACEF - 7500MG/VIAL	cefuroxime sodium	J01DA	powder for injectable solution	
02229639	ZOFRAN - 0.8MG/ML	ondansetron hydrochloride	A04AA	oral solution	
01911821	ZOFRAN - 2MG/ML	ondansetron hydrochloride	A04AA	injectable solution	
02213567	ZOFRAN - 4MG/TAB	ondansetron hydrochloride	A04AA	tablet	
02213575	ZOFRAN - 8MG/TAB	ondansetron hydrochloride	A04AA	tablet	
00590924	ZOVIRAX - 200MG/CAP	acyclovir	J05AB	capsule	
00569771	ZOVIRAX - 50MG/G	acyclovir	D06BB	ointment	



DIN/GP	Brand Name	Generic Name	ATC*	Dosage Form	Comments
02039524	ZOVIRAX - 50MG/G	acyclovir	D06BB	cream	
00886157	ZOVIRAX - 40MG/ML	acyclovir	J05AB	oral suspension	
00634506	ZOVIRAX - 200MG/TAB	acyclovir	J05AB	tablet	
01911627	ZOVIRAX - 400MG/TAB	acyclovir	J05AB	tablet	
01911635	ZOVIRAX - 800MG/TAB	acyclovir	J05AB	tablet	
00605336	ZOVIRAX - 500MG/VIAL	acyclovir sodium	J05AB	powder for injectable solution	
00899321	ZOVIRAX - 1000MG/VIAL	acyclovir sodium	J05AB	powder for injectable solution	

## HOECHST MARION ROUSSEL CANADA INC.

### Human:

02231463	ALLEGRA - 60MG/CAP	fexofenadine hydrochloride	R06AX	capsule	not sold
02231462	ALLEGRA - 60MG/TAB	fexofenadine hydrochloride	R06AX	tablet	introduced (nas)
02050943	ALTACE - 1.25MG/CAP	ramipril	C09AA	capsule	
02050951	ALTACE - 2.5MG/CAP	ramipril	C09AA	capsule	
02050978	ALTACE - 5MG/CAP	ramipril	C09AA	capsule	
02050986	ALTACE - 10MG/CAP	ramipril	C09AA	capsule	
00863890	ANANDRON - 50MG/TAB	nilutamide	L02BB	tablet	expired
00863904	ANANDRON - 100MG/TAB	nilutamide	L02BB	tablet	expired
02231380	ANZEMET - 20MG/ML	dolasetron mesylate	A04AA	injectable solution	introduced (nas)
02231378	ANZEMET - 50MG/TAB	dolasetron mesylate	A04AA	tablet	introduced (nas)
02231379	ANZEMET - 100MG/TAB	dolasetron mesylate	A04AA	tablet	introduced (nas)
00760439	CITRUCEL - 166.66666MG/G	methylcellulose	A06AC	powder	not sold
00546208	CLAFORAN - 500MG/VIAL	cefotaxime sodium	J01DA	powder for injectable solution	
00546216	CLAFORAN - 1000MG/VIAL	cefotaxime sodium	J01DA	powder for injectable solution	
00546224	CLAFORAN - 2000MG/VIAL	cefotaxime sodium	J01DA	powder for injectable solution	
00839248	CLAFORAN ADD-VANTAGE - 1000MG/VIAL	cefotaxime sodium	J01DA	powder for injectable solution	
00839256	CLAFORAN ADD-VANTAGE - 2000MG/VIAL	cefotaxime sodium	J01DA	powder for injectable solution	not sold
02059754	DERMATOP - 1MG/G	prednicarbate	D07AC	ointment	not sold
02093111	NICODERM 7 - 36MG/PATCH	nicotine	N07BA	transdermal patch	
02093138	NICODERM 14 - 78MG/PATCH	nicotine	N07BA	transdermal patch	
02093146	NICODERM 21 - 114MG/PATCH	nicotine	N07BA	transdermal patch	
02179725	ORELOX - 100MG/TAB	cefpodoxime proxetil	J01DA	tablet	not sold
00894869	PENTASA - 250MG/CAP	5-aminosalicylic acid	A07EC	capsule	not sold
00894877	PENTASA - 250MG/TAB	5-aminosalicylic acid	A07EC	tablet	
01940384	PENTASA - 500MG/TAB	5-aminosalicylic acid	A07EC	tablet	
02069539	RENEDIL - 2.5MG/TAB	felodipine	C08CA	sustained-release tablet	
01989618	RENEDIL - 5MG/TAB	felodipine	C08CA	sustained-release tablet	
01989596	RENEDIL - 10MG/TAB	felodipine	C08CA	sustained-release tablet	
00619760	RYTHMODAN LA - 250MG/TAB	disopyramide	C01BA	sustained-release tablet	
02068036	SABRIL - 500MG/POUCH	vigabatrin	N03AG	powder for oral solution	expired
02068028	SABRIL - 1000MG/POUCH	vigabatrin	N03AG	powder for oral solution	expired
02068001	SABRIL - 2000MG/POUCH	vigabatrin	N03AG	powder for oral solution	expired
02067994	SABRIL - 3000MG/POUCH	vigabatrin	N03AG	powder for oral solution	expired
02065819	SABRIL - 500MG/TAB	vigabatrin	N03AG	tablet	expired
00590908	SELDANE - 60MG/TAB	terfenadine	R06AX	tablet	
00786624	SELDANE - 120MG/TAB	terfenadine	R06AX	tablet	
00680028	SUPREFACT - 1MG/ML	buserelin acetate	L02AE	injectable solution	expired
00680036	SUPREFACT - 1MG/ML	buserelin acetate	L02AE	nasal solution	expired
02228955	SUPREFACT DEPOT - 6.6MG/VIAL	buserelin acetate	L02AE	injectable implant	introduced
00870927	TERFENADINE - 60MG/TAB	terfenadine	R06AX	tablet	
	TERFENADINE - 120MG/TAB	terfenadine	R06AX	tablet	
00586625	TRENTAL - 400MG/TAB	pentoxifylline	C04AD	sustained-release tablet	expired

## HOFFMANN-LA ROCHE LIMITED

### Human:

02162725	ANAPROX - 275MG/TAB	naproxen sodium	M01AE	tablet	
02162717	ANAPROX DS - 550MG/TAB	naproxen sodium	M01AE	tablet	
00874019	ANEXATE - 0.1MG/ML	flumazenil	V03AB	injectable solution	
00550078	BACTRIM 16/80	trimethoprim/ sulfamethoxazole	J01EE	injectable solution	
00272477	BACTRIM 20/100	trimethoprim/ sulfamethoxazole	J01EE	tablet	not sold
00272485	BACTRIM 8/40	trimethoprim/ sulfamethoxazole	J01EE	oral suspension	
00272469	BACTRIM 80/400	trimethoprim/ sulfamethoxazole	J01EE	tablet	

DIN/GP	Brand Name	Generic Name	ATC*	Dosage Form	Comments
00371823	BACTRIM DS 160/800	trimethoprim/ sulfamethoxazole	J01EE	tablet	
02162741	CARDENE - 20MG/CAP	nicardipine hydrochloride	C08CA	capsule	
02162733	CARDENE - 30MG/CAP	nicardipine hydrochloride	C08CA	capsule	
02143348	CARDENE - 2.5MG/ML	nicardipine hydrochloride	C08CA	injectable solution	not sold
02034514	CARDENE SR - 30MG/CAP	nicardipine hydrochloride	C08CA	sustained-release capsule	not sold
01950657	CARDENE SR - 45MG/CAP	nicardipine hydrochloride	C08CA	sustained-release capsule	not sold
01950649	CARDENE SR - 60MG/CAP	nicardipine hydrochloride	C08CA	sustained-release capsule	not sold
02192748	CELLCEPT - 250MG/CAP	mycophenolate mofetil	L04AA	capsule	
02186802	CYTOVENE - 250MG/CAP	ganciclovir	J05AB	capsule	
02162695	CYTOVENE - 500MG/VIAL	ganciclovir sodium	J05AB	powder for injectable solution	
00692719	FANSIDAR 500/25	sulfadoxine/pyrimethamine	P01BD	tablet	
00776173	FEMSTAT - 20MG/G	butoconazole nitrate	G01AF	cream	expired
00890987	FEMSTAT - 20MG/G	butoconazole nitrate	G01AF	cream	expired
00890979	FEMSTAT - 100MG/SUP	butoconazole nitrate	G01AF	suppository	expired
	GARDRIN - 0.035MG/CAP	enprostil	A02BB	capsule	not sold
01990918	HIVID - 0.375MG/TAB	zalcitabine	J05AB	tablet	
01990896	HIVID - 0.75MG/TAB	zalcitabine	J05AB	tablet	
01951874	IN-EX DUAL PACK	sulconazole and butoconazole nitrate	G01AF	topical and vaginal cream	expired
01955535	IN-EX DUAL PACK	sulconazole and butoconazole nitrate	G01AF	topical cream and vaginal ovule	expired
01909959	INHIBACE - 0.5MG/TAB	cilazapril	C09AA	tablet	not sold
01911465	INHIBACE - 1MG/TAB	cilazapril	C09AA	tablet	
01911473	INHIBACE - 2.5MG/TAB	cilazapril	C09AA	tablet	
01911481	INHIBACE - 5MG/TAB	cilazapril	C09AA	tablet	
02181479	INHIBACE PLUS 5/12.5	cilazapril/hydrochlorothiazide	C09BA	tablet	not sold
02216965	INVIRASE - 200MG/CAP	saquinavir mesylate	J05AE	capsule	introduced (nas)
00899348	MANERIX - 100MG/TAB	moclobemide	N06AG	tablet	
00899356	MANERIX - 150MG/TAB	moclobemide	N06AG	tablet	
02166747	MANERIX - 300MG/TAB	moclobemide	N06AG	tablet	
02227371	MEGALONE - 4MG/ML	floxacin	J01MA	injectable solution	not sold
02227398	MEGALONE - 200MG/TAB	floxacin	J01MA	tablet	not sold
02227401	MEGALONE - 400MG/TAB	floxacin	J01MA	tablet	not sold
02162431	NAPROSYN - 25MG/ML	naproxen	M01AE	oral suspension	
02162458	NAPROSYN - 500MG/SUP	naproxen	M01AE	suppository	
00299413	NAPROSYN - 125MG/TAB	naproxen	M01AE	tablet	not sold
02162474	NAPROSYN - 250MG/TAB	naproxen	M01AE	tablet	
02162482	NAPROSYN - 375MG/TAB	naproxen	M01AE	tablet	
02162490	NAPROSYN - 500MG/TAB	naproxen	M01AE	tablet	
02162792	NAPROSYN E - 250MG/TAB	naproxen	M01AE	tablet	
02162415	NAPROSYN E - 375MG/TAB	naproxen	M01AE	tablet	
02162423	NAPROSYN E - 500MG/TAB	naproxen	M01AE	tablet	
02162466	NAPROSYN SR - 750MG/TAB	naproxen	M01AE	sustained-release tablet	
02168871	NAPROSYN SR - 1000MG/TAB	naproxen	M01AE	sustained-release tablet	not sold
02216183	NUTROPIN - 5MG/VIAL	somatropin	H01AC	powder for injectable solution	introduced
02216191	NUTROPIN - 10MG/VIAL	somatropin	H01AC	powder for injectable solution	not sold
02229722	NUTROPIN AQ - 5MG/ML	somatropin	H01AC	injectable solution	introduced
02204584	PROTROPIN - 5MG/VIAL	somatrem	H01AC	powder for injectable solution	
02204576	PROTROPIN - 10MG/VIAL	somatrem	H01AC	powder for injectable solution	
02162687	RHINALAR - 0.25MG/ML	flunisolide	R01AD	nasal aerosol	
00481823	ROCALTROL - 0.00025MG/CAP	calcitriol	A11CC	capsule	
00481815	ROCALTROL - 0.0005MG/CAP	calcitriol	A11CC	capsule	
00824291	ROCALTROL - 0.001MG/ML	calcitriol	A11CC	oral solution	
00657387	ROCEPHIN - 250MG/VIAL	ceftriaxone disodium	J01DA	powder for injectable solution	
00657425	ROCEPHIN - 500MG/VIAL	ceftriaxone disodium	J01DA	powder for injectable solution	not sold
00657417	ROCEPHIN - 1000MG/VIAL	ceftriaxone disodium	J01DA	powder for injectable solution	
00657409	ROCEPHIN - 2000MG/VIAL	ceftriaxone disodium	J01DA	powder for injectable solution	
00851957	ROCEPHIN - 10000MG/VIAL	ceftriaxone disodium	J01DA	powder for injectable solution	
00894699	ROCEPHIN ADD-VANTAGE - 1000MG/VIAL	ceftriaxone disodium	J01DA	powder for injectable solution	
00894702	ROCEPHIN ADD-VANTAGE - 2000MG/VIAL	ceftriaxone disodium	J01DA	powder for injectable solution	not sold
01911988	ROFERON-A - 3000000UNIT/VIAL	interferon alfa-2a	L03AA	powder for injectable solution	not sold
02217015	ROFERON-A - 3000000UNIT/VIAL	interferon alfa-2a	L03AA	injectable solution	
02217023	ROFERON-A - 4500000UNIT/VIAL	interferon alfa-2a	L03AA	injectable solution	introduced
02217031	ROFERON-A - 6000000UNIT/VIAL	interferon alfa-2a	L03AA	injectable solution	introduced
01911996	ROFERON-A - 9000000UNIT/VIAL	interferon alfa-2a	L03AA	powder for injectable solution	not sold
02217058	ROFERON-A - 9000000UNIT/VIAL	interferon alfa-2a	L03AA	injectable solution	

DIN/GP	Brand Name	Generic Name	ATC*	Dosage Form	Comments
00812471	ROFERON-A - 18000000UNIT/VIAL	interferon alfa-2a	L03AA	powder for injectable solution	not sold
01912003	ROFERON-A - 18000000UNIT/VIAL	interferon alfa-2a	L03AA	powder for injectable solution	not sold
02217066	ROFERON-A - 18000000UNIT/VIAL	interferon alfa-2a	L03AA	injectable solution	
00891002	ROFERON-A - 36000000UNIT/VIAL	interferon alfa-2a	L03AA	injectable solution	
02235914	TASMAR - 100MG/TAB	tolcapone	N04BX	tablet	introduced (nas)
02235921	TASMAR - 200MG/TAB	tolcapone	N04BX	tablet	introduced (nas)
01911767	TICLID - 125MG/TAB	ticlopidine hydrochloride	B01AC	tablet	not sold
02162776	TICLID - 250MG/TAB	ticlopidine hydrochloride	B01AC	tablet	
00884499	TORADOL - 5MG/ML	ketorolac tromethamine	S01BC	ophthalmic solution	not sold
02162644	TORADOL - 10MG/ML	ketorolac tromethamine	M01AB	injectable solution	
01908499	TORADOL - 15MG/ML	ketorolac tromethamine	M01AB	injectable solution	not sold
02162652	TORADOL - 30MG/ML	ketorolac tromethamine	M01AB	injectable solution	
02162660	TORADOL - 10MG/TAB	ketorolac tromethamine	M01AB	tablet	
00784516	VERSED - 1MG/ML	midazolam hydrochloride	N05CD	injectable solution	
00766011	VERSED - 5MG/ML	midazolam hydrochloride	N05CD	injectable solution	

#### Veterinary:

	AUREO S-700 - 154000MG/KG	chlortetracycline hydrochloride/sulfamethazine		oral powder	not sold
02230809	AUREO S-700G - 154000MG/KG	chlortetracycline hydrochloride/sulfamethazine		feed premix	
02230721	AUREO SP250 G	chlortetracycline hydrochl./sulfamethazine/penicillin g proc.		feed premix	
	AUREOMIX 500G	chlortetracycline hydrochl./sulfamethazine/penicillin g proc.		feed premix	not sold
02230722	AUREOMIX 625G	chlortetracycline hydrochl./sulfamethazine/penicillin g proc.		feed premix	
02230724	AUREOMYCIN 100G - 220000MG/KG	chlortetracycline hydrochloride		feed premix	
02230723	AUREOMYCIN 50G - 110000MG/KG	chlortetracycline hydrochloride		feed premix	
02230778	CYGRO - 10000MG/KG	maduramicin ammonium		oral powder	

#### ICN CANADA LTD.

##### Human:

00704008	VIRAZOLE - 6000MG/VIAL	ribavirin	J05AB	powder for inhalation	
----------	------------------------	-----------	-------	-----------------------	--

#### JANSSEN-ORTHO INC.

##### Human:

00755818	ALFENTA - 0.5MG/ML	alfentanil hydrochloride	N01AH	injectable solution	
01968440	CYCLEN 0.25/0.035	norgestimate/ethinyl estradiol	G03AA	tablet	expired
01992872	CYCLEN 0.25/0.035	norgestimate/ethinyl estradiol	G03AA	tablet	expired
01937383	DURAGESIC - 2.5MG/PATCH	fentanyl	N02AB	transdermal patch	
01937391	DURAGESIC - 5MG/PATCH	fentanyl	N02AB	transdermal patch	
01937405	DURAGESIC - 7.5MG/PATCH	fentanyl	N02AB	transdermal patch	
01937413	DURAGESIC - 10MG/PATCH	fentanyl	N02AB	transdermal patch	
00590665	DURALITH - 300MG/TAB	lithium carbonate	N05AN	sustained-release tablet	
02126575	EPREX - 2000UNIT/ML	epoetin alfa	B03XA	injectable solution	introduced (nas)
02126583	EPREX - 4000UNIT/ML	epoetin alfa	B03XA	injectable solution	introduced (nas)
02126591	EPREX - 10000UNIT/ML	epoetin alfa	B03XA	injectable solution	introduced (nas)
02206072	EPREX - 20000UNIT/ML	epoetin alfa	B03XA	injectable solution	introduced (nas)
02231583	EPREX - 1000UNIT/SYRINGE	epoetin alfa	B03XA	injectable solution	introduced
02231584	EPREX - 2000UNIT/SYRINGE	epoetin alfa	B03XA	injectable solution	introduced
02231585	EPREX - 3000UNIT/SYRINGE	epoetin alfa	B03XA	injectable solution	introduced
02231586	EPREX - 4000UNIT/SYRINGE	epoetin alfa	B03XA	injectable solution	introduced
02231587	EPREX - 10000UNIT/SYRINGE	epoetin alfa	B03XA	injectable solution	introduced
02049430	FLOXIN - 4MG/ML	ofloxacin	J01MA	injectable solution	not sold
02049414	FLOXIN - 20MG/ML	ofloxacin	J01MA	injectable solution	not sold
02049422	FLOXIN - 40MG/ML	ofloxacin	J01MA	injectable solution	not sold
01968424	FLOXIN - 200MG/TAB	ofloxacin	J01MA	tablet	
01968416	FLOXIN - 300MG/TAB	ofloxacin	J01MA	tablet	
01968408	FLOXIN - 400MG/TAB	ofloxacin	J01MA	tablet	
02022117	LEUSTATIN - 1MG/ML	cladribine	L01BB	injectable solution	
02236839	LEVAQUIN - 5MG/ML	levofloxacin	J01MA	injectable solution	not sold
02236840	LEVAQUIN - 25MG/ML	levofloxacin	J01MA	injectable solution	not sold
02236841	LEVAQUIN - 250MG/TAB	levofloxacin	J01MA	tablet	not sold

DIN/GP	Brand Name	Generic Name	ATC*	Dosage Form	Comments
02236842	LEVAQUIN - 500MG/TAB	levofloxacin	J01MA	tablet	not sold
02020017	LIVOSTIN - 0.5MG/ML	levocabastine hydrochloride	R01AC	nasal suspension	
00642851	MOTILIUM - 10MG/TAB	domperidone	A03FA	tablet	expired
00855820	MOTILIUM - 10MG/TAB	domperidone maleate	A03FA	tablet	expired
00703974	NIZORAL - 20MG/G	ketoconazole	D01AC	cream	
00788813	NIZORAL - 20MG/ML	ketoconazole	J02AB	oral suspension	
00633836	NIZORAL - 200MG/TAB	ketoconazole	J02AB	tablet	
00602957	ORTHO 7/7/7 .5-.75-1/.035	norethindrone/ethinyl estradiol	G03AB	tablet	
00602965	ORTHO 7/7/7 .5-.75-1/.035	norethindrone/ethinyl estradiol	G03AB	tablet	
02042541	ORTHO-CEPT 0.15/0.03	desogestrel/ethinyl estradiol	G03AA	tablet	expired
02042533	ORTHO-CEPT 0.15/0.03	desogestrel/ethinyl estradiol	G03AA	tablet	expired
02015978	ORTHOCLONE-OKT3 - 1MG/ML	muromonab-cd3	L04AA	injectable solution	
00836354	PREPULSID - 1MG/ML	cisapride monohydrate	A03FA	oral suspension	
00836311	PREPULSID - 5MG/TAB	cisapride monohydrate	A03FA	tablet	
00836338	PREPULSID - 10MG/TAB	cisapride monohydrate	A03FA	tablet	
02054817	PREPULSID - 20MG/TAB	cisapride monohydrate	A03FA	tablet	
02236435	PREPULSID QS - 5MG/TAB	cisapride monohydrate	A03FA	tablet	not sold
02236441	PREPULSID QS - 10MG/TAB	cisapride monohydrate	A03FA	tablet	not sold
02236443	PREPULSID QS - 20MG/TAB	cisapride monohydrate	A03FA	tablet	not sold
02052407	RENOVA - 0.5MG/G	tretinoin	D10AD	cream	
02236950	RISPERDAL - 1MG/ML	risperidone	N05AX	oral solution	not sold
02025280	RISPERDAL - 1MG/TAB	risperidone	N05AX	tablet	
02025299	RISPERDAL - 2MG/TAB	risperidone	N05AX	tablet	
02025302	RISPERDAL - 3MG/TAB	risperidone	N05AX	tablet	
02025310	RISPERDAL - 4MG/TAB	risperidone	N05AX	tablet	
02047454	SPORANOX - 100MG/CAP	itraconazole	J02AC	capsule	
02231347	SPORANOX - 10MG/ML	itraconazole	J02AC	oral solution	introduced
01951319	SUFENTA - 0.05MG/ML	sufentanil citrate	N01AH	injectable solution	expired
01934155	TERAZOL 3 - 8MG/G	terconazole	G01AG	vaginal cream	
00894710	TERAZOL 3 - 80MG/SUP	terconazole	G01AG	vaginal suppository	
02130874	TERAZOL 3 DUALPAK	terconazole	G01AG	vaginal cream and suppository	
00894729	TERAZOL 7 - 4MG/G	terconazole	G01AG	vaginal cream	
00484938	TOLECTIN - 400MG/CAP	tolmetin sodium	M01AB	capsule	
00364126	TOLECTIN - 200MG/TAB	tolmetin sodium	M01AB	tablet	
00632740	TOLECTIN - 600MG/TAB	tolmetin sodium	M01AB	tablet	
02230893	TOPAMAX - 25MG/TAB	topiramate	N03AX	tablet	introduced (nas)
02230894	TOPAMAX - 100MG/TAB	topiramate	N03AX	tablet	introduced (nas)
02230896	TOPAMAX - 200MG/TAB	topiramate	N03AX	tablet	introduced (nas)
02028700	TRI-CYCLEN .18-.215-.25/.035	norgestimate/ethinyl estradiol	G03AB	tablet	
02029421	TRI-CYCLEN .18-.215-.25/.035	norgestimate/ethinyl estradiol	G03AB	tablet	
<b>Veterinary:</b>					
00788724	APPERTX - 2.5MG/TAB	clazuril		tablet	not sold
00731374	WILDNIL - 3MG/ML	carfentanil citrate		injectable solution	expired
<b>JOHNSON &amp; JOHNSON-MERCK</b>					
<b>Human:</b>					
02182912	HISMANAL - 10MG/TAB	astemizole	R06AX	tablet	
02185911	PEPCID AC - 10MG/TAB	famotidine	A02BA	chewable tablet	introduced
02185938	PEPCID AC - 10MG/TAB	famotidine	A02BA	tablet	
<b>JOUVEINAL INC.</b>					
<b>Human:</b>					
	CERICLAMINE - 100MG/CAP	cericlamine	N06AB	capsule	not sold
	CERICLAMINE - 150MG/CAP	cericlamine	N06AB	capsule	not sold
<b>KNOLL PHARMA INC.</b>					
<b>Human:</b>					
02231457	MAVIK - 0.5MG/CAP	trandolapril	C09AA	capsule	not sold
02231459	MAVIK - 1MG/CAP	trandolapril	C09AA	capsule	not sold
02231460	MAVIK - 2MG/CAP	trandolapril	C09AA	capsule	not sold



DIN/GP	Brand Name	Generic Name	ATC*	Dosage Form	Comments
<b>LEO LABORATORIES CANADA LTD.</b>					
<b>Human:</b>					
01976133	DOVONEX - 0.05MG/G	calcipotriol	D05AX	ointment	
02150956	DOVONEX - 0.05MG/G	calcipotriol	D05AX	cream	
02194341	DOVONEX - 0.05MG/ML	calcipotriol	D05AX	scalp lotion	
02167840	INNOHEP - 10000UNIT/ML	tinzaparin sodium	B01AB	injectable suspension	
02229755	INNOHEP - 10000UNIT/ML	tinzaparin sodium	B01AB	injectable suspension	introduced
02167859	INNOHEP - 11700UNIT/ML	tinzaparin sodium	B01AB	injectable suspension	
02229515	INNOHEP - 20000UNIT/ML	tinzaparin sodium	B01AB	injectable suspension	introduced
02231478	INNOHEP - 20000UNIT/ML	tinzaparin sodium	B01AB	injectable suspension	not sold
00474517	ONE-ALPHA - 0.00025MG/CAP	alfacalcidol	A11CC	capsule	
00474525	ONE-ALPHA - 0.001MG/CAP	alfacalcidol	A11CC	capsule	
00759546	ONE-ALPHA - 0.0002MG/ML	alfacalcidol	A11CC	oral solution	
<b>LIGAND PHARMACEUTICALS INC.</b>					
<b>Human:</b>					
02020033	PHOTOFRIN - 15MG/VIAL	porfimer sodium	L01XX	powder for injectable solution	
02019876	PHOTOFRIN - 75MG/VIAL	porfimer sodium	L01XX	powder for injectable solution	
02130181	PROLEUKIN - 22000000UNIT/VIAL	aldesleukin	L03AA	powder for injectable solution	
<b>LIPOSOME COMPANY, INC. (THE)</b>					
<b>Human:</b>					
02231590	ABELCET - 5MG/ML	amphotericin b lipid complex	J02AA	powder for injectable solution	
<b>MALLINCKRODT MEDICAL INC.</b>					
<b>Human:</b>					
	99MTC TECHNESCAN MAG3 UD PED.	technetium tc-99m mertiatide	V09CA	powder for injectable solution	not sold
	99MTC TECHNESCAN MAG3 UD REG.	technetium tc-99m mertiatide	V09CA	powder for injectable solution	
00727725	HEXABRIX 160 - 294.5MG/ML	meglumine and sodium ioxaglate	V08AB	injectable solution	expired
00788805	HEXABRIX 200 - 369MG/ML	meglumine and sodium ioxaglate	V08AB	injectable solution	expired
00603740	HEXABRIX 320 - 589MG/ML	meglumine and sodium ioxaglate	V08AB	injectable solution	expired
01900838	OPTIRAY 160 - 339MG/ML	ioversol	V08AB	injectable solution	not sold
01900846	OPTIRAY 240 - 509MG/ML	ioversol	V08AB	injectable solution	
02034492	OPTIRAY 300 - 636MG/ML	ioversol	V08AB	injectable solution	not sold
01900854	OPTIRAY 320 - 678MG/ML	ioversol	V08AB	injectable solution	
02034484	OPTIRAY 350 - 742MG/ML TECHNESCAN MAG3	ioversol technetium tc-99m mertiatide	V08AB V09CA	injectable solution powder for injectable solution	
<b>MALLINCKRODT VETERINARY INC.</b>					
<b>Veterinary:</b>					
01950576	CLINACOX - 5000MG/KG	diclazuril		feed premix	not sold
00670898	ESTRUMATE - 0.25MG/ML	cloprostenol sodium		injectable solution	expired
00673056	PLANATE - 0.0875MG/ML	cloprostenol sodium		injectable solution	expired
<b>MERCK FROSST CANADA INC.</b>					
<b>Human:</b>					
02182815	COZAAR - 25MG/TAB	losartan potassium	C09CA	tablet	
02182874	COZAAR - 50MG/TAB	losartan potassium	C09CA	tablet	
02182882	COZAAR - 100MG/TAB	losartan potassium	C09CA	tablet	not sold
02229153	CRIXIVAN - 100MG/CAP	indinavir sulfate	J05AE	capsule	not sold
02229161	CRIXIVAN - 200MG/CAP	indinavir sulfate	J05AE	capsule	introduced (nas)
02229188	CRIXIVAN - 300MG/CAP	indinavir sulfate	J05AE	capsule	not sold
02229196	CRIXIVAN - 400MG/CAP	indinavir sulfate	J05AE	capsule	introduced (nas)
00587699	DOLOBID - 250MG/TAB	diflunisal	N02BA	tablet	
00576131	DOLOBID - 500MG/TAB	diflunisal	N02BA	tablet	
02233055	FOSAMAX - 5MG/TAB	alendronate sodium	M05BA	tablet	introduced
02201011	FOSAMAX - 10MG/TAB	alendronate sodium	M05BA	tablet	
02201038	FOSAMAX - 40MG/TAB	alendronate sodium	M05BA	tablet	
00568368	HEPTAVAX-B	vaccine - hepatitis B	J07BC	injectable suspension	not sold
02230047	HYZAAR 50/12.5	losartan potassium/ hydrochlorothiazide	C09DA	tablet	

DIN/GP	Brand Name	Generic Name	ATC*	Dosage Form	Comments
00463248 00466085	INDOCID-SR - 75MG/CAP M-M-R II	indomethacin vaccine - measles/mumps/ rubella	M01AB J07BD	sustained-release capsule injectable suspension	
00893668	MEFOXIN ADD-VANTAGE - 1000MG/VIAL	cefoxitin sodium	J01DA	powder for injectable solution	
00893676	MEFOXIN ADD-VANTAGE - 2000MG/VIAL	cefoxitin sodium	J01DA	powder for injectable solution	
00795844	MEVACOR - 10MG/TAB	lovastatin	C10AA	tablet	not sold
00795860	MEVACOR - 20MG/TAB	lovastatin	C10AA	tablet	
00795852	MEVACOR - 40MG/TAB	lovastatin	C10AA	tablet	
01908294	NOROXIN - 3MG/ML	norfloxacin	S01AX	ophthalmic solution	
00643025	NOROXIN - 400MG/TAB	norfloxacin	J01MA	tablet	
01942948	PEDVAXHIB	vaccine - hemophilus influenzae b	J07AG	injectable suspension	
00728101	PEPCID - 8MG/ML	famotidine	A02BA	oral suspension	not sold
00728128	PEPCID - 10MG/ML	famotidine	A02BA	injectable solution	
00710121	PEPCID - 20MG/TAB	famotidine	A02BA	tablet	
00710113	PEPCID - 40MG/TAB	famotidine	A02BA	tablet	
00431648	PNEUMOVAX 23	vaccine - polyvalent pneumococcal	J07AL	injectable suspension	
00717274	PRIMAXIN 250/250	imipenem/cilastatin sodium	J01DH	powder for injectable solution	
01911430	PRIMAXIN 250/250 ADD-VANTAGE	imipenem/cilastatin sodium	J01DH	powder for injectable solution	
00717282	PRIMAXIN 500/500	imipenem/cilastatin sodium	J01DH	powder for injectable solution	
01911449	PRIMAXIN 500/500 ADD-VANTAGE	imipenem/cilastatin sodium	J01DH	powder for injectable solution	
00890952	PRIMAXIN IM 500/500	imipenem/cilastatin sodium	J01DH	powder for injectable solution	not sold
00893684	PRIMAXIN IM 750/750	imipenem/cilastatin sodium	J01DH	powder for injectable solution	not sold
00839388	PRINIVIL - 5MG/TAB	lisinopril	C09AA	tablet	
00839396	PRINIVIL - 10MG/TAB	lisinopril	C09AA	tablet	
00839418	PRINIVIL - 20MG/TAB	lisinopril	C09AA	tablet	
00839426	PRINIVIL - 40MG/TAB	lisinopril	C09AA	tablet	not sold
00839434	PRINIVIL - 80MG/TAB	lisinopril	C09AA	tablet	not sold
02108194	PRINZIDE 10/12.5	lisinopril/hydrochlorothiazide	C09BA	tablet	
00884413	PRINZIDE 20/12.5	lisinopril/hydrochlorothiazide	C09BA	tablet	
00884421	PRINZIDE 20/25	lisinopril/hydrochlorothiazide	C09BA	tablet	
02010909	PROSCAR - 5MG/TAB	finasteride	G04BX	tablet	
00749486	RECOMBIVAX HB - 0.01MG/ML	vaccine - hepatitis B(rDNA)	J07BC	injectable suspension	
01934023	RECOMBIVAX HB - 0.04MG/ML	vaccine - hepatitis B(rDNA)	J07BC	injectable suspension	
02171880	TIMOPTIC XE - 2.5MG/ML	timolol maleate	S01ED	ophthalmic gel	
02171899	TIMOPTIC XE - 5MG/ML	timolol maleate	S01ED	ophthalmic gel	
02216205	TRUSOPT - 20MG/ML	dorzolamide hydrochloride	S01EC	ophthalmic solution	
02229702	VAQTA - 50UNIT/ML	hepatitis A vaccine (inactivated)	J07BC	injectable suspension	
00657298	VASERETIC 10/25	enalapril maleate/ hydrochlorothiazide	C09BA	tablet	
00851795	VASOTEC - 2.5MG/TAB	enalapril maleate	C09AA	tablet	
00708879	VASOTEC - 5MG/TAB	enalapril maleate	C09AA	tablet	
00670901	VASOTEC - 10MG/TAB	enalapril maleate	C09AA	tablet	
00670928	VASOTEC - 20MG/TAB	enalapril maleate	C09AA	tablet	
00708887	VASOTEC - 40MG/TAB	enalapril maleate	C09AA	tablet	not sold
01923846	VASOTEC I.V. - 1.25MG/ML	enalaprilat	C09AA	injectable solution	
00884324	ZOCOR - 5MG/TAB	simvastatin	C10AA	tablet	
00884332	ZOCOR - 10MG/TAB	simvastatin	C10AA	tablet	
00884340	ZOCOR - 20MG/TAB	simvastatin	C10AA	tablet	
00884359	ZOCOR - 40MG/TAB	simvastatin	C10AA	tablet	
02186810	ZYMAXIN - 200MG/TAB	ibuprofen lysine	M01AE	tablet	expired

## MERCK FROSST-MSD AGVET

### Veterinary:

02060531	ENACARD - 1MG/TAB	enalapril maleate		tablet	
02060558	ENACARD - 2.5MG/TAB	enalapril maleate		tablet	
02060566	ENACARD - 5MG/TAB	enalapril maleate		tablet	
02060574	ENACARD - 10MG/TAB	enalapril maleate		tablet	
02060582	ENACARD - 20MG/TAB	enalapril maleate		tablet	
00717150	EQVALAN LIQUID FOR HORSES - 10MG/ML	ivermectin		oral liquid	
00594431	EQVALAN PASTE FOR HORSES - 18.6916MG/G	ivermectin		oral paste	
00651966	HEARTGARD 30 - 0.068MG/TAB	ivermectin		tablet	
00651982	HEARTGARD 30 - 0.136MG/TAB	ivermectin		tablet	



DIN/GP	Brand Name	Generic Name	ATC*	Dosage Form	Comments
00651990	HEARTGARD 30 - 0.272MG/TAB	ivermectin		tablet	
00812315	HEARTGARD 30 CHEW - 0.068MG/TAB	ivermectin		tablet	
00812323	HEARTGARD 30 CHEW - 0.136MG/TAB	ivermectin		tablet	
00870064	HEARTGARD 30 CHEW - 0.272MG/TAB	ivermectin		tablet	
02216604	HEARTGARD 30 FX - 0.055MG/TAB	ivermectin		tablet	not sold
02216612	HEARTGARD 30 FX - 0.165MG/TAB	ivermectin		tablet	not sold
01909975	HEARTGARD 30 PLUS 0.068/57	ivermectin/pyrantel pamoate		tablet	
01909983	HEARTGARD 30 PLUS 0.136/114	ivermectin/pyrantel pamoate		tablet	
01909991	HEARTGARD 30 PLUS 0.272/227	ivermectin/pyrantel pamoate		tablet	
00622125	IVOMEC DRENCH FOR SHEEP - 0.83MG/ML	ivermectin		injectable suspension	
00630470	IVOMEC INJ. FOR CATTLE - 10MG/ML	ivermectin		injectable suspension	
00583340	IVOMEC INJ. FOR SWINE - 10MG/ML	ivermectin		injectable suspension	not sold
00761842	IVOMEC POUR-ON - 5MG/ML	ivermectin		topical solution	
01926950	IVOMEC SR BOLUS FOR CATTLE - 1720MG/BOLUS	ivermectin		sustained-release bolus	
01913085	IVOMEC SWINE PREMIX - 6000MG/KG	ivermectin		oral powder	

### McNEIL CONSUMER PRODUCTS COMPANY

#### Human:

02236894	CHILDREN'S MOTRIN - 20MG/ML	ibuprofen	M01AE	oral suspension	
	HISMANAL - 1MG/ML	astemizole	R06AX	oral suspension	not sold
02184656	HISMANAL - 2MG/ML	astemizole	R06AX	oral suspension	not sold
02230542	IMODIUM LINGUAL - 2MG/TAB	loperamide hydrochloride	A07DA	tablet	introduced
02132575	MEDIPREN - 20MG/ML	ibuprofen	M01AE	oral suspension	not sold
02182920	NIZORAL - 20MG/ML	ketoconazole	D11AC	shampoo	

### NEXSTAR PHARMACEUTICALS, INC.

#### Human:

02218046	DAUNOXOME - 50MG/VIAL	daunorubicin, liposomal	L01DB	powder for injectable solution	introduced
----------	-----------------------	-------------------------	-------	--------------------------------	------------

### NOVARTIS ANIMAL HEALTH CANADA INC.

#### Veterinary:

02220563	FORTEKOR - 5MG/TAB	benazepril hydrochloride		tablet	
02220555	FORTEKOR - 20MG/TAB	benazepril hydrochloride		tablet	
00846422	INTERCEPTOR - 2.3MG/TAB	milbemycin oxime		tablet	not sold
00846430	INTERCEPTOR - 5.75MG/TAB	milbemycin oxime		tablet	not sold
00846449	INTERCEPTOR - 11.5MG/TAB	milbemycin oxime		tablet	not sold
00846457	INTERCEPTOR - 23MG/TAB	milbemycin oxime		tablet	not sold
02016710	INTERCEPTOR CHEW - 2.3MG/TAB	milbemycin oxime		tablet	not sold
02016699	INTERCEPTOR CHEW - 5.75MG/TAB	milbemycin oxime		tablet	not sold
02016702	INTERCEPTOR CHEW - 11.5MG/TAB	milbemycin oxime		tablet	not sold
02016729	INTERCEPTOR CHEW - 23MG/TAB	milbemycin oxime		tablet	not sold
02141434	INTERCEPTOR FLAVOUR - 2.3MG/TAB	milbemycin oxime		tablet	
02141426	INTERCEPTOR FLAVOUR - 5.75MG/TAB	milbemycin oxime		tablet	
02141418	INTERCEPTOR FLAVOUR - 11.5MG/TAB	milbemycin oxime		tablet	
02141396	INTERCEPTOR FLAVOUR - 23MG/TAB	milbemycin oxime		tablet	
02087332	PROGRAM - 45MG/TAB	lufenuron		tablet	
02087340	PROGRAM - 90MG/TAB	lufenuron		tablet	
02087359	PROGRAM - 204.9MG/TAB	lufenuron		tablet	
02087367	PROGRAM - 409.8MG/TAB	lufenuron		tablet	
02057832	PROGRAM - 133MG/UNIT	lufenuron		oral suspension	
02192632	PROGRAM - 266MG/UNIT	lufenuron		oral suspension	
02229547	SENTINEL 115/5.75	lufenuron/milbemycin oxime		tablet	introduced
02229548	SENTINEL 230/11.5	lufenuron/milbemycin oxime		tablet	introduced
02229551	SENTINEL 46/2.3	lufenuron/milbemycin oxime		tablet	introduced
02229549	SENTINEL 460/23	lufenuron/milbemycin oxime		tablet	introduced

DIN/GP	Brand Name	Generic Name	ATC*	Dosage Form	Comments
<b>NOVARTIS CONSUMER HEALTH</b>					
<b>Human:</b>					
02018411	CORSYM 7.5/0.8	phenylpropanolamine/ chlorpheniramine polistirex	R01BA	sustained-release oral suspension	
02018403	DELSYM - 6MG/ML	dextromethorphan polistirex	R05DA	sustained-release oral suspension	expired
02018381	DURAFEDRIN - 12MG/ML	pseudoephedrine polistirex	R01BA	sustained-release oral suspension	expired
00667285	LIPACTIN - 5MG/G	heparin sodium/zinc sulfate	D11AX	gel	
02162318	MAALOX HRF	antacid-alginate compound	A02EA	oral suspension	
02162326	MAALOX HRF	antacid-alginate compound	A02EA	tablet	
00651184	PROBAX - 20MG/G	propolis	D02AX	ointment	not sold
02162245	PRODIEM PLAIN - 672MG/G	psyllium	A06AC	oral granules	
02162253	PRODIEM PLUS 542/124	psyllium/senna	A06AC	oral granules	

## NOVARTIS PHARMA CANADA INC.

<b>Human:</b>					
02059762	AREDIA - 30MG/VIAL	pamidronate disodium	M05BA	powder for injectable solution	
02059770	AREDIA - 60MG/VIAL	pamidronate disodium	M05BA	powder for injectable solution	
02059789	AREDIA - 90MG/VIAL	pamidronate disodium	M05BA	powder for injectable solution	
01968130	DYNACIRC - 1.25MG/CAP	isradipine	C08CA	capsule	not sold
00872385	DYNACIRC - 2.5MG/CAP	isradipine	C08CA	capsule	not sold
00872393	DYNACIRC - 5MG/CAP	isradipine	C08CA	capsule	not sold
02108186	ESTRACOMB .05/.05-.25	estradiol 17b/estradiol 17b & norethindrone acetate	G03FA	transdermal patch	
00756792	ESTRADERM 100 - 8MG/PATCH	estradiol 17b	G03CA	transdermal patch	
00756849	ESTRADERM 25 - 2MG/PATCH	estradiol 17b	G03CA	transdermal patch	
00756857	ESTRADERM 50 - 4MG/PATCH	estradiol 17b	G03CA	transdermal patch	
02231384	FEMARA - 2.5MG/TAB	letrozole	L02BG	tablet	introduced (nas)
02230898	FORADIL - 0.012MG/DOSE	formoterol fumarate	R03AC	powder for inhalation	introduced (nas)
01943065	HABITROL 14 - 35MG/PATCH	nicotine	N07BA	transdermal patch	
01943073	HABITROL 21 - 52.5MG/PATCH	nicotine	N07BA	transdermal patch	
01943057	HABITROL 7 - 17.5MG/PATCH	nicotine	N07BA	transdermal patch	
02031094	LAMISIL - 10MG/G	terbinafine hydrochloride	D01AE	cream	
02031108	LAMISIL - 125MG/TAB	terbinafine hydrochloride	D01BA	tablet	not sold
02031116	LAMISIL - 250MG/TAB	terbinafine hydrochloride	D01BA	tablet	
02128209	LENTARON - 250MG/VIAL	formestane	L02BG	powder for injectable solution	
02061562	LESCOL - 20MG/CAP	fluvastatin sodium	C10AA	capsule	
02061570	LESCOL - 40MG/CAP	fluvastatin sodium	C10AA	capsule	
00885835	LOTENSIN - 5MG/TAB	benazepril hydrochloride	C09AA	tablet	
00885843	LOTENSIN - 10MG/TAB	benazepril hydrochloride	C09AA	tablet	
00885851	LOTENSIN - 20MG/TAB	benazepril hydrochloride	C09AA	tablet	
02162873	LOTENSIN-HCT 10/12.5	benazepril hydrochloride/ hydrochlorothiazide	C09BA	tablet	not sold
02162881	LOTENSIN-HCT 20/25	benazepril hydrochloride/ hydrochlorothiazide	C09BA	tablet	not sold
02162865	LOTENSIN-HCT 5/6.25	benazepril hydrochloride/ hydrochlorothiazide	C09BA	tablet	not sold
01990926	MIACALCIN - 50UNIT/ML	calcitonin salmon	V03AG	injectable solution	not sold
01992880	MIACALCIN - 100UNIT/ML	calcitonin salmon	V03AG	injectable solution	not sold
02228947	MIGRANAL - 4MG/ML	dihydroergotamine mesylate	N02CA	nasal aerosol	
02223740	NORPROLAC - 0.025MG/TAB	quinagolide hydrochloride	G02CB	tablet	not sold
02223759	NORPROLAC - 0.05MG/TAB	quinagolide hydrochloride	G02CB	tablet	not sold
02223767	NORPROLAC - 0.075MG/TAB	quinagolide hydrochloride	G02CB	tablet	not sold
02223775	NORPROLAC - 0.15MG/TAB	quinagolide hydrochloride	G02CB	tablet	not sold
02229854	RESTORIL - 7.5MG/CAP	temazepam	N05CD	capsule	not sold
00755591	SANDIMMUNE - 25MG/CAP	cyclosporine	L04AA	capsule	
01907182	SANDIMMUNE - 50MG/CAP	cyclosporine	L04AA	capsule	
00755605	SANDIMMUNE - 100MG/CAP	cyclosporine	L04AA	capsule	
00593257	SANDIMMUNE - 50MG/ML	cyclosporine	L04AA	injectable solution	
00593249	SANDIMMUNE - 100MG/ML	cyclosporine	L04AA	oral solution	
02150689	NEORAL - 25MG/CAP	cyclosporine	L04AA	capsule	
02150662	NEORAL - 50MG/CAP	cyclosporine	L04AA	capsule	
02150670	NEORAL - 100MG/CAP	cyclosporine	L04AA	capsule	
02150697	NEORAL - 100MG/ML	cyclosporine	L04AA	oral solution	
00839191	SANDOSTATIN - 0.05MG/ML	octreotide	H01CB	injectable solution	
00839205	SANDOSTATIN - 0.1MG/ML	octreotide	H01CB	injectable solution	
02049392	SANDOSTATIN - 0.2MG/ML	octreotide	H01CB	injectable solution	
00839213	SANDOSTATIN - 0.5MG/ML	octreotide	H01CB	injectable solution	
00584223	TRANSDERM-NITRO 0.2 - 25MG/PATCH	nitroglycerin	C01DA	transdermal patch	

DIN/GP	Brand Name	Generic Name	ATC*	Dosage Form	Comments
00852384	TRANSDERM-NITRO 0.4 - 50MG/PATCH	nitroglycerin	C01DA	transdermal patch	
02046156	TRANSDERM-NITRO 0.6 - 75MG/PATCH	nitroglycerin	C01DA	transdermal patch	
02046164	TRANSDERM-NITRO 0.8 - 100MG/PATCH	nitroglycerin	C01DA	transdermal patch	
00568627	VISKAZIDE 10/25	pindolol/hydrochlorothiazide	C07BA	tablet	
00568635	VISKAZIDE 10/50	pindolol/hydrochlorothiazide	C07BA	tablet	
02204444	VIVELLE 100 - 8.66MG/PATCH	estradiol 17b	G03CA	transdermal patch	
02204401	VIVELLE 37.5 - 3.28MG/PATCH	estradiol 17b	G03CA	transdermal patch	
02204428	VIVELLE 50 - 4.33MG/PATCH	estradiol 17b	G03CA	transdermal patch	
02204436	VIVELLE 75 - 6.56MG/PATCH	estradiol 17b	G03CA	transdermal patch	

## NOVO NORDISK CANADA INC.

### Human:

01986813	INSULATARD NPH - 100UNIT/ML	insulin (isophane) human semi-synthetic	A10AC	injectable suspension	not sold
02056682	LOGIPARIN - 10000UNIT/ML	tinzaparin sodium	B01AB	injectable suspension	not sold
02056690	LOGIPARIN - 11700UNIT/ML	tinzaparin sodium	B01AB	injectable suspension	not sold
01985973	MIXTARD 15/85 - 100UNIT/ML	insulin (regular/isophane) human semi-synthetic	A10AE	injectable suspension	not sold
01986821	MIXTARD 30/70 - 100UNIT/ML	insulin (regular/isophane) human semi-synthetic	A10AE	injectable suspension	not sold
01985965	MIXTARD 50/50 - 100UNIT/ML	insulin (regular/isophane) human semi-synthetic	A10AE	injectable suspension	not sold
02024292	NOVOLIN GE 10/90 - 100UNIT/ML	insulin (regular/isophane) human biosynthetic	A10AE	injectable suspension	
02024306	NOVOLIN GE 20/80 - 100UNIT/ML	insulin (regular/isophane) human biosynthetic	A10AE	injectable suspension	
02024217	NOVOLIN GE 30/70 - 100UNIT/ML	insulin (regular/isophane) human biosynthetic	A10AE	injectable suspension	
02025248	NOVOLIN GE 30/70 - 100UNIT/ML	insulin (regular/isophane) human biosynthetic	A10AE	injectable suspension	
02024314	NOVOLIN GE 40/60 - 100UNIT/ML	insulin (regular/isophane) human biosynthetic	A10AE	injectable suspension	
02024322	NOVOLIN GE 50/50 - 100UNIT/ML	insulin (regular/isophane) human biosynthetic	A10AE	injectable suspension	
02024241	NOVOLIN GE LENTE - 100UNIT/ML	insulin (lente) human biosynthetic	A10AC	injectable suspension	
02024225	NOVOLIN GE NPH - 100UNIT/ML	insulin (isophane) human biosynthetic	A10AC	injectable suspension	
02024268	NOVOLIN GE NPH - 100UNIT/ML	insulin (isophane) human biosynthetic	A10AC	injectable suspension	
02024233	NOVOLIN GE TORONTO - 100UNIT/ML	insulin (regular) human biosynthetic	A10AB	injectable suspension	
02024284	NOVOLIN GE TORONTO - 100UNIT/ML	insulin (regular) human biosynthetic	A10AB	injectable suspension	
02024276	NOVOLIN GE ULTRALENTE - 100UNIT/ML	insulin (ultralente) human biosynthetic	A10AD	injectable suspension	
01988700	NOVOLINSET 30/70 - 100UNIT/ML	insulin (regular/isophane) human semi-synthetic	A10AE	injectable suspension	not sold
02024411	NOVOLINSET GE 10/90 - 100UNIT/ML	insulin (regular/isophane) human biosynthetic	A10AE	injectable suspension	not sold
02024438	NOVOLINSET GE 20/80 - 100UNIT/ML	insulin (regular/isophane) human biosynthetic	A10AE	injectable suspension	not sold
02024446	NOVOLINSET GE 30/70 - 100UNIT/ML	insulin (regular/isophane) human biosynthetic	A10AE	injectable suspension	not sold
02024454	NOVOLINSET GE 40/60 - 100UNIT/ML	insulin (regular/isophane) human biosynthetic	A10AE	injectable suspension	not sold
02025264	NOVOLINSET GE 50/50 - 100UNIT/ML	insulin (regular/isophane) human biosynthetic	A10AE	injectable suspension	not sold
02024403	NOVOLINSET GE NPH - 100UNIT/ML	insulin (isophane) human biosynthetic	A10AC	injectable suspension	not sold
02025256	NOVOLINSET GE TORONTO - 100UNIT/ML	insulin (regular) human biosynthetic	A10AB	injectable suspension	not sold
01986090	NOVOLINSET NPH - 100UNIT/ML	insulin (isophane) human semi-synthetic	A10AC	injectable suspension	not sold
01927477	NOVOLINSET TORONTO - 100UNIT/ML	insulin (regular) human semi-synthetic	A10AB	injectable suspension	not sold
01986805	VELOSULIN HUMAN - 100UNIT/ML	insulin (regular) human semi-synthetic	A10AB	injectable suspension	not sold

DIN/GP	Brand Name	Generic Name	ATC*	Dosage Form	Comments
NYCOMED CANADA INC.					
Human:					
01962973	OMNIPAQUE 140 - 302MG/ML	iohexol	V08AB	injectable solution	not sold
02172720	OMNIPAQUE 180 - 389MG/ML	iohexol	V08AB	injectable solution	
02172739	OMNIPAQUE 240 - 518MG/ML	iohexol	V08AB	injectable solution	
02172747	OMNIPAQUE 300 - 647MG/ML	iohexol	V08AB	injectable solution	
02172755	OMNIPAQUE 350 - 755MG/ML	iohexol	V08AB	injectable solution	
02172771	OMNISCAN - 287MG/ML	gadodiamide	V08CA	injectable solution	
02145766	VISIPAQUE 270 - 550MG/ML	iodixanol	V08AB	injectable solution	
02145774	VISIPAQUE 320 - 652MG/ML	iodixanol	V08AB	injectable solution	
OHMEDA, DIVISION OF CANADIAN OXYGEN LIMITED					
Human:					
00418994	STADOL - 2MG/ML	butorphanol tartrate	N02AF	injectable solution	not sold
ORGANON CANADA LTD. (AKZO)					
Human:					
02042487	MARVELON 0.15/0.03	desogestrel/ethinyl estradiol	G03AA	tablet	expired
02042479	MARVELON 0.15/0.03	desogestrel/ethinyl estradiol	G03AA	tablet	expired
00687405	NORCURON - 10MG/VIAL	vecuronium bromide	M03AC	powder for injectable solution	
02129043	ORGARAN - 1250UNIT/ML	danaparoid sodium	B01AB	injectable solution	
02108208	ZEMURON - 10MG/ML	rocuronium bromide	M03AC	injectable solution	
PFIZER CANADA INC.					
Human:					
02232043	ARICEPT - 5MG/TAB	donepezil hydrochloride	N07AA	tablet	introduced (nas)
02232044	ARICEPT - 10MG/TAB	donepezil hydrochloride	N07AA	tablet	introduced (nas)
00871044	CARDURA - 1MG/TAB	doxazosin mesylate	C02CA	tablet	expired
00871052	CARDURA - 2MG/TAB	doxazosin mesylate	C02CA	tablet	expired
00871060	CARDURA - 4MG/TAB	doxazosin mesylate	C02CA	tablet	expired
00871079	CARDURA - 8MG/TAB	doxazosin mesylate	C02CA	tablet	expired
02141442	DIFLUCAN - 150MG/CAP	fluconazole	J02AC	capsule	
00891835	DIFLUCAN - 2MG/ML	fluconazole	J02AC	injectable solution	
02024152	DIFLUCAN - 10MG/ML	fluconazole	J02AC	oral suspension	
02024160	DIFLUCAN - 40MG/ML	fluconazole	J02AC	oral suspension	not sold
00891800	DIFLUCAN - 50MG/TAB	fluconazole	J02AC	tablet	
00891819	DIFLUCAN - 100MG/TAB	fluconazole	J02AC	tablet	
00891827	DIFLUCAN - 200MG/TAB	fluconazole	J02AC	tablet	not sold
02230443	GLUCOTROL XL - 5MG/TAB	glipizide	A10BB	sustained-release tablet	not sold
02230444	GLUCOTROL XL - 10MG/TAB	glipizide	A10BB	sustained-release tablet	not sold
02093170	MINIPRESS XL - 2.5MG/TAB	prazosin hydrochloride	C02CA	sustained-release tablet	not sold
02093189	MINIPRESS XL - 5MG/TAB	prazosin hydrochloride	C02CA	sustained-release tablet	not sold
00878901	NORVASC - 2.5MG/TAB	amlodipine besylate	C08CA	tablet	not sold
00878928	NORVASC - 5MG/TAB	amlodipine besylate	C08CA	tablet	
00878936	NORVASC - 10MG/TAB	amlodipine besylate	C08CA	tablet	
01942441	PLAX PEPPERMINT 20/2/2.5	sodium benzoate/sodium salicylate/sodium lauryl sulfate	A01AD	oral rinse	
01942506	PLAX REGULAR 20/2/2.5	sodium benzoate/sodium salicylate/sodium lauryl sulfate	A01AD	oral rinse	
01942409	PLAX SOFT MINT 20/2/2.5	sodium benzoate/sodium salicylate/sodium lauryl sulfate	A01AD	oral rinse	
02223546	REACTINE - 5MG/TAB	cetirizine hydrochloride	R06AE	tablet	introduced
02223554	REACTINE - 10MG/TAB	cetirizine hydrochloride	R06AE	tablet	
01900978	REACTINE - 20MG/TAB	cetirizine hydrochloride	R06AE	tablet	not sold
00874116	UNASYN 1000/2000	sulbactam sodium/ampicillin sodium	J01CR	powder for injectable solution	not sold
01955527	UNASYN 1000/2000	sulbactam sodium/ampicillin sodium	J01CR	powder for injectable solution	not sold
00874108	UNASYN 500/1000	sulbactam sodium/ampicillin sodium	J01CR	powder for injectable solution	not sold
01955519	UNASYN 500/1000	sulbactam sodium/ampicillin sodium	J01CR	powder for injectable solution	not sold
02091291	ZITHROMAX - 250MG/CAP	azithromycin	J01FA	capsule	
02223716	ZITHROMAX - 20MG/ML	azithromycin	J01FA	powder for oral suspension	
02223724	ZITHROMAX - 40MG/ML	azithromycin	J01FA	powder for oral suspension	
02229971	ZITHROMAX - 1000MG/POUCH	azithromycin	J01FA	powder for oral solution	not sold

DIN/GP	Brand Name	Generic Name	ATC*	Dosage Form	Comments
02212021	ZITHROMAX - 250MG/TAB	azithromycin	J01FA	tablet	not sold
02231143	ZITHROMAX - 600MG/TAB	azithromycin	J01FA	tablet	introduced
02132702	ZOLOFT - 25MG/CAP	sertraline hydrochloride	N06AB	capsule	
01962817	ZOLOFT - 50MG/CAP	sertraline hydrochloride	N06AB	capsule	
01962779	ZOLOFT - 100MG/CAP	sertraline hydrochloride	N06AB	capsule	
01962787	ZOLOFT - 150MG/CAP	sertraline hydrochloride	N06AB	capsule	not sold
01962795	ZOLOFT - 200MG/CAP	sertraline hydrochloride	N06AB	capsule	not sold

## PFIZER CANADA INC., ANIMAL HEALTH GROUP

### Veterinary:

02229543	AVIAx - 50000MG/KG	semduramicin sodium		oral powder	introduced (nas)
01913034	CESTEX - 12.5MG/TAB	epsiprantel		tablet	
01913026	CESTEX - 25MG/TAB	epsiprantel		tablet	
01913018	CESTEX - 50MG/TAB	epsiprantel		tablet	
01912992	CESTEX - 100MG/TAB	epsiprantel		tablet	
02038331	CLAVAMOX 100/25	amoxicillin trihydrate/ clavulanate potassium		tablet	
02038315	CLAVAMOX 200/50	amoxicillin trihydrate/ clavulanate potassium		tablet	
02038358	CLAVAMOX 300/75	amoxicillin trihydrate/ clavulanate potassium		tablet	
02027879	CLAVAMOX 50/12.5	amoxicillin trihydrate/ clavulanate potassium		oral suspension	
02038323	CLAVAMOX 50/12.5	amoxicillin trihydrate/ clavulanate potassium		tablet	
01950673	DOMITOR - 1MG/ML	medetomidine hydrochloride		injectable solution	not sold
00755559	DORMOSEDAN - 10MG/ML	detomidine hydrochloride		solution	
	ENDURALL - K	inactivated rabies vaccine, porcine cell line origin		injectable solution	not sold
	FELOCELL CVR	modified live feline rhinotracheitis-		injectable solution	expired
	FELOCELL CVR-C	panleukopenia virus modified live feline rhinotracheitis		injectable solution	expired
	FELOMUNE CVR	modified live feline rhinotracheitis-calici-virus vaccine		injectable solution	expired
	FIRSTDOSE CPV	modified live canine parvovirus vaccine		injectable solution	
	LEUKOCELL	inactivated feline leukaemia vaccine		injectable solution	not sold
	LEUKOCELL 2	feline leukemia vaccine		injectable solution	
00725064	LIFE-GUARD-H.E.	nutrients/electrolytes		oral powder	
00606081	PARATECT BOLUS - 22700MG/TAB	morantel tartrate		sustained-release oral device	not sold
00778923	PARATECT FLEX - 19800MG/TAB	morantel tartrate		sustained-release oral device	not sold
00606103	POSISTAC - 12500MG/KG	salinomycin		oral powder	not sold
00633828	POSISTAC - 50000MG/KG	salinomycin		oral powder	not sold
00603724	POSISTAC - 60000MG/KG	salinomycin		oral powder	
	RABGUARD-TC	inactivated rabies vaccine		injectable solution	not sold
02006936	RESORB	electrolyte product		powder for oral suspension	expired
00698083	SYNERGISTIN 60/120	sulbactam/ampicillin		injectable suspension	
	VANGUARD 5	modified live canine distemper-adenovirus type 2		injectable solution	
	VANGUARD 5 CV	canine combination vaccine		injectable solution	
	VANGUARD 5B	modified live canine distemper-adenovirus type 2		injectable solution	
	VANGUARD 5L	modified live canine distemper-adenovirus type 2		injectable solution	
	VANGUARD CPV (KILLED)	inactivated canine parvovirus vaccine		injectable solution	
	VANGUARD CPV (MLV)	modified live canine parvovirus vaccine		injectable solution	not sold

## PHARMACIA & UPJOHN INC.

### Human:

02071002	ADRIAMYCIN PFS - 2MG/ML	doxorubicin hydrochloride	L01DB	injectable solution	
02065657	ADRIAMYCIN RDF - 10MG/VIAL	doxorubicin hydrochloride	L01DB	powder for injectable solution	
00698040	ADRIAMYCIN RDF - 20MG/VIAL	doxorubicin hydrochloride	L01DB	powder for injectable solution	not sold
02069555	ADRIAMYCIN RDF - 50MG/VIAL	doxorubicin hydrochloride	L01DB	powder for injectable solution	



DIN/GP	Brand Name	Generic Name	ATC*	Dosage Form	Comments
02069563	ADRIAMYCIN RDF - 150MG/VIAL	doxorubicin hydrochloride	L01DB	powder for injectable solution	
	AMPEROZIDE - 0.5MG/TAB	amperozide		tablet	not sold
	AMPEROZIDE - 2.5MG/TAB	amperozide		tablet	not sold
	AMPEROZIDE - 5MG/TAB	amperozide		tablet	not sold
02231622	CAMPTOSAR - 20MG/ML	irinotecan hydrochloride	L01XX	injectable solution	introduced (nas)
02132680	COLESTID - 1000MG/TAB	colestipol hydrochloride	C10AC	tablet	
02132699	COLESTID ORANGE - 5000MG/DOSE	colestipol hydrochloride	C10AC	oral granules	
00030910	CORTEF - 10MG/TAB	hydrocortisone	H02AB	tablet	
00030929	CORTEF - 20MG/TAB	hydrocortisone	H02AB	tablet	
02063808	DIPENTUM - 250MG/CAP	olsalazine sodium	A07EC	capsule	
00875856	DIPENTUM - 500MG/TAB	olsalazine sodium	A07EC	tablet	not sold
02063794	EMCYT - 140MG/CAP	estramustine phosphate disodium	L01XX	capsule	expired
02168898	ESTRING - 2MG/RING	estradiol	G03CA	vaginal ring	
02132656	FRAGMIN - 2500UNIT/ML	dalteparin sodium	B01AB	injectable solution	
02132664	FRAGMIN - 10000UNIT/ML	dalteparin sodium	B01AB	injectable solution	
02132621	FRAGMIN - 12500UNIT/ML	dalteparin sodium	B01AB	injectable solution	
02132648	FRAGMIN - 25000UNIT/ML	dalteparin sodium	B01AB	injectable solution	
02231171	FRAGMIN - 25000UNIT/ML	dalteparin sodium	B01AB	injectable solution	introduced
02166100	IDAMYCIN - 5MG/CAP	idarubicin hydrochloride	L01DB	capsule	
02166119	IDAMYCIN - 10MG/CAP	idarubicin hydrochloride	L01DB	capsule	not sold
02166127	IDAMYCIN - 25MG/CAP	idarubicin hydrochloride	L01DB	capsule	not sold
02065630	IDAMYCIN - 5MG/VIAL	idarubicin hydrochloride	L01DB	powder for injectable solution	
02068095	IDAMYCIN - 10MG/VIAL	idarubicin hydrochloride	L01DB	powder for injectable solution	
	LINOMIDE - 2.5MG/TAB	roquinimex	L03AX	tablet	not sold
	LINOMIDE - 5MG/TAB	roquinimex	L03AX	tablet	not sold
	LINOMIDE - 10MG/TAB	roquinimex	L03AX	tablet	not sold
02063786	MYCOBUTIN - 150MG/CAP	rifabutin	J04AB	capsule	expired
00194913	NEO-CORTEF 10/5	hydrocortisone acetate/ neomycin sulfate	D07CA	ointment	
00194921	NEO-CORTEF 15/5	hydrocortisone acetate/ neomycin sulfate	S01CA	ophthalmic ointment	not sold
00194948	NEO-CORTEF 15/5	hydrocortisone acetate/ neomycin sulfate	S01CA	ophthalmic suspension	
00194883	NEO-CORTEF 5/5	hydrocortisone acetate/ neomycin sulfate	S01CA	ophthalmic ointment	not sold
00194891	NEO-CORTEF 5/5	hydrocortisone acetate/ neomycin sulfate	D07CA	ointment	
02065703	PHARMORUBICIN PFS - 2MG/ML	epirubicin hydrochloride	L01DB	injectable solution	
02065746	PHARMORUBICIN RDF - 10MG/VIAL	epirubicin hydrochloride	L01DB	powder for injectable solution	
00698202	PHARMORUBICIN RDF - 20MG/VIAL	epirubicin hydrochloride	L01DB	powder for injectable solution	not sold
02069512	PHARMORUBICIN RDF - 50MG/VIAL	epirubicin hydrochloride	L01DB	powder for injectable solution	
01951882	PHARMORUBICIN RDF - 150MG/VIAL	epirubicin hydrochloride	L01DB	powder for injectable solution	not sold
00860786	PREPIDIL - 0.5MG/SYRINGE	dinoprostone	G02AD	intra-uterine gel	
02028689	PROMIT - 150MG/ML	dextran 1	B05AA	injectable solution	not sold
01919679	PROSTIN E2 - 1MG/SYRINGE	dinoprostone	G02AD	intra-uterine gel	
01919687	PROSTIN E2 - 2MG/SYRINGE	dinoprostone	G02AD	intra-uterine gel	
00030600	SOLU-CORTEF - 100MG/VIAL	hydrocortisone sodium succinate	H02AB	powder for injectable solution	
00030619	SOLU-CORTEF - 250MG/VIAL	hydrocortisone sodium succinate	H02AB	powder for injectable solution	
00030627	SOLU-CORTEF - 500MG/VIAL	hydrocortisone sodium succinate	H02AB	powder for injectable solution	
00030635	SOLU-CORTEF - 1000MG/VIAL	hydrocortisone sodium succinate	H02AB	powder for injectable solution	
	STERECYT - 20MG/TAB	prednimustine	L01AA	tablet	not sold
	STERECYT - 100MG/TAB	prednimustine	L01AA	tablet	not sold
02231493	XALATAN - 0.05MG/ML	latanoprost	S01EX	ophthalmic solution	introduced (nas)
02153432	ZINECARD - 250MG/VIAL	dexrazoxane	V03AF	powder for injectable solution	
02153440	ZINECARD - 500MG/VIAL	dexrazoxane	V03AF	powder for injectable solution	
<b>Veterinary:</b>					
00813567	EXCENEL - 50MG/ML	ceftiofur sodium		powder for injectable solution	
02207753	PIRSUE AQUEOUS GEL - 50MG/SYRINGE	pirlimycin hydrochloride		intramammary gel	



DIN/GP	Brand Name	Generic Name	ATC*	Dosage Form	Comments
<b>PROCTER &amp; GAMBLE PHARMACEUTICALS CANADA INC.</b>					
<b>Human:</b>					
01997580	ASACOL - 400MG/TAB	5-aminosalicylic acid	A07EC	tablet	not sold
02231062	CREST GUM CARE - 4.54MG/G	stannous fluoride	A01AA	toothpaste	
02176017	DIDROCAL	etidronate disodium and calcium carbonate	M05BB	tablet	
02063662	MACROBID - 100MG/CAP	nitrofurantoin	G04AC	capsule	
<b>PROVEL, DIVISION OF ELI LILLY CANADA INC.</b>					
<b>Veterinary:</b>					
00616338	CARBIGRAN - 250000MG/KG	nicarbazin		feed premix	not sold
00590932	COMPUDOSE - 24MG/IMP	estradiol		injectable implant	
02123355	ENDECTO - 10MG/ML	abamectin		injectable solution	
01902687	MAXIBAN PREMIX	narasin/nicarbazin		feed premix	
00857602	MICOTIL - 300MG/ML	tilmicosin sulfate		injectable solution	
00707538	MONTEBAN 70 PREMIX - 70000MG/KG	narasin		feed premix	
00637645	TYLAN 50 SULFA G	tylosin phosphate/sulfamethazine		feed premix	
<b>PURDUE FREDERICK</b>					
<b>Human:</b>					
02163756	GASTROBID - 20MG/TAB	metoclopramide hydrochloride	A03FA	sustained-release tablet	not sold
02125323	HYDROMORPH CONTIN - 3MG/CAP	hydromorphone hydrochloride	N02AA	sustained-release capsule	
02125331	HYDROMORPH CONTIN - 6MG/CAP	hydromorphone hydrochloride	N02AA	sustained-release capsule	
02125358	HYDROMORPH CONTIN - 10MG/CAP	hydromorphone hydrochloride	N02AA	sustained-release capsule	not sold
02125366	HYDROMORPH CONTIN - 12MG/CAP	hydromorphone hydrochloride	N02AA	sustained-release capsule	
02125374	HYDROMORPH CONTIN - 20MG/CAP	hydromorphone hydrochloride	N02AA	sustained-release capsule	not sold
02125382	HYDROMORPH CONTIN - 24MG/CAP	hydromorphone hydrochloride	N02AA	sustained-release capsule	
02125390	HYDROMORPH CONTIN - 30MG/CAP	hydromorphone hydrochloride	N02AA	sustained-release capsule	not sold
02202441	OXYCONTIN - 10MG/TAB	oxycodone hydrochloride	N02AA	sustained-release tablet	
02202468	OXYCONTIN - 20MG/TAB	oxycodone hydrochloride	N02AA	sustained-release tablet	
02202476	OXYCONTIN - 40MG/TAB	oxycodone hydrochloride	N02AA	sustained-release tablet	
02202484	OXYCONTIN - 80MG/TAB	oxycodone hydrochloride	N02AA	sustained-release tablet	
00449636	TRILISATE 293/362	choline salicylate/magnesium salicylate	N02BA	tablet	expired
<b>RHÔNE-POULENC RORER CANADA INC.</b>					
<b>Human:</b>					
00555649	INTAL INHALER - 1MG/DOSE	sodium cromoglycate	R03BC	aerosol for inhalation	expired
00261238	INTAL SPINCAPS - 20MG/CARTRIDGE	sodium cromoglycate	R03BC	powder for inhalation	
00638641	INTAL SYNCRONER - 1MG/DOSE	sodium cromoglycate	R03BC	aerosol for inhalation	not sold expired
00888397	MYKROX - 0.5MG/TAB	metolazone	C03BA	tablet	
00842702	PENNTUSS 2/0.8	codeine/chlorpheniramine polistirex	R05DA	sustained-release oral suspension	
02195992	SUPRAX - 20MG/ML	cefixime	J01DA	oral suspension	
02195976	SUPRAX - 200MG/TAB	cefixime	J01DA	tablet	
02195984	SUPRAX - 400MG/TAB	cefixime	J01DA	tablet	
02177099	TAXOTERE - 20MG/VIAL	docetaxel	L01CD	injectable solution	
02177080	TAXOTERE - 80MG/VIAL	docetaxel	L01CD	injectable solution	
00766038	TILADE - 2MG/DOSE	nedocromil sodium	R03BC	aerosol for inhalation	
<b>ROBERTS PHARMACEUTICAL CANADA INC.</b>					
<b>Human:</b>					
02229390	EMINASE - 30UNIT/VIAL	anistreplase	B01AD	powder for injectable solution	introduced (nas)

DIN/GP	Brand Name	Generic Name	ATC*	Dosage Form	Comments
<b>SANOFI WINTHROP INC.</b>					
<b>Human:</b>					
	COROTROPE - 5MG/CAP	milrinone	C01CE	caplet	not sold
	COROTROPE - 7.5MG/CAP	milrinone	C01CE	caplet	not sold
	COROTROPE - 10MG/CAP	milrinone	C01CE	caplet	not sold
02236913	FRAXIPARINE - 9500UNIT/ML	nadroparin calcium	B01AB	injectable solution	not sold
02017644	INOCOR - 5MG/ML	amrinone lactate	C01CE	injectable solution	expired
02006391	PRIMACOR - 1MG/ML	milrinone lactate	C01CE	injectable solution	
02230643	SKELID - 200MG/TAB	tiludronate disodium	M05BA	tablet	not sold
<b>SCHERING CANADA INC.</b>					
<b>Human:</b>					
02070855	ALDERM - 0.5MG/G	alclometasone dipropionate	D07AB	ointment	not sold
02070871	ALDERM - 0.5MG/G	alclometasone dipropionate	D07AB	cream	not sold
02165465	CEDAX - 200MG/CAP	ceftibuten	J01DA	capsule	not sold
02165473	CEDAX - 400MG/CAP	ceftibuten	J01DA	capsule	not sold
02165449	CEDAX - 18MG/ML	ceftibuten	J01DA	powder for oral suspension	not sold
02165457	CEDAX - 36MG/ML	ceftibuten	J01DA	powder for oral suspension	not sold
01970399	CHLOR-TRIPOLON N.D. 5/120	loratadine/pseudoephedrine sulfate	R06AX	tablet	
02019973	CLARITIN - 1MG/ML	loratadine	R06AX	syrup	
00782696	CLARITIN - 10MG/TAB	loratadine	R06AX	tablet	
01945157	CLARITIN EXTRA 5/120	loratadine/pseudoephedrine sulfate	R06AX	tablet	
00851736	ELOCOM - 1MG/G	mometasone furoate	D07AC	ointment	
00851744	ELOCOM - 1MG/G	mometasone furoate	D07AC	cream	
00871095	ELOCOM - 1MG/ML	mometasone furoate	D07AC	lotion	
00889067	INTRON-A - 5000000UNIT/ML	interferon alfa-2b	L03AA	injectable solution	
00705896	INTRON-A - 3000000UNIT/VIAL	interferon alfa-2b	L03AA	powder for injectable suspension	
00705918	INTRON-A - 5000000UNIT/VIAL	interferon alfa-2b	L03AA	powder for injectable suspension	
00705926	INTRON-A - 10000000UNIT/VIAL	interferon alfa-2b	L03AA	powder for injectable suspension	
02231651	INTRON-A - 18000000UNIT/VIAL	interferon alfa-2b	L03AA	powder for injectable suspension	introduced
02231652	INTRON-A - 30000000UNIT/VIAL	interferon alfa-2b	L03AA	powder for injectable suspension	not sold
02231653	INTRON-A - 50000000UNIT/VIAL	interferon alfa-2b	L03AA	powder for injectable suspension	not sold
00713376	K-DUR - 1500MG/TAB	potassium chloride	A12BA	sustained-release tablet	
02230921	LEUCOMAX - 0.15MG/VIAL	molgramostim	L03AA	powder for injectable solution	not sold
02230922	LEUCOMAX - 0.3MG/VIAL	molgramostim	L03AA	powder for injectable solution	not sold
02230923	LEUCOMAX - 0.4MG/VIAL	molgramostim	L03AA	powder for injectable solution	not sold
02230924	LEUCOMAX - 0.7MG/VIAL	molgramostim	L03AA	powder for injectable solution	not sold
00611174	LOTRIDERM 0.5/10	betamethasone dipropionate/ clotrimazole	D01AC	cream	
00503363	NETROMYCIN - 25MG/ML	netilmicin sulfate	J01GB	injectable solution	not sold
00503371	NETROMYCIN - 50MG/ML	netilmicin sulfate	J01GB	injectable solution	
00503398	NETROMYCIN - 100MG/ML	netilmicin sulfate	J01GB	injectable solution	
01911910	NITRO-DUR 0.2 - 40MG/PATCH	nitroglycerin	C01DA	transdermal patch	
02213370	NITRO-DUR 0.3 - 60MG/PATCH	nitroglycerin	C01DA	transdermal patch	
01911902	NITRO-DUR 0.4 - 80MG/PATCH	nitroglycerin	C01DA	transdermal patch	
01911929	NITRO-DUR 0.6 - 120MG/PATCH	nitroglycerin	C01DA	transdermal patch	
02011271	NITRO-DUR 0.8 - 160MG/PATCH	nitroglycerin	C01DA	transdermal patch	
<b>Veterinary:</b>					
02231742	AQUAFLO - 500000MG/KG	florfenicol		powder	
00882887	DURA SE-120 - 360MG/BOLUS	selenite sodium		bolus	not sold
02216558	NUFLOR - 300MG/ML	florfenicol		injectable solution	
02142155	OPTIMMUNE - 2MG/G	cyclosporine		ophthalmic ointment	
<b>SEARLE CANADA INC.</b>					
<b>Human:</b>					
02205971	AMBIEN - 5MG/TAB	zolpidem tartrate	N05CG	tablet	not sold
02205998	AMBIEN - 10MG/TAB	zolpidem tartrate	N05CG	tablet	not sold
02231676	CHRONOVERA - 180MG/TAB	verapamil hydrochloride	C08DA	sustained-release tablet	not sold
02231677	CHRONOVERA - 240MG/TAB	verapamil hydrochloride	C08DA	sustained-release tablet	not sold
01946188	KERLONE - 10MG/TAB	betaxolol hydrochloride	C07AB	tablet	expired
01946161	KERLONE - 20MG/TAB	betaxolol hydrochloride	C07AB	tablet	expired
02010925	MAXAQUIN - 400MG/TAB	lomefloxacin	J01MA	tablet	not sold
00874213	NITRODISC 0.2 - 16MG/PATCH	nitroglycerin	C01DA	transdermal patch	not sold
00874221	NITRODISC 0.3 - 24MG/PATCH	nitroglycerin	C01DA	transdermal patch	not sold
00874248	NITRODISC 0.4 - 32MG/PATCH	nitroglycerin	C01DA	transdermal patch	not sold
02188783	SYNAREL - 2MG/ML	nafarelin acetate	H01CA	nasal solution	
02187108	SYNPHASIC 1.0-0.5/0.035	norethindrone/ethinyl estradiol	G03AB	tablet	
02187116	SYNPHASIC 1.0-0.5/0.035	norethindrone/ethinyl estradiol	G03AB	tablet	

DIN/GP	Brand Name	Generic Name	ATC*	Dosage Form	Comments
<b>SMITHKLINE BEECHAM PHARMA INC.</b>					
<b>Human:</b>					
01911937	AUGMENTIN 25/6.25	amoxicillin trihydrate/ clavulanate potassium	J01CR	oral suspension	not sold
01911953	AUGMENTIN 250/125	amoxicillin trihydrate/ clavulanate potassium	J01CR	tablet	not sold
01911945	AUGMENTIN 50/12.5	amoxicillin trihydrate/ clavulanate potassium	J01CR	oral suspension	not sold
01911961	AUGMENTIN 500/125	amoxicillin trihydrate/ clavulanate potassium	J01CR	tablet	not sold
01916947	BACTROBAN - 20MG/G	mupirocin	D06AX	ointment	not sold
02236776	BACTROBAN NASAL - 20MG/G	mupirocin calcium	D06AX	nasal ointment	
01919490	CEFIZOX - 1000MG/VIAL	ceftizoxime sodium	J01DA	powder for injectable solution	
01919504	CEFIZOX - 2000MG/VIAL	ceftizoxime sodium	J01DA	powder for injectable solution	
01916882	CLAVULIN 25/6.25	amoxicillin trihydrate/ clavulanate potassium	J01CR	oral suspension	
01916866	CLAVULIN 250/125	amoxicillin trihydrate/ clavulanate potassium	J01CR	tablet	
01916874	CLAVULIN 50/12.5	amoxicillin trihydrate/ clavulanate potassium	J01CR	oral suspension	
01916858	CLAVULIN 500/125	amoxicillin trihydrate/ clavulanate potassium	J01CR	tablet	
02229650	COREG - 3.125MG/TAB	carvedilol	C07AG	tablet	
02229651	COREG - 6.25MG/TAB	carvedilol	C07AG	tablet	
02229652	COREG - 12.5MG/TAB	carvedilol	C07AG	tablet	
02229653	COREG - 25MG/TAB	carvedilol	C07AG	tablet	
00632767	EMEX - 5MG/ML	metoclopramide hydrochloride	A03FA	injectable solution	not sold
01919431	ENGRIX-B	hepatitis B vaccine	J07BC	injectable suspension	
02229110	FAMVIR - 125MG/TAB	famciclovir	J05AB	tablet	
02229129	FAMVIR - 250MG/TAB	famciclovir	J05AB	tablet	
02177102	FAMVIR - 500MG/TAB	famciclovir	J05AB	tablet	
02187078	HAVRIX 1440 - 1440EUNIT/ML	hepatitis A vaccine (inactivated)	J07BC	injectable suspension	
02108216	HAVRIX 720 - 720EUNIT/ML	hepatitis A vaccine (inactivated)	J07BC	injectable suspension	
02231056	HAVRIX 720 JUNIOR - 1440EUNIT/ML	hepatitis A vaccine (inactivated)	J07BC	injectable suspension	introduced
02231116	HYCANTIN - 4MG/VIAL	topotecan hydrochloride	L01XX	powder for injectable solution	introduced (nas)
02230307	INFANRIX	DaPT vaccine	J07AJ	injectable suspension	not sold
02154471	KREDEX - 25MG/TAB	carvedilol	C07AG	tablet	not sold
02154498	KREDEX - 50MG/TAB	carvedilol	C07AG	tablet	not sold
02185881	KYTRIL - 1MG/TAB	granisetron hydrochloride	A04AA	tablet	
02088371	KYTRIL INJECTION - 1MG/ML	granisetron hydrochloride	A04AA	injectable solution	
01970410	MONOCID - 500MG/VIAL	cefonicid sodium	J01DA	powder for injectable solution	expired
01970429	MONOCID - 1000MG/VIAL	cefonicid sodium	J01DA	powder for injectable solution	expired
02027887	PAXIL - 10MG/TAB	paroxetine hydrochloride	N06AB	tablet	introduced
01940481	PAXIL - 20MG/TAB	paroxetine hydrochloride	N06AB	tablet	
01940473	PAXIL - 30MG/TAB	paroxetine hydrochloride	N06AB	tablet	
02027895	PAXIL - 50MG/TAB	paroxetine hydrochloride	N06AB	tablet	not sold
02083531	RELAFEN - 500MG/TAB	nabumetone	M01AX	tablet	
02083558	RELAFEN - 750MG/TAB	nabumetone	M01AX	tablet	not sold
02231352	RELAFEN - 1000MG/TAB	nabumetone	M01AX	tablet	not sold
02232565	REQUIP - 0.25MG/TAB	ropinirole hydrochloride	N04BC	tablet	introduced (nas)
02232566	REQUIP - 0.5MG/TAB	ropinirole hydrochloride	N04BC	tablet	not sold
02232567	REQUIP - 1MG/TAB	ropinirole hydrochloride	N04BC	tablet	introduced (nas)
02232568	REQUIP - 2MG/TAB	ropinirole hydrochloride	N04BC	tablet	introduced (nas)
02232569	REQUIP - 5MG/TAB	ropinirole hydrochloride	N04BC	tablet	introduced (nas)
01927280	TAGAMET - 6MG/ML	cimetidine hydrochloride	A02BA	injectable solution	
01916750	TAGAMET - 60MG/ML	cimetidine hydrochloride	A02BA	oral solution	
01916807	TAGAMET - 150MG/ML	cimetidine hydrochloride	A02BA	injectable solution	
01916793	TAGAMET - 200MG/TAB	cimetidine	A02BA	tablet	not sold
01916815	TAGAMET - 300MG/TAB	cimetidine	A02BA	tablet	
01916785	TAGAMET - 400MG/TAB	cimetidine	A02BA	tablet	
01916777	TAGAMET - 600MG/TAB	cimetidine	A02BA	tablet	
01916769	TAGAMET - 800MG/TAB	cimetidine	A02BA	tablet	not sold
01916920	TICAR - 1000MG/VIAL	ticarcillin disodium	J01CA	powder for injectable solution	not sold
01916912	TICAR - 3000MG/VIAL	ticarcillin disodium	J01CA	powder for injectable solution	
01916904	TICAR - 6000MG/VIAL	ticarcillin disodium	J01CA	powder for injectable solution	not sold
01916890	TICAR - 20000MG/VIAL	ticarcillin disodium	J01CA	powder for injectable solution	not sold

DIN/GP	Brand Name	Generic Name	ATC*	Dosage Form	Comments
00803480	TICAR - 30000MG/VIAL	ticarcillin disodium	J01CA	powder for injectable solution	not sold
01916939	TIMENTIN 3000/100	ticarcillin disodium/ clavulanate potassium	J01CR	powder for injectable solution	expired
02230578	TWINRIX 720/20	combined hepatitis A & B vaccine	J07BC	injectable suspension	introduced

### SOLVAY PHARMA INC.

#### Human:

01919334	LUVOX - 25MG/TAB	fluvoxamine maleate	N06AB	tablet	expired
01919342	LUVOX - 50MG/TAB	fluvoxamine maleate	N06AB	tablet	expired
01919350	LUVOX - 75MG/TAB	fluvoxamine maleate	N06AB	tablet	expired
01919369	LUVOX - 100MG/TAB	fluvoxamine maleate	N06AB	tablet	expired
02224151	PANTO-BYK - 40MG/TAB	pantoprazole sodium	A02BC	tablet	not sold
02229453	PANTOLOC - 40MG/TAB	pantoprazole sodium	A02BC	tablet	introduced (nas)

### WARNER-LAMBERT CANADA INC. (PARKE-DAVIS)

#### Human:

01947664	ACCUPRIL - 5MG/TAB	quinapril hydrochloride	C09AA	tablet	
01947672	ACCUPRIL - 10MG/TAB	quinapril hydrochloride	C09AA	tablet	
01947680	ACCUPRIL - 20MG/TAB	quinapril hydrochloride	C09AA	tablet	
01947699	ACCUPRIL - 40MG/TAB	quinapril hydrochloride	C09AA	tablet	
	COGNEX - 10MG/CAP	tacrine hydrochloride	N07AA	capsule	
	COGNEX - 20MG/CAP	tacrine hydrochloride	N07AA	capsule	
	COGNEX - 30MG/CAP	tacrine hydrochloride	N07AA	capsule	
	COGNEX - 40MG/CAP	tacrine hydrochloride	N07AA	capsule	
02230711	LIPITOR - 10MG/TAB	atorvastatin calcium	C10AA	tablet	introduced (nas)
02230713	LIPITOR - 20MG/TAB	atorvastatin calcium	C10AA	tablet	introduced (nas)
02230714	LIPITOR - 40MG/TAB	atorvastatin calcium	C10AA	tablet	introduced (nas)
02053136	MAXAIR - 0.25MG/DOSE	pirbuterol acetate	R03AC	aerosol for inhalation	
02231095	REZULIN - 200MG/TAB	troglitazone	A10BG	tablet	not sold
02231096	REZULIN - 400MG/TAB	troglitazone	A10BG	tablet	not sold

### WESTWOOD-SQUIBB PHARMACEUTICALS INC.

#### Human:

02010291	HALOG - 1MG/ML	halcinonide	D07AD	topical solution	expired
01909150	LACHYDRIN - 120MG/ML	lactic acid	D02AX	lotion	
01962701	ULTRAVATE - 0.5MG/G	halobetasol propionate	D07AD	cream	
01962728	ULTRAVATE - 0.5MG/G	halobetasol propionate	D07AD	ointment	

### WYETH-AYERST CANADA INC.

#### Human:

02215063	ACEL-IMUNE	DaPT vaccine	J07AJ	injectable suspension	not sold
02215071	ACEL-P	acellular pertussis vaccine	J07AJ	injectable suspension	introduced
	ALREDASE - 200MG/TAB	tolrestat	A10XA	tablet	not sold
02036274	CEFOTAN - 1000MG/VIAL	cefotetan disodium	J01DA	powder for injectable solution	
02036428	CEFOTAN - 2000MG/VIAL	cefotetan disodium	J01DA	powder for injectable solution	
02103664	EFFEXOR - 12.5MG/TAB	venlafaxine hydrochloride	N06AA	tablet	not sold
02103672	EFFEXOR - 25MG/TAB	venlafaxine hydrochloride	N06AA	tablet	not sold
02103680	EFFEXOR - 37.5MG/TAB	venlafaxine hydrochloride	N06AA	tablet	
02103699	EFFEXOR - 50MG/TAB	venlafaxine hydrochloride	N06AA	tablet	not sold
02103702	EFFEXOR - 75MG/TAB	venlafaxine hydrochloride	N06AA	tablet	
02103710	EFFEXOR - 100MG/TAB	venlafaxine hydrochloride	N06AA	tablet	not sold
02126206	HIBTITER	vaccine - hemophilus influenzae b	J07AG	injectable suspension	not sold
02042231	INDERAL-L.A. - 60MG/CAP	propranolol hydrochloride	C07AA	sustained-release capsule	
02042258	INDERAL-L.A. - 80MG/CAP	propranolol hydrochloride	C07AA	sustained-release capsule	
02042266	INDERAL-L.A. - 120MG/CAP	propranolol hydrochloride	C07AA	sustained-release capsule	
02042274	INDERAL-L.A. - 160MG/CAP	propranolol hydrochloride	C07AA	sustained-release capsule	
00673013	MAGNACEF - 500MG/VIAL	ceftazidime pentahydrate	J01DA	powder for injectable solution	not sold
00673021	MAGNACEF - 1000MG/VIAL	ceftazidime pentahydrate	J01DA	powder for injectable solution	not sold
00673048	MAGNACEF - 2000MG/VIAL	ceftazidime pentahydrate	J01DA	powder for injectable solution	not sold
02042304	MICRO-K EXTENCAPS - 600MG/CAP	potassium chloride	A12BA	sustained-release capsule	
02042312	MICRO-K EXTENCAPS - 750MG/CAP	potassium chloride	A12BA	sustained-release capsule	
01919644	MICRO-K LS - 1875MG/PCK	potassium chloride	A12BA	oral suspension	not sold
00665117	MINOCIN - 50MG/TAB	minocycline hydrochloride	J01AA	tablet	not sold
00665126	MINOCIN - 100MG/TAB	minocycline hydrochloride	J01AA	tablet	not sold

DIN/GP	Brand Name	Generic Name	ATC*	Dosage Form	Comments
02170728	MONOCOR - 5MG/TAB	bisoprolol fumarate	C07AB	tablet	not sold
02170701	MONOCOR - 10MG/TAB	bisoprolol fumarate	C07AB	tablet	not sold
02173468	NOVANTRONE - 2MG/ML	mitoxantrone hydrochloride	L01DB	injectable solution	
00564974	PIPRACIL - 2000MG/VIAL	piperacillin sodium	J01CA	powder for injectable solution	
00564982	PIPRACIL - 3000MG/VIAL	piperacillin sodium	J01CA	powder for injectable solution	
00564990	PIPRACIL - 4000MG/VIAL	piperacillin sodium	J01CA	powder for injectable solution	
00857548	PIPRACIL - 40000MG/VIAL	piperacillin sodium	J01CA	powder for injectable solution	
02230175	PNU-IMUNE 23	vaccine - polyvalent pneumococcal	J07AL	injectable suspension	introduced
01970348	REV-EYES - 25MG/VIAL	dapiprazole hydrochloride	S01EX	ophthalmic solution	not sold
02170817	TAZOCIN 2000/250	piperacillin sodium/tazobactam sodium	J01CR	powder for injectable solution	
02170795	TAZOCIN 3000/375	piperacillin sodium/tazobactam sodium	J01CR	powder for injectable solution	
02170809	TAZOCIN 4000/500	piperacillin sodium/tazobactam sodium	J01CR	powder for injectable solution	
02093405	TETRAMUNE	DPT-hemophilus b conjugate vaccine	J07CA	injectable suspension	not sold

## ZENECA PHARMA INC.

### Human:

02224135	ARIMIDEX - 1MG/TAB	anastrozole	L02BG	tablet	
02188880	BREVIBLOC - 10MG/ML	esmolol hydrochloride	C07AB	injectable solution	
02188872	BREVIBLOC - 100MG/ML	esmolol hydrochloride	C07AB	injectable solution	not sold
02188864	BREVIBLOC - 250MG/ML	esmolol hydrochloride	C07AB	injectable solution	
02184478	CASODEX - 50MG/TAB	bicalutamide	L02BB	tablet	
02218488	MERREM - 500MG/VIAL	meropenem	J01DH	powder for injectable solution	
02218496	MERREM - 1000MG/VIAL	meropenem	J01DH	powder for injectable solution	
02219018	MERREM ADD-VANTAGE - 500MG/VIAL	meropenem	J01DH	powder for injectable solution	not sold
02219026	MERREM ADD-VANTAGE - 1000MG/VIAL	meropenem	J01DH	powder for injectable solution	not sold
02236951	SEROQUEL - 25MG/TAB	quetiapine fumarate	N05AX	tablet	not sold
02236952	SEROQUEL - 100MG/TAB	quetiapine fumarate	N05AX	tablet	not sold
02236953	SEROQUEL - 200MG/TAB	quetiapine fumarate	N05AX	tablet	not sold
02227428	SUPRANE	desflurane	N01AB	inhalation anesthetic	introduced (nas)
02229566	TOMUDEX - 2MG/VIAL	raltitrexed	L01BA	powder for injectable solution	
02103729	ZESTORETIC 10/12.5	lisinopril/hydrochlorothiazide	C09BA	tablet	
02045737	ZESTORETIC 20/12.5	lisinopril/hydrochlorothiazide	C09BA	tablet	
02045729	ZESTORETIC 20/25	lisinopril/hydrochlorothiazide	C09BA	tablet	
02049333	ZESTRIL - 5MG/TAB	lisinopril	C09AA	tablet	
02049376	ZESTRIL - 10MG/TAB	lisinopril	C09AA	tablet	
02049384	ZESTRIL - 20MG/TAB	lisinopril	C09AA	tablet	
00839345	ZESTRIL - 40MG/TAB	lisinopril	C09AA	tablet	not sold
02049325	ZOLADEX - 3.6MG/VIAL	goserelin acetate	L02AE	injectable implant	
02225905	ZOLADEX LA - 10.8MG/VIAL	goserelin acetate	L02AE	injectable implant	